

**(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)**

**(19) World Intellectual Property Organization  
International Bureau**



**(43) International Publication Date  
27 July 2006 (27.07.2006)**

PCT

**(10) International Publication Number  
WO 2006/078941 A2**

**(51) International Patent Classification:**

*C07D 403/04* (2006.01)      *A61P 3/10* (2006.01)  
*A61K 31/4025* (2006.01)

(74) **Agents:** VINCENT, Matthew, P. et al.; Fish & Neave IP Group, Ropes & Gray LLP, One International Place, Boston, Massachusetts 02110-2624 (US).

**(21) International Application Number:**

PCT/US2006/002092

**(81) Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

**(22) International Filing Date:** 20 January 2006 (20.01.2006)

English

**(26) Publication Language:**

English

**(30) Priority Data:**

**Priority Data:** 60/645 916 30 January 2005 (20.01.2005) US

(71) **Applicant (for all designated States except US): SIRTRIS PHARMACEUTICALS, INC. [US/US]; 790 Memorial Drive, Suite 104, Cambridge, Massachusetts 02139 (US).**

(72) Inventors: and

(75) **Inventors/Applicants** (*for US only*): **MILBURN, Michael** [US/US]; 508 Hollowridge Court, Cary, North Carolina 27519-9725 (US). **ECKSTEIN, Jens, W.** [DE/US]; 18 Riga Road, Dover, Massachusetts 02030 (US).

**(84) Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT,

[Continued on next page]

**(54) Title:** NOVEL SIRTUIN ACTIVATING COMPOUNDS AND METHODS OF USE THEREOF

SIR2.1	-----MADEAALALQPQGGSPSAAGADREAASSPAGEPLRKPRRDGPGLERSPGEPGG	53
SIRT1		
SIRT2		
SIR2	MNILLMQRIVSFILVVSQGRYFHVGELTMTMLKRPQEESDNNATKKLKTRLTYPICALGK	60
 SIR2.1	-----MSRDSGNDEVAVTIGEVQEITEE---NPEIGSMHITQE	36
SIRT1	AAPEREVPAAARGCPGAAAAALWREAEAAAAGGEQEAQATAAAGEGDNGPGLQGPSRE	113
SIRT2		MAEPDPS 7
SIR2	DKVTGKFIFPAITKDDVMNARLFLKDNDLKTFLEYFLPVEVNSIYIYFMIKLLGFDVKDK	120
 SIR2.1	TDISDAPETN TDSSRQRTTESTTSVSSSEWQN---NDEMMSN-----	74
SIRT1	PPLADNL YDED DDDDEGE EEEEEEAAAAAIGYRDNL LGFDEI ITNGFHS CSES DEEDRASHASS	173
SIRT2	HPLETQAGKVQEAQDSDS DSEGGAAG-----	33
SIR2	ELFMALNSNITSNKERSSAELSSIHAKAED-----	151
 SIR2.1	-----LRRAQRLLDDGATPLQIIQQIFPPDFNASRIATMSENAHFAILSDLERA	123
SIRT1	SDWTPRPRIGPYTFVQQHLMIGTDPTILKDLLPETI P--PELDDMTLWQIVINILSEP	231
SIRT2		GeadMDFLRNLFSQLTLSLG 52
SIR2	-----DELTDPLEKKHAVKLKDLQKAINKVL	178
 SIR2.1	PVRQKLTNYNSLADAVELFKT--KKHILVLTGAGVS VSCGIPDFRS-KDGIYARLRSEFP	180
SIRT1	PKRKKRKDINTIEDAVKLLQE--CKKII VLTGAGVS VSCGIPDFRS-RDGIYARLA VDFP	288
SIRT2	SQKERLLDELTLEGVARYMQSERCRRVICLVGAGISTSAGI PPDFRSPSTGLYDNLEKYH-	111
SIR2	STRRLRPNFNTIDHTATLRN--AKKILVLTGAGVSTS LGIPDFRS-SEGFYSKIRHLG-	234
 SIR2.1	DLPDP TAMFDI RYFREN PAPFYN FARE IF PGQF VPSV SHRF I KELET SGRL RNY TQN ID	240
SIRT1	DLPDPQAMFDIEYFRKDRPFFKFAKEI YPGQF QPSLCHKFIALSDKEG KLLRNY TQN ID	348
SIRT2	-LPYPEAIFEI SYFKKHEPFFA LAKELY PGQF KPTICHY FMRL LDKG LLLRCY TQN ID	170
SIR2	-LED P QDVFNLDIFLQDPSVF YNIAH MVL P PEN MYSPLHSFI KMLQDKG KLLRNY TQN ID	293
 SIR2.1	TLEHQ TGIKR--VVECHGSFSKCTCT--RCGQKYDGNEIREEV LAMRV AHCKRCEG---	292
SIRT1	TLEQVAGIQR--IIQCHGSFATASCL--ICKYKVDCEAVRGDIFNQVVPRCP RCP PAD--	401
SIRT2	TLERIAGLEQEDLVEAHGTFTSHCVSASC RHEYPLSWMKEKIFSEVTPK CEDCQS--	226
SIR2	NLESYAGIDPDKL VQCHGSFATASCV--TCHWQTPG EKIFENIRNLELPLCPYCYQKRKQ	351
 SIR2.1	-----VIKP NIVFFGEDLGREFHQHVTEDKHKV DLI VVI	326
SIRT1	-----EPLA IMKPEI VFFFGENLPEQF HRAM KYD KDEV D L LIVI	439
SIRT2	-----LVKP D I VFFFGE SLP ARFFSCM QSDFLK VD L L L V	260
SIR2	YFPMSNGNNTVQTNINFNSPILKSYGVLKPD MTFFGEALPSRFHKTIRKD I LECD L LICI	411
 SIR2.1	GSSLKVRPVALIPHCVDKNPQILINRESLPHYNADI ELLGN CDDI IRD ICFSL GGSFTE	386
SIRT1	GSSLKVRPVALIPSSIPHE VPQILINREPLPHLHF DVELLGDCDVTI INELCHRLGGEYAK	499
SIRT2	GTSLQVQPFA S LISKAPLSTPRLLINKE--KAGQSDPFLG---MIMGLGGGMDFDSKK	313
SIR2	GTSLK VAPVSEI VN M VPSH VPQILINR DMVTHAEFDLNLLG-----FCDDVAS	459

**(57) Abstract:** Provided herein are novel sirtuin-activating compounds and methods of use thereof. The sirtuin-activating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing. Also provided are compositions comprising a sirtuin-activating compound in combination with another therapeutic agent.



RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA,  
GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Published:**

- *without international search report and to be republished upon receipt of that report*

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

**NOVEL SIRTUIN ACTIVATING COMPOUNDS AND METHODS OF USE  
THEREOF**

**RELATED APPLICATIONS**

5        This application claims the benefit of priority to U.S. Provisional Patent Application No. 60/645,916, filed January 20, 2005, which is hereby incorporated by reference in its entirety.

**BACKGROUND**

10       The Silent Information Regulator (SIR) family of genes represents a highly conserved group of genes present in the genomes of organisms ranging from archaebacteria to a variety of eukaryotes (Frye, 2000). The encoded SIR proteins are involved in diverse processes from regulation of gene silencing to DNA repair. The proteins encoded by members of the SIR2 gene family show high sequence conservation in a 250 amino acid core domain. A well-characterized gene in this family is *S. cerevisiae* SIR2, which is 15 involved in silencing HM loci that contain information specifying yeast mating type, telomere position effects and cell aging (Guarente, 1999; Kaeberlein et al., 1999; Shore, 2000). The yeast Sir2 protein belongs to a family of histone deacetylases (reviewed in Guarente, 2000; Shore, 2000). The Sir2 homolog, CobB, in *Salmonella typhimurium*, 20 functions as an NAD (nicotinamide adenine dinucleotide)-dependent ADP-ribosyl transferase (Tsang and Escalante-Semerena, 1998).

The Sir2 protein is a deacetylase which uses NAD as a cofactor (Imai et al., 2000; Moazed, 2001; Smith et al., 2000; Tanner et al., 2000; Tanny and Moazed, 2001). Unlike other deacetylases, many of which are involved in gene silencing, Sir2 is insensitive to 25 histone deacetylase inhibitors like trichostatin A (TSA) (Imai et al., 2000; Landry et al., 2000a; Smith et al., 2000).

Deacetylation of acetyl-lysine by Sir2 is tightly coupled to NAD hydrolysis, producing nicotinamide and a novel acetyl-ADP ribose compound (1-O-acetyl-ADP-ribose) (Tanner et al., 2000; Landry et al., 2000b; Tanny and Moazed, 2001). The NAD-dependent deacetylase activity of Sir2 is essential for its functions which can connect its biological 30 role with cellular metabolism in yeast (Guarente, 2000; Imai et al., 2000; Lin et al., 2000; Smith et al., 2000). Mammalian Sir2 homologs have NAD-dependent histone deacetylase


activity (Imai et al., 2000; Smith et al., 2000). Most information about Sir2 mediated functions comes from the studies in yeast (Gartenberg, 2000; Gottschling, 2000).

Biochemical studies have shown that Sir2 can readily deacetylate the amino-terminal tails of histones H3 and H4, resulting in the formation of 1-*O*-acetyl-ADP-ribose and nicotinamide. Strains with additional copies of *SIR2* display increased rDNA silencing and a 30% longer life span. It has recently been shown that additional copies of the *C. elegans* *SIR2* homolog, *sir-2.1*, greatly extend life span in that organism. This implies that the *SIR2*-dependent regulatory pathway for aging arose early in evolution and has been well conserved. Yeast life span, like that of metazoans, is also extended by interventions that resemble caloric restriction. Mutations that reduce the activity of the glucose-responsive cAMP (adenosine 3'5'-monophosphate)-dependent (PKA) pathway extend life span in wild type cells but not in mutant *sir2* strains, demonstrating that *SIR2* is a key downstream component of the caloric restriction pathway.

## 15 SUMMARY

Provided herein are novel sirtuin-activating compounds and methods of use thereof.

In one aspect, the invention provides novel sirtuin-activating compounds of Formula (Ia):



20 or a salt thereof, wherein:

Ring A' is a 5- to 7-membered ring optionally fused to a second 5- to 7-membered ring, which is optionally substituted with one to three functional groups selected from the group consisting of halogen, -OR, -CN, -CO<sub>2</sub>R, -OCOR, -OCO<sub>2</sub>R, -C(O)NRR', -OC(O)NRR', -C(O)R, -COR, -SR, -OSO<sub>3</sub>H, -S(O)<sub>n</sub>R, -S(O)<sub>n</sub>OR, -S(O)<sub>n</sub>NRR', -NRR', -NRC(O)OR, -NRC(O)R, -NO<sub>2</sub>, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted non-aromatic heterocyclic and substituted or unsubstituted aryl;

25 Ring B' is a 5- to 7-membered ring optionally substituted with one to four functional groups selected from the group consisting of halogen, -OR, -CN, -CO<sub>2</sub>R,

-OCOR, -OCO<sub>2</sub>R, -C(O)NRR', -OC(O)NRR', -C(O)R, -COR, -SR, -OSO<sub>3</sub>H, -S(O)<sub>n</sub>R, -S(O)<sub>n</sub>OR, -S(O)<sub>n</sub>NRR', -NRR', -NRC(O)OR, -NRC(O)R, -NO<sub>2</sub>, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted non-aromatic heterocyclic and substituted or unsubstituted aryl;

5 J is O or S;

L is -C=C- or -NH-(CH<sub>2</sub>)<sub>k</sub>-;

R and R' are independently -H, a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkenyl group, a substituted or unsubstituted non-aromatic heterocyclic group or a substituted or unsubstituted aryl group;


10 a is 0 or 1;

k is an integer from 1 to 4; and

n is 1 or 2,

provided that Ring A' and Ring B' are not both phenyl and at least one is substituted with at least one hydrogen bond donating group, and provided that the 15 compound is not 4-((E)-2-(pyridin-4-yl)vinyl)phenol.

In another aspect, the invention provides novel sirtuin-activating compounds of Formula (I):



or a salt thereof, wherein:

20 W is CH or N;

X is CH or N;

Y is CH or N;

Z is S, O or NH;

W' is CH or N;

25 X' is CH or N;

Y' is CH or N;

Z' is S, O or NH;

R and R' are independently -H, a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkenyl group, a substituted or unsubstituted non-aromatic 30 heterocyclic group or a substituted or unsubstituted aryl group;

n is 1 or 2;

Ring A is substituted with at least one hydrogen bond donating group and is optionally substituted with one to three functional groups selected from the group consisting of halogen, -OR, -CN, -CO<sub>2</sub>R, -OCOR, -OCO<sub>2</sub>R, -C(O)NRR', -OC(O)NRR', -C(O)R, -COR, -SR, -OSO<sub>3</sub>H, -S(O)<sub>n</sub>R, -S(O)<sub>n</sub>OR, -S(O)<sub>n</sub>NRR', -NRR', -NRC(O)OR, 5 -NRC(O)R, -NO<sub>2</sub>, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted non-aromatic heterocyclic and substituted or unsubstituted aryl; and

Ring B is optionally substituted with one to four functional groups selected from the group consisting of halogen, -OR, -CN, -CO<sub>2</sub>R, -OCOR, -OCO<sub>2</sub>R, -C(O)NRR', -OC(O)NRR', -C(O)R, -COR, -SR, -S(O)<sub>n</sub>R, -S(O)<sub>n</sub>OR, -S(O)<sub>n</sub>NRR', -NRR', -NRC(O)OR, 10 -NRC(O)R, -NO<sub>2</sub>, -OSO<sub>3</sub>H, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted non-aromatic heterocyclic and substituted or unsubstituted aryl.

In another aspect, the invention provides novel sirtuin-activating compounds of 15 Formulas (I)-(XVIII) (including (IA)), including salts, prodrugs and metabolites thereof. Also provided are pharmaceutical compositions comprising a compounds of Formulas (I)-(XVIII) (including (IA)), or a salt, prodrug or metabolites thereof.

In another aspect, the invention provides methods for using sirtuin-activating 20 compounds, or compositions comprising sirtuin-activating compounds, for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing, etc. As described further below, the methods comprise administering to a subject in need thereof a pharmaceutically effective amount of a sirtuin- 25 activating compound.

In certain aspects, the sirtuin-activating compounds may be administered alone or in combination with other compounds, including other sirtuin-activating compounds, or other therapeutic agents.

### 30 BRIEF DESCRIPTION OF THE FIGURES

FIGURE 1 shows the complete mRNA sequence for human SIRT1 (SEQ ID NO: 1) which corresponds to GenBank Accession Number NM\_012238.

FIGURE 2 shows the complete mRNA sequence for human SIRT2 (SEQ ID NO: 3) which corresponds to GenBank Accession Number NM\_030593.

FIGURE 3 shows an alignment of the polypeptide sequences of human SIRT1 (SEQ ID NO: 2) which corresponds to GenBank Accession Number NP\_036370, *C. elegans* Sir2.1 (SEQ ID NO: 4) which corresponds to GenBank Accession Number NP\_501912, human SIRT2 (SEQ ID NO: 5) which corresponds to GenBank Accession Number NM\_030593, and *S. cerevisiae* Sir2 (SEQ ID NO: 6) which corresponds to GenBank Accession Number P53685. The alignment was created using the Clustal Program which is available on the world wide web at ebi.ac.uk/clustalw/index.html?.

FIGURE 4 shows Table 1 which contains exemplary combinatorial therapies for the treatment of cancer.

## DETAILED DESCRIPTION

### 1. Definitions

As used herein, the following terms and phrases shall have the meanings set forth below. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood to one of ordinary skill in the art.

The singular forms "a," "an," and "the" include plural reference unless the context clearly dictates otherwise.

The term "agent" is used herein to denote a chemical compound, a mixture of chemical compounds, a biological macromolecule (such as a nucleic acid, an antibody, a protein or portion thereof, e.g., a peptide), or an extract made from biological materials such as bacteria, plants, fungi, or animal (particularly mammalian) cells or tissues. The activity of such agents may render it suitable as a "therapeutic agent" which is a biologically, physiologically, or pharmacologically active substance (or substances) that acts locally or systemically in a subject.

The term "bioavailable" when referring to a compound is art-recognized and refers to a form of a compound that allows for it, or a portion of the amount of compound administered, to be absorbed by, incorporated to, or otherwise physiologically available to a subject or patient to whom it is administered.

"Biologically active portion of a sirtuin" refers to a portion of a sirtuin protein having a biological activity, such as the ability to deacetylate. Biologically active portions of sirtuins may comprise the core domain of sirtuins. For example, amino acids 62-293 of

SIRT1 having SEQ ID NO: 2, which are encoded by nucleotides 237 to 932 of SEQ ID NO: 1, encompass the NAD<sup>+</sup> binding domain and the substrate binding domain. Therefore, this region is sometimes referred to as the core domain. Other biologically active portions of SIRT1, also sometimes referred to as core domains, include about amino acids 261 to 447 of SEQ ID NO: 2, which are encoded by nucleotides 834 to 1394 of SEQ ID NO: 1; about amino acids 242 to 493 of SEQ ID NO: 2, which are encoded by nucleotides 777 to 1532 of SEQ ID NO: 1; or about amino acids 254 to 495 of SEQ ID NO: 2, which are encoded by nucleotides 813 to 1538 of SEQ ID NO: 1.

The term "companion animals" refers to cats and dogs. As used herein, the term "dog(s)" denotes any member of the species *Canis familiaris*, of which there are a large number of different breeds. The term "cat(s)" refers to a feline animal including domestic cats and other members of the family Felidae, genus *Felis*.

The terms "comprise" and "comprising" are used in the inclusive, open sense, meaning that additional elements may be included.

The term "conserved residue" refers to an amino acid that is a member of a group of amino acids having certain common properties. The term "conservative amino acid substitution" refers to the substitution (conceptually or otherwise) of an amino acid from one such group with a different amino acid from the same group. A functional way to define common properties between individual amino acids is to analyze the normalized frequencies of amino acid changes between corresponding proteins of homologous organisms (Schulz, G. E. and R. H. Schirmer., Principles of Protein Structure, Springer-Verlag). According to such analyses, groups of amino acids may be defined where amino acids within a group exchange preferentially with each other, and therefore resemble each other most in their impact on the overall protein structure (Schulz, G. E. and R. H. Schirmer, Principles of Protein Structure, Springer-Verlag). One example of a set of amino acid groups defined in this manner include: (i) a charged group, consisting of Glu and Asp, Lys, Arg and His, (ii) a positively-charged group, consisting of Lys, Arg and His, (iii) a negatively-charged group, consisting of Glu and Asp, (iv) an aromatic group, consisting of Phe, Tyr and Trp, (v) a nitrogen ring group, consisting of His and Trp, (vi) a large aliphatic nonpolar group, consisting of Val, Leu and Ile, (vii) a slightly-polar group, consisting of Met and Cys, (viii) a small-residue group, consisting of Ser, Thr, Asp, Asn, Gly, Ala, Glu, Gln and Pro, (ix) an aliphatic group consisting of Val, Leu, Ile, Met and Cys, and (x) a small hydroxyl group consisting of Ser and Thr.

“Diabetes” refers to high blood sugar or ketoacidosis, as well as chronic, general metabolic abnormalities arising from a prolonged high blood sugar status or a decrease in glucose tolerance. “Diabetes” encompasses both the type I and type II (Non Insulin Dependent Diabetes Mellitus or NIDDM) forms of the disease. The risk factors for diabetes include the following factors: waistline of more than 40 inches for men or 35 inches for women, blood pressure of 130/85 mmHg or higher, triglycerides above 150 mg/dl, fasting blood glucose greater than 100 mg/dl or high-density lipoprotein of less than 40 mg/dl in men or 50 mg/dl in women.

5 A “direct activator” of a sirtuin is a molecule that activates a sirtuin by binding to it.

10 The term “ED<sub>50</sub>” is art-recognized. In certain embodiments, ED<sub>50</sub> means the dose of a drug which produces 50% of its maximum response or effect, or alternatively, the dose which produces a pre-determined response in 50% of test subjects or preparations. The term “LD<sub>50</sub>” is art-recognized. In certain embodiments, LD<sub>50</sub> means the dose of a drug which is lethal in 50% of test subjects. The term “therapeutic index” is an art-recognized term which 15 refers to the therapeutic index of a drug, defined as LD<sub>50</sub>/ED<sub>50</sub>.

The term “hyperinsulinemia” refers to a state in an individual in which the level of insulin in the blood is higher than normal.

12 The term “including” is used to mean “including but not limited to”. “Including” and “including but not limited to” are used interchangeably.

20 The term “insulin resistance” refers to a state in which a normal amount of insulin produces a subnormal biologic response relative to the biological response in a subject that does not have insulin resistance.

An “insulin resistance disorder,” as discussed herein, refers to any disease or condition that is caused by or contributed to by insulin resistance. Examples include: 25 diabetes, obesity, metabolic syndrome, insulin-resistance syndromes, syndrome X, insulin resistance, high blood pressure, hypertension, high blood cholesterol, dyslipidemia, hyperlipidemia, dyslipidemia, atherosclerotic disease including stroke, coronary artery disease or myocardial infarction, hyperglycemia, hyperinsulinemia and/or hyperproinsulinemia, impaired glucose tolerance, delayed insulin release, diabetic 30 complications, including coronary heart disease, angina pectoris, congestive heart failure, stroke, cognitive functions in dementia, retinopathy, peripheral neuropathy, nephropathy, glomerulonephritis, glomerulosclerosis, nephrotic syndrome, hypertensive nephrosclerosis some types of cancer (such as endometrial, breast, prostate, and colon), complications of

pregnancy, poor female reproductive health (such as menstrual irregularities, infertility, irregular ovulation, polycystic ovarian syndrome (PCOS)), lipodystrophy, cholesterol related disorders, such as gallstones, cholescystitis and cholelithiasis, gout, obstructive sleep apnea and respiratory problems, osteoarthritis, and prevention and treatment of bone loss, e.g. osteoporosis.

The term "livestock animals" refers to domesticated quadrupeds, which includes those being raised for meat and various byproducts, e.g., a bovine animal including cattle and other members of the genus *Bos*, a porcine animal including domestic swine and other members of the genus *Sus*, an ovine animal including sheep and other members of the genus *Ovis*, domestic goats and other members of the genus *Capra*; domesticated quadrupeds being raised for specialized tasks such as use as a beast of burden, e.g., an equine animal including domestic horses and other members of the family Equidae, genus *Equus*.

The term "mammal" is known in the art, and exemplary mammals include humans, primates, livestock animals (including bovines, porcines, etc.), companion animals (e.g., canines, felines, etc.) and rodents (e.g., mice and rats).

The term "naturally occurring form" when referring to a compound means a compound that is in a form, e.g., a composition, in which it can be found naturally. For example, since resveratrol can be found in red wine, it is present in red wine in a form that is naturally occurring. A compound is not in a form that is naturally occurring if, e.g., the compound has been purified and separated from at least some of the other molecules that are found with the compound in nature. A "naturally occurring compound" refers to a compound that can be found in nature, i.e., a compound that has not been designed by man. A naturally occurring compound may have been made by man or by nature.

A "naturally occurring compound" refers to a compound that can be found in nature, i.e., a compound that has not been designed by man. A naturally occurring compound may have been made by man or by nature. For example, resveratrol is a naturally-occurring compound. A "non-naturally occurring compound" is a compound that is not known to exist in nature or that does not occur in nature.

"Obese" individuals or individuals suffering from obesity are generally individuals having a body mass index (BMI) of at least 25 or greater. Obesity may or may not be associated with insulin resistance.

The terms "parenteral administration" and "administered parenterally" are art-  
recognized and refer to modes of administration other than enteral and topical  
administration, usually by injection, and includes, without limitation, intravenous,  
intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal,  
5 intraperitoneal, transtracheal, subcutaneous, subcuticular, intra-articulare, subcapsular,  
subarachnoid, intraspinal, and intrasternal injection and infusion.

A "patient", "subject", "individual" or "host" refers to either a human or a non-  
human animal.

The term "percent identical" refers to sequence identity between two amino acid  
10 sequences or between two nucleotide sequences. Identity can each be determined by  
comparing a position in each sequence which may be aligned for purposes of comparison.  
When an equivalent position in the compared sequences is occupied by the same base or  
amino acid, then the molecules are identical at that position; when the equivalent site  
occupied by the same or a similar amino acid residue (e.g., similar in steric and/or  
15 electronic nature), then the molecules can be referred to as homologous (similar) at that  
position. Expression as a percentage of homology, similarity, or identity refers to a  
function of the number of identical or similar amino acids at positions shared by the  
compared sequences. Expression as a percentage of homology, similarity, or identity refers  
to a function of the number of identical or similar amino acids at positions shared by the  
20 compared sequences. Various alignment algorithms and/or programs may be used,  
including FASTA, BLAST, or ENTREZ. FASTA and BLAST are available as a part of the  
GCG sequence analysis package (University of Wisconsin, Madison, Wis.), and can be  
used with, e.g., default settings. ENTREZ is available through the National Center for  
Biotechnology Information, National Library of Medicine, National Institutes of Health,  
25 Bethesda, MD. In one embodiment, the percent identity of two sequences can be  
determined by the GCG program with a gap weight of 1, e.g., each amino acid gap is  
weighted as if it were a single amino acid or nucleotide mismatch between the two  
sequences.

Other techniques for alignment are described in Methods in Enzymology, vol. 266:  
30 Computer Methods for Macromolecular Sequence Analysis (1996), ed. Doolittle, Academic  
Press, Inc., a division of Harcourt Brace & Co., San Diego, California, USA. Preferably, an  
alignment program that permits gaps in the sequence is utilized to align the sequences. The  
Smith-Waterman is one type of algorithm that permits gaps in sequence alignments. See

Meth. Mol. Biol. 70: 173-187 (1997). Also, the GAP program using the Needleman and Wunsch alignment method can be utilized to align sequences. An alternative search strategy uses MPSRCH software, which runs on a MASPARI computer. MPSRCH uses a Smith-Waterman algorithm to score sequences on a massively parallel computer. This  
5 approach improves ability to pick up distantly related matches, and is especially tolerant of small gaps and nucleotide sequence errors. Nucleic acid-encoded amino acid sequences can be used to search both protein and DNA databases.

The term "pharmaceutically acceptable carrier" is art-recognized and refers to a pharmaceutically-acceptable material, composition or vehicle, such as a liquid or solid  
10 filler, diluent, excipient, solvent or encapsulating material, involved in carrying or transporting any subject composition or component thereof from one organ, or portion of the body, to another organ, or portion of the body. Each carrier must be "acceptable" in the sense of being compatible with the subject composition and its components and not injurious to the patient. Some examples of materials which may serve as pharmaceutically  
15 acceptable carriers include: (1) sugars, such as lactose, glucose and sucrose; (2) starches, such as corn starch and potato starch; (3) cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; (4) powdered tragacanth; (5) malt; (6) gelatin; (7) talc; (8) excipients, such as cocoa butter and suppository waxes; (9)  
20 oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; (10) glycols, such as propylene glycol; (11) polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; (12) esters, such as ethyl oleate and ethyl laurate; (13) agar; (14) buffering agents, such as magnesium hydroxide and aluminum hydroxide; (15) alginic acid; (16) pyrogen-free water; (17) isotonic saline; (18) Ringer's solution; (19) ethyl alcohol; (20) phosphate buffer solutions; and (21) other non-toxic compatible substances  
25 employed in pharmaceutical formulations.

The terms "polynucleotide", and "nucleic acid" are used interchangeably. They refer to a polymeric form of nucleotides of any length, either deoxyribonucleotides or ribonucleotides, or analogs thereof. Polynucleotides may have any three-dimensional structure, and may perform any function, known or unknown. The following are non-limiting examples of polynucleotides: coding or non-coding regions of a gene or gene fragment, loci (locus) defined from linkage analysis, exons, introns, messenger RNA (mRNA), transfer RNA, ribosomal RNA, ribozymes, cDNA, recombinant polynucleotides, branched polynucleotides, plasmids, vectors, isolated DNA of any sequence, isolated RNA  
30

of any sequence, nucleic acid probes, and primers. A polynucleotide may comprise modified nucleotides, such as methylated nucleotides and nucleotide analogs. If present, modifications to the nucleotide structure may be imparted before or after assembly of the polymer. The sequence of nucleotides may be interrupted by non-nucleotide components.

5 A polynucleotide may be further modified, such as by conjugation with a labeling component. The term "recombinant" polynucleotide means a polynucleotide of genomic, cDNA, semisynthetic, or synthetic origin which either does not occur in nature or is linked to another polynucleotide in a nonnatural arrangement.

The term "prophylactic" or "therapeutic" treatment is art-recognized and refers to 10 administration of a drug to a host. If it is administered prior to clinical manifestation of the unwanted condition (e.g., disease or other unwanted state of the host animal) then the treatment is prophylactic, i.e., it protects the host against developing the unwanted condition, whereas if administered after manifestation of the unwanted condition, the treatment is therapeutic (i.e., it is intended to diminish, ameliorate or maintain the existing 15 unwanted condition or side effects therefrom).

The term "protecting group" is art-recognized and refers to temporary substituents that protect a potentially reactive functional group from undesired chemical transformations. Examples of such protecting groups include esters of carboxylic acids, silyl ethers of alcohols, and acetals and ketals of aldehydes and ketones, respectively. The 20 field of protecting group chemistry has been reviewed by Greene and Wuts in Protective Groups in Organic Synthesis (2<sup>nd</sup> ed., Wiley: New York, 1991).

"Relicative lifespan" of a cell refers to the number of daughter cells produced by an individual "mother cell." "Chronological aging" or "chronological lifespan," on the other hand, refers to the length of time a population of non-dividing cells remains viable 25 when deprived of nutrients. "Increasing the lifespan of a cell" or "extending the lifespan of a cell," as applied to cells or organisms, refers to increasing the number of daughter cells produced by one cell; increasing the ability of cells or organisms to cope with stresses and combat damage, e.g., to DNA, proteins; and/or increasing the ability of cells or organisms to survive and exist in a living state for longer under a particular condition, 30 e.g., stress. Lifespan can be increased by at least about 20%, 30%, 40%, 50%, 60% or between 20% and 70%, 30% and 60%, 40% and 60% or more using methods described herein.

“Sirtuin-activating compound” refers to a compound of Formulas (I)-(XVIII) as described herein, including compounds of Formula (Ia). In an exemplary embodiment, a sirtuin-activating compound may increase the level and/or activity of a sirtuin protein.

“Sirtuin activation” refers to increasing at least one activity of a sirtuin protein, 5 preferably by at least about 10%, 50%, 100% or more. “Activating a sirtuin protein” refers to the action of producing an activated sirtuin protein, i.e., a sirtuin protein that is capable of performing at least one of its biological activities with an increase of activity of at least about 10%, 50%, 2 fold or more. Biological activities of sirtuin proteins include deacetylation, e.g., of histones and p53; extending lifespan; increasing genomic stability; 10 silencing transcription; and controlling the segregation of oxidized proteins between mother and daughter cells.

“Sirtuin protein” refers to a member of the sirtuin deacetylase protein family, or preferably to the sir2 family, which include yeast Sir2 (GenBank Accession No. P53685), *C. elegans* Sir-2.1 (GenBank Accession No. NP\_501912), and human SIRT1 (GenBank 15 Accession No. NM\_012238 and NP\_036370 (or AF083106)) and SIRT2 (GenBank Accession No. NM\_030593 and AF083107) proteins. Other family members include the four additional yeast Sir2-like genes termed “*HST* genes” (homologues of Sir two) HST1, HST2, HST3 and HST4, and the five other human homologues hSIRT3, hSIRT4, hSIRT5, hSIRT6 and hSIRT7 (Brachmann et al. (1995) *Genes Dev.* 9:2888 and Frye et al. (1999) 20 *BBRC* 260:273). Preferred sirtuins are those that share more similarities with SIRT1, i.e., hSIRT1, and/or Sir2 than with SIRT2, such as those members having at least part of the N-terminal sequence present in SIRT1 and absent in SIRT2 such as SIRT3 has.

“SIRT1 protein” refers to a member of the sir2 family of sirtuin deacetylases. In one embodiment, a SIRT1 protein includes yeast Sir2 (GenBank Accession No. P53685), *C. elegans* Sir-2.1 (GenBank Accession No. NP\_501912), human SIRT1 (GenBank Accession 25 No. NM\_012238 and NP\_036370 (or AF083106)), human SIRT2 (GenBank Accession No. NM\_030593 and AF083107) proteins, and equivalents and fragments thereof. In another embodiment, a SIRT1 protein includes a polypeptide comprising a sequence consisting of, or consisting essentially of, the amino acid sequence set forth in SEQ ID NOs: 2, 4, 5 or 6. 30 SIRT1 proteins include polypeptides comprising all or a portion of the amino acid sequence set forth in SEQ ID NOs: 2, 4, 5 or 6; the amino acid sequence set forth in SEQ ID NOs: 2, 4, 5 or 6 with 1 to about 2, 3, 5, 7, 10, 15, 20, 30, 50, 75 or more conservative amino acid substitutions; an amino acid sequence that is at least 60%, 70%, 80%, 90%, 95%, 96%,

97%, 98%, or 99% identical to SEQ ID NOs: 2, 4, 5 or 6; and functional fragments thereof. Polypeptides of the invention also include homologs, e.g., orthologs and paralogs, of SEQ ID NOs: 2, 4, 5 or 6.

The term "substantially homologous" when used in connection with amino acid sequences, refers to sequences which are substantially identical to or similar in sequence with each other, giving rise to a homology of conformation and thus to retention, to a useful degree, of one or more biological (including immunological) activities. The term is not intended to imply a common evolution of the sequences.

The term "synthetic" is art-recognized and refers to production by *in vitro* chemical or enzymatic synthesis.

The terms "systemic administration," "administered systemically," "peripheral administration" and "administered peripherally" are art-recognized and refer to the administration of a subject composition, therapeutic or other material other than directly into the central nervous system, such that it enters the patient's system and, thus, is subject to metabolism and other like processes.

The term "therapeutic agent" is art-recognized and refers to any chemical moiety that is a biologically, physiologically, or pharmacologically active substance that acts locally or systemically in a subject. The term also means any substance intended for use in the diagnosis, cure, mitigation, treatment or prevention of disease or in the enhancement of desirable physical or mental development and/or conditions in an animal or human.

The term "therapeutic effect" is art-recognized and refers to a local or systemic effect in animals, particularly mammals, and more particularly humans caused by a pharmacologically active substance. The phrase "therapeutically-effective amount" means that amount of such a substance that produces some desired local or systemic effect at a reasonable benefit/risk ratio applicable to any treatment. The therapeutically effective amount of such substance will vary depending upon the subject and disease condition being treated, the weight and age of the subject, the severity of the disease condition, the manner of administration and the like, which can readily be determined by one of ordinary skill in the art. For example, certain compositions described herein may be administered in a sufficient amount to produce a desired effect at a reasonable benefit/risk ratio applicable to such treatment.

"Transcriptional regulatory sequence" is a generic term used throughout the specification to refer to DNA sequences, such as initiation signals, enhancers, and

promoters, which induce or control transcription of protein coding sequences with which they are operably linked. In preferred embodiments, transcription of one of the recombinant genes is under the control of a promoter sequence (or other transcriptional regulatory sequence) which controls the expression of the recombinant gene in a cell-type 5 which expression is intended. It will also be understood that the recombinant gene can be under the control of transcriptional regulatory sequences which are the same or which are different from those sequences which control transcription of the naturally-occurring forms of genes as described herein.


“Treating” a condition or disease refers to curing as well as ameliorating at least one 10 symptom of the condition or disease.

A “vector” is a self-replicating nucleic acid molecule that transfers an inserted nucleic acid molecule into and/or between host cells. The term includes vectors that function primarily for insertion of a nucleic acid molecule into a cell, replication of vectors that function primarily for the replication of nucleic acid, and expression vectors that 15 function for transcription and/or translation of the DNA or RNA. Also included are vectors that provide more than one of the above functions. As used herein, “expression vectors” are defined as polynucleotides which, when introduced into an appropriate host cell, can be transcribed and translated into a polypeptide(s). An “expression system” usually connotes a suitable host cell comprised of an expression vector that can function to yield a desired 20 expression product.

## 2. Sirtuin Activators

In one aspect, the invention provides novel sirtuin-activating compounds for treating and/or preventing a wide variety of diseases and disorders including, for example, 25 diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing, etc.

In one embodiment, sirtuin-activating compounds of the invention are represented by Structural Formula (Ia):



or a salt thereof, where:

Ring A' is a 5- to 7-membered ring optionally fused to a second 5- to 7-membered ring, which is optionally substituted with one to three functional groups selected from the group consisting of halogen, -OR, -CN, -CO<sub>2</sub>R, -OCOR, -OCO<sub>2</sub>R, -C(O)NRR', -OC(O)NRR', -C(O)R, -COR, -SR, -S(O)<sub>n</sub>R, -S(O)<sub>n</sub>OR, -S(O)<sub>n</sub>NRR', -NRR', -NRC(O)OR, -NRC(O)R, -NO<sub>2</sub>, -OSO<sub>3</sub>H, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted non-aromatic heterocyclic and substituted or unsubstituted aryl;

Ring B' is a 5- to 7-membered ring optionally substituted with one to four functional groups selected from the group consisting of halogen, -OR, -CN, -CO<sub>2</sub>R, -OCOR, -OCO<sub>2</sub>R, -C(O)NRR', -OC(O)NRR', -C(O)R, -COR, -SR, -S(O)<sub>n</sub>R, -S(O)<sub>n</sub>OR, -S(O)<sub>n</sub>NRR', -NRR', -NRC(O)OR, -NRC(O)R, -NO<sub>2</sub>, -OSO<sub>3</sub>H, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted non-aromatic heterocyclic and substituted or unsubstituted aryl;

J is O or S;

L is -C=C- or -NH-(CH<sub>2</sub>)<sub>k</sub>-;

R and R' are independently -H, a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkenyl group, a substituted or unsubstituted non-aromatic heterocyclic group or a substituted or unsubstituted aryl group;

a is 0 or 1;

k is an integer from 1 to 4; and

n is 1 or 2,

provided that Ring A' and Ring B' are not both phenyl, provided that at least one of Ring A' and Ring B' is substituted with at least one hydrogen bond donating group, and provided that the compound is not 4-((E)-2-(pyridin-4-yl)vinyl)phenol.

Preferably, one or both of Ring A' and Ring B' are aromatic, more preferably, both are aromatic. Suitable aromatic groups include, but are not limited to, pyridyl, phenyl,

thienyl, furanyl, indolyl, pyrrolyl, imidazolyl, oxazolyl and thiazolyl. Particularly suitable aromatic groups are phenyl and pyridyl.

For one class of compounds encompassed by Structural Formula (I), a is 0. When a is 0, L is typically  $-\text{CH}=\text{CH}-$ .


5 For another class of compounds encompassed by Structural Formula (I), a is 1.

When a is 1, J is typically 0. When a is 1 and J is 0, k is typically 1.

Typically, the hydrogen bond donating group is  $-\text{OR}$ ,  $-\text{OCOR}$ ,  $-\text{OSO}_3\text{H}$ ,  $-\text{COOH}$ ,  $-\text{SH}$  or  $-\text{NHR}$ . Preferably, the hydrogen bond donating group is  $-\text{OR}$ ,  $-\text{OCOR}$ , or  $-\text{OSO}_3\text{H}$ .

10 When the hydrogen bond donating group is  $-\text{OR}$ , the group is preferably hydrolyzable or metabolically cleavable to  $-\text{OH}$  (e.g., R is a sugar).

In another embodiment, sirtuin-activating compounds of the invention are represented by Structural Formula (I):



or a salt thereof, where:

15      W is CH or N;

      X is CH or N;

      Y is CH or N;

      Z is S, O or NH;

      W' is CH or N;

20      X' is CH or N;

      Y' is CH or N;

      Z' is S, O or NH;

R and R' are independently  $-\text{H}$ , a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkenyl group, a substituted or unsubstituted non-aromatic heterocyclic group or a substituted or unsubstituted aryl group;

25      n is 1 or 2;


Ring A is substituted with at least one hydrogen bond donating group and is optionally substituted with one to three functional groups selected from the group consisting of halogen,  $-\text{OR}$ ,  $-\text{CN}$ ,  $-\text{CO}_2\text{R}$ ,  $-\text{OCOR}$ ,  $-\text{OCO}_2\text{R}$ ,  $-\text{C(O)NRR}'$ ,  $-\text{OC(O)NRR}'$ ,  $-\text{C(O)R}$ ,  $-\text{COR}$ ,  $-\text{SR}$ ,  $-\text{S(O)}_n\text{R}$ ,  $-\text{S(O)}_n\text{OR}$ ,  $-\text{S(O)}_n\text{NRR}'$ ,  $-\text{NRR}'$ ,  $-\text{NRC(O)OR}$ ,  $-\text{NRC(O)R}$ ,  $-\text{NO}_2$ ,  $-\text{OSO}_3\text{H}$ , substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl,

substituted or unsubstituted non-aromatic heterocyclic and substituted or unsubstituted aryl; and

Ring B is optionally substituted with one to four functional groups selected from the group consisting of halogen, -OR, -CN, -CO<sub>2</sub>R, -OCOR, -OCO<sub>2</sub>R, -C(O)NRR',

- 5 -OC(O)NRR', -C(O)R, -COR, -SR, -S(O)<sub>n</sub>R, -S(O)<sub>n</sub>OR, -S(O)<sub>n</sub>NRR', -NRR', -NRC(O)OR, -NRC(O)R, -NO<sub>2</sub>, -OSO<sub>3</sub>H, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted non-aromatic heterocyclic and substituted or unsubstituted aryl.


One group of sirtuin-activating compounds encompassed by Structural Formula (I) 10 is represented by Structural Formula (II):



or a salt thereof.

Particular compounds represented by Structural Formula (II) include those where X is CH and Z is NH, O or S, or X is N and Z is S; and X' is CH and Z' is NH, O or S, or X is 15 N and Z is S.


One group of sirtuin-activating compounds encompassed by Structural Formula (II) is represented by Structural Formula (III):



or a salt thereof, where:

- 20 R<sub>1</sub> is -OR, -OSO<sub>3</sub>H, -SH, -NHR or -COOR;  
 R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub>, R<sub>5</sub> and R<sub>6</sub> are independently -H, halogen, -OR, -CN, -CO<sub>2</sub>R, -OCOR, -OCO<sub>2</sub>R, -C(O)NRR', -OC(O)NRR', -C(O)R, -COR, -SR, -S(O)<sub>n</sub>R, -S(O)<sub>n</sub>OR, -S(O)<sub>n</sub>NRR', -NRR', -NRC(O)OR, -NRC(O)R, -NO<sub>2</sub>, -OSO<sub>3</sub>H, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl or substituted or unsubstituted aryl; and  
 25 R<sub>7</sub> and R<sub>8</sub> are independently -H, a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkenyl group or a substituted or unsubstituted aryl group.

A particular group of sirtuin-activating compounds encompassed by Structural Formula (III) is represented by Structural Formula (IV):



where:


- 5         $R_{10}$ ,  $R_{11}$  and  $R_{12}$  are independently  $-H$ , halogen,  $-OR$ ,  $-CN$ ,  $-CO_2R$ ,  $-OCO_2R$ ,  
 $-C(O)NRR'$ ,  $-OC(O)NRR'$ ,  $-C(O)R$ ,  $-COR$ ,  $-SR$ ,  $-S(O)_nR$ ,  $-S(O)_nOR$ ,  $-S(O)_nNRR'$ ,  $-NRR'$ ,  
 $-NRC(O)OR$ ,  $-NRC(O)R$ ,  $-NO_2$ ,  $-OSO_3H$ , substituted or unsubstituted alkyl, substituted or  
unsubstituted alkenyl or substituted or unsubstituted aryl, provided that at least one of  $R_{10}$ ,  
 $R_{11}$  and  $R_{12}$  is  $-OH$ ,  $-NHR$ ,  $-SH$  or  $-COOR$ ;
- 10       $R_{13}$ ,  $R_{14}$  and  $R_{15}$  are independently  $-H$ , halogen,  $-OR$ ,  $-CN$ ,  $-CO_2R$ ,  $-OCO_2R$ ,  
 $-C(O)NRR'$ ,  $-OC(O)NRR'$ ,  $-C(O)R$ ,  $-COR$ ,  $-SR$ ,  $-S(O)_nR$ ,  $-S(O)_nOR$ ,  $-S(O)_nNRR'$ ,  $-NRR'$ ,  
 $-NRC(O)OR$ ,  $-NRC(O)R$ ,  $-NO_2$ ,  $-OSO_3H$ , substituted or unsubstituted alkyl, substituted or  
unsubstituted alkenyl or substituted or unsubstituted aryl.

In a preferred embodiment, at least one of  $R_{10}$ ,  $R_{11}$  and  $R_{12}$  is  $-OR$ ,  $-OCOR$ , or  
15       $-OSO_3H$ , such as where two of these variables are  $-OR$ ,  $-OCOR$ , or  $-OSO_3H$ . When the  
hydrogen bond donating group is  $-OR$ , the group is preferably hydrolyzable or  
metabolically cleavable to  $-OH$  (e.g., R is a sugar).

In another embodiment, at least one of  $R_{10}$ ,  $R_{11}$  and  $R_{12}$  is a dihalomethyl group,  
such as a dihalomethyl (e.g., difluoromethyl, dichloromethyl) group.

20      When  $R_{10}$ ,  $R_{11}$  and  $R_{12}$  have the values described above, in certain embodiments at  
least one of  $R_{13}$ ,  $R_{14}$  and  $R_{15}$  is  $-OR$ ,  $-OCOR$ ,  $-OSO_3H$ ,  $-NHR$ ,  $-SH$  or  $-COOR$ , preferably  
 $-OR$ ,  $-OCOR$ , or  $-OSO_3H$ . When the hydrogen bond donating group is  $-OR$ , the group is  
preferably hydrolyzable or metabolically cleavable to  $-OH$  (e.g., R is a sugar).

25      In another embodiment, sirtuin-activating compounds of the invention are  
represented by Structural Formula (V):



or a salt thereof, where:

A is O, NH or S;

R<sub>20</sub>, R<sub>21</sub>, R<sub>22</sub>, R<sub>23</sub> and R<sub>24</sub> are independently –H, halogen, -OR, -CN, -CO<sub>2</sub>R,


5 -OCOR, -OCO<sub>2</sub>R, -C(O)NRR', -OC(O)NRR', -C(O)R, -COR, -SR, -S(O)<sub>n</sub>R, -S(O)<sub>n</sub>OR, -S(O)<sub>n</sub>NRR', -NRR', -NRC(O)OR, -NRC(O)R, -NO<sub>2</sub>, -OSO<sub>3</sub>H, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted non-aromatic heterocyclic or substituted or unsubstituted aryl;

10 R and R' are independently –H, a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkenyl group, a substituted or unsubstituted non-aromatic heterocyclic group or a substituted or unsubstituted aryl group;


n is 1 or 2; and

Ring C is optionally substituted with one to four functional groups selected from the group consisting of halogen, -OR, -CN, -CO<sub>2</sub>R, -OCOR, -OCO<sub>2</sub>R, -C(O)NRR', -OC(O)NRR', -C(O)R, -COR, -SR, -S(O)<sub>n</sub>R, -S(O)<sub>n</sub>OR, -S(O)<sub>n</sub>NRR', -NRR', -NRC(O)OR, -NRC(O)R, -NO<sub>2</sub>, -OSO<sub>3</sub>H, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted non-aromatic heterocyclic and substituted or unsubstituted aryl.

One group of sirtuin-activating compounds encompassed by Structural Formula (V) 20 is represented by Structural Formula (VI):




One group of sirtuin-activating compounds encompassed by Structural Formula (VI) is represented by Structural Formula (VII):



5      Typically, Ring C is unsubstituted. When Ring C is unsubstituted, A is typically O. When Ring C and A have the values described above, one or two of R<sub>20</sub>, R<sub>21</sub>, R<sub>22</sub>, R<sub>23</sub> and R<sub>24</sub> can be -OR, -OCOR, -OSO<sub>3</sub>H, -NHR, -SH or -COOR, preferably -OR, -OCOR, or -OSO<sub>3</sub>H, and the remainder of R<sub>20</sub>, R<sub>21</sub>, R<sub>22</sub>, R<sub>23</sub> and R<sub>24</sub> can be -H. In another embodiment, one or two of R<sub>20</sub>, R<sub>21</sub>, R<sub>22</sub>, R<sub>23</sub> and R<sub>24</sub> is a dihalomethyl group, preferably a difluoromethyl group. When the hydrogen bond donating group is -OR, the group is preferably hydrolyzable or metabolically cleavable to -OH (e.g., R is a sugar).

10     In one embodiment where compounds having the values of A, R<sub>20</sub>, R<sub>21</sub>, R<sub>22</sub>, R<sub>23</sub> and R<sub>24</sub> described above and where Ring C is substituted or unsubstituted, one or two of R<sub>21</sub>, R<sub>22</sub> and R<sub>23</sub> are -OR, -OCOR, or -OSO<sub>3</sub>H. When the hydrogen bond donating group is -OR, the group is preferably hydrolyzable or metabolically cleavable to -OH (e.g., R is a sugar).

15     In a further embodiment, sirtuin-activating compounds of the invention are represented by Structural Formula (VIII):



20     or a salt thereof, where:

A is O, NH or S;

X'' is CH or N;

Z'' is NH, O or S;

R and R' are independently -H, a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkenyl group, a substituted or unsubstituted non-aromatic heterocyclic group or a substituted or unsubstituted aryl group;


n is 1 or 2;

5 Ring D is optionally substituted with one to four functional groups selected from the group consisting of halogen, -OR, -CN, -CO<sub>2</sub>R, -OCOR, -OCO<sub>2</sub>R, -C(O)NRR', -OC(O)NRR', -C(O)R, -COR, -SR, -S(O)<sub>n</sub>R, -S(O)<sub>n</sub>OR, -S(O)<sub>n</sub>NRR', -NRR', -NRC(O)OR, -NRC(O)R, -NO<sub>2</sub>, -OSO<sub>3</sub>H, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted non-aromatic heterocyclic and  
10 substituted or unsubstituted aryl; and

Ring E is optionally substituted with one to three functional groups selected from the group consisting of halogen, -OR, -CN, -CO<sub>2</sub>R, -OCO<sub>2</sub>R, -OCOR, -C(O)NRR', -OC(O)NRR', -C(O)R, -COR, -SR, -S(O)<sub>n</sub>R, -S(O)<sub>n</sub>OR, -S(O)<sub>n</sub>NRR', -NRR', -NRC(O)OR, -NRC(O)R, -NO<sub>2</sub>, -OSO<sub>3</sub>H, substituted or unsubstituted alkyl, substituted or  
15 unsubstituted alkenyl, substituted or unsubstituted non-aromatic heterocyclic and substituted or unsubstituted aryl.


Typically, A is O. When A is O, X" can be CH.

One group of sirtuin-activating compounds encompassed by Structural Formula (VIII) is represented by Structural Formula (IX):




20

One group of sirtuin-activating compounds encompassed by Structural Formula (IX) is represented by Structural Formula (X):




A particular group of sirtuin-activating compounds encompassed by Structural Formula (X) is represented by Structural Formula (XI):



Typically,  $Z''$  for compounds of Structural Formulae (VIII)-(XI) is NH. When  $Z''$  is 5 NH, Ring D is preferably unsubstituted and Ring E is optionally substituted with one or two -OR, -OCOR, -OSO<sub>3</sub>H, -NHR, -SH or -COOR groups, preferably one or two -OR, -OCOR, or -OSO<sub>3</sub>H groups. When the hydrogen bond donating group is -OR, the group is 10 preferably hydrolyzable or metabolically cleavable to -OH (e.g., R is a sugar).

In another group of compounds of the invention,  $Z''$  and Ring D are as described 10 above, and Ring E is substituted with one or two dihalomethyl groups. Preferably, the dihalomethyl group is a difluoromethyl group.

Further sirtuin-activating compounds of the invention are represented by Structural Formula (XII):



15 or a salt thereof, where:

Ring A is substituted with at least one dihalomethyl group and at least one group capable of donating hydrogen bonds; and


Ring B is optionally substituted.

When Ring B is substituted, one or more of the substituents are preferably a group 20 capable of donating hydrogen bonds.

For both Ring A and Ring B, typical hydrogen bond donating groups are -OR, -OCOR, -OSO<sub>3</sub>H, -NHR, -SH and -COOR (where R is as defined above), preferably -OR, -OCOR, or -OSO<sub>3</sub>H. When the hydrogen bond donating group is -OR, the group is preferably hydrolyzable or metabolically cleavable to -OH (e.g., R is a sugar).


Suitable dihalomethyl groups include dichloromethyl, dibromomethyl and difluoromethyl, preferably difluoromethyl.

A particular sirtuin-activating compound encompassed by Structural Formula (XII) is represented by Structural Formula (XIII):



5

In one embodiment, sirtuin-activating compounds of the invention are represented by Structural Formula (XIV):



or a salt thereof, where:

10

$R_{30}$  is  $-OR_z$ ,  $-OCH_3$ ,  $-Cl$ ,  $-OC_6H_5$  or  $-CH_3$ ;

$R_{31}$  is  $-H$ ,  $-OR_z$ ,  $-OCH_3$ ,  $-F$  or  $-CH_3$ ;


$R_{32}$  is  $-OR_z$ ,  $-OCHF_2$ ,  $-OCHCl_2$ ,  $-OCHBr_2$  or  $-OCH_3$ ; and

$R_z$  is  $-SO_3H$ , an acyl group (e.g., acetyl or the acyl group of a fatty acid) or a sugar, provided that  $R_{32}$  is  $-OCHF_2$ ,  $-OCHCl_2$ ,  $-OCHBr_2$  or  $-OCH_3$  when  $R_{30}$  and  $R_{31}$  are both

15


$-OH$ .


Particular sirtuin-activating compounds encompassed by Structural Formula (XIV) are represented by the following structural formulae:



The hydroxyl groups of these compounds can be replaced with  $-OSO_3H$  or  $-OR_z$ , where  $R_z$  is an acyl group (e.g., acetyl or the acyl group of a fatty acid) or a naturally or non-naturally occurring sugar.


Additional sirtuin-activating compounds encompassed by Structural Formula (XIV) are represented by the following formulae:





The hydroxyl groups of these compounds can be replaced with  $-OSO_3H$  or  $-OR_z$ , where  $R_z$  is an acyl group (e.g., acetyl or the acyl group of a fatty acid) or a naturally or non-naturally occurring sugar.


5 In another embodiment, sirtuin-activating compounds of the invention are represented by Structural Formula (XV):



or a salt thereof, where:


j is 1 or 2;  
10 m is 0 or 1;  
Q is CH or N; and  
 $R_z'$  is  $-H$ ,  $-SO_3H$ , acyl or a sugar,  
provided that the compound is not 4-((E)-2-(pyridin-4-yl)vinyl)phenol.

One group of sirtuin-activating compounds encompassed by Structural Formula (XV) is represented by Structural Formula (XVI):




or a salt thereof, where Q is CH or N, provided that Q is N when the nitrogen atom is para to the double bond. The hydroxyl groups of these compounds can be replaced with  $-OSO_3H$  or  $-OR_z$ , where  $R_z$  is an acyl group (e.g., acetyl or the acyl group of a fatty acid) or a naturally or non-naturally occurring sugar.

20 Particular sirtuin-activating compounds encompassed by Structural Formula (XVI) are represented by the following structural formulae:




The hydroxyl groups of these compounds can be replaced with  $-\text{OSO}_3\text{H}$  or  $-\text{OR}_z$ , where  $\text{R}_z$  is an acyl group (e.g., acetyl or the acyl group of a fatty acid) or a naturally or non-naturally occurring sugar.


Another group of sirtuin-activating compounds encompassed by Structural Formula (XV) is represented by Structural Formula (XVII):



or a salt thereof, where  $\text{Q}$  is  $\text{CH}$  or  $\text{N}$ . The hydroxyl groups of these compounds can be replaced with  $-\text{OSO}_3\text{H}$  or  $-\text{OR}_z$ , where  $\text{R}_z$  is an acyl group (e.g., acetyl or the acyl group of a fatty acid) or a naturally or non-naturally occurring sugar.


Particular sirtuin-activating compounds encompassed by Structural Formula (XVII) are represented by the following structural formulae:






The hydroxyl groups of these compounds can be replaced with  $-OSO_3H$  or  $-OR_z$ , where  $R_z$  is an acyl group (e.g., acetyl or the acyl group of a fatty acid) or a naturally or non-naturally occurring sugar.

Other particular sirtuin-activating compounds encompassed by Structural Formula (XV) are represented by the following:



The hydroxyl groups of these compounds can be replaced with  $-OSO_3H$  or  $-OR_z$ , where  $R_z$  is an acyl group (e.g., acetyl or the acyl group of a fatty acid) or a naturally or non-naturally occurring sugar.

In yet another embodiment, sirtuin-activating compounds of the invention are represented by Structural Formula (XVIII):



or a salt thereof, where:


Ring F is substituted with at least one hydrogen bond donating group and the compound is optionally substituted with one or more groups selected from the group  
 5 consisting of halogen, -OR, -CN, -CO<sub>2</sub>R, -OCOR, -OCO<sub>2</sub>R, -C(O)NRR', -OC(O)NRR',  
 -C(O)R, -COR, -SR, -S(O)<sub>n</sub>R, -S(O)<sub>n</sub>OR, -S(O)<sub>n</sub>NRR', -NRR', -NRC(O)OR, -NRC(O)R, -  
 NO<sub>2</sub>, -OSO<sub>3</sub>H, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl,  
 substituted or unsubstituted non-aromatic heterocyclic and substituted or unsubstituted aryl;


10 R and R' are independently -H, a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkenyl group, a substituted or unsubstituted non-aromatic heterocyclic group or a substituted or unsubstituted aryl group; and

n is 1 or 2.


The hydrogen bonding donating group on Ring F is typically -OR, -OSO<sub>3</sub>H, -SH, -NHR or  
 -COOR, preferably -OR or -OSO<sub>3</sub>H. When the hydrogen bond donating group is -OR, the  
 15 group is preferably hydrolyzable or metabolically cleavable to -OH (e.g., R is a sugar or an acyl group).

Groups of sirtuin-activating compounds encompassed by Structural Formula (XVIII) are represented by the following structural formulae:





Sirtuin-activating compounds of the invention having hydroxyl substituents, unless otherwise indicated, also include the related secondary metabolites, particularly sulfate, acyl (e.g., acetyl, fatty acid acyl) and sugar (e.g., glucurondate, glucose) derivatives. In 5 other words, substituent groups —OH also include —OSO<sub>3</sub><sup>-</sup> M<sup>+</sup>, where M<sup>+</sup> is a suitable cation (preferably H<sup>+</sup>, NH<sub>4</sub><sup>+</sup> or an alkali metal ion such as Na<sup>+</sup> or K<sup>+</sup>) and sugars such as



These groups are generally cleavable to —OH by hydrolysis or by metabolic (e.g., enzymatic) cleavage.

10 Sirtuin-activating compounds of the invention advantageously increase the level or activity of a SIRT1 protein, particularly the deacetylase activity of the SIRT1 protein.

Separately or in addition to the above properties, certain sirtuin-activating compounds of the invention do not substantially have one or more of the following activities: inhibition of PI3-kinase, inhibition of aldoreductase, inhibition of tyrosine 15 kinase, transactivation of EGFR tyrosine kinase, coronary dilation, or spasmolytic activity, at concentrations of the compound that are effective for increasing the deacetylation activity of the SIRT1 protein.

An alkyl group is a straight chained, branched or cyclic non-aromatic hydrocarbon which is completely saturated. Typically, a straight chained or branched alkyl group has 20 from 1 to about 20 carbon atoms, preferably from 1 to about 10, and a cyclic alkyl group has from 3 to about 10 carbon atoms, preferably from 3 to about 8. Examples of straight chained and branched alkyl groups include methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-

butyl, tert-butyl, pentyl, hexyl, pentyl and octyl. A C1-C4 straight chained or branched alkyl group is also referred to as a "lower alkyl" group.

An alkenyl group is a straight chained, branched or cyclic non-aromatic hydrocarbon which contains one or more double bonds. Typically, the double bonds are 5 not located at the terminus of the alkenyl group, such that the double bond is not adjacent to another functional group.

An alkynyl group is a straight chained, branched or cyclic non-aromatic hydrocarbon which contains one or more triple bonds. Typically, the triple bonds are not located at the terminus of the alkynyl group, such that the triple bond is not adjacent to 10 another functional group.

A 5- to 7-membered ring includes carbocyclic and heterocyclic rings. Such rings can be saturated or unsaturated, including aromatic. Heterocyclic rings typically contain 1 to 4 heteroatoms, although oxygen and sulfur atoms cannot be adjacent to each other.

Aromatic (aryl) groups include carbocyclic aromatic groups such as phenyl, 15 naphthyl, and anthracyl, and heteroaryl groups such as imidazolyl, thienyl, furanyl, pyridyl, pyrimidyl, pyranyl, pyrazolyl, pyrrolyl, pyrazinyl, thiazolyl, oxazolyl, and tetrazolyl.

Aromatic groups also include fused polycyclic aromatic ring systems in which a carbocyclic aromatic ring or heteroaryl ring is fused to one or more other heteroaryl rings. Examples include benzothienyl, benzofuranyl, indolyl, quinolinyl, benzothiazole, 20 benzoxazole, benzimidazole, quinolinyl, isoquinolinyl and isoindolyl.


Non-aromatic heterocyclic rings are non-aromatic carbocyclic rings which include 25 one or more heteroatoms such as nitrogen, oxygen or sulfur in the ring. The ring can be five, six, seven or eight-membered. Examples include tetrahydrofuranyl, tetrahyrothiophenyl, morpholino, thiomorpholino, pyrrolidinyl, piperazinyl, piperidinyl, and thiazolidinyl, along with the cyclic form of sugars.

A ring fused to a second ring shares at least one common bond.

Suitable substituents on an alkyl, alkenyl, alkynyl, aryl, non-aromatic heterocyclic or aryl group (carbocyclic and heteroaryl) are those which do not substantially interfere 30 with the ability of the disclosed compounds to have one or more of the properties disclosed herein. A substituent substantially interferes with the properties of a compound when the magnitude of the property is reduced by more than about 50% in a compound with the substituent compared with a compound without the substituent. Examples of suitable substituents include -OH, halogen (-Br, -Cl, -I and -F), -OR<sup>a</sup>, -O-COR<sup>a</sup>, -COR<sup>a</sup>, -C(O)R<sup>a</sup>,

-CN, -NO<sup>2</sup>, -COOH, -COOR<sup>a</sup>, -OCO<sub>2</sub>R<sup>a</sup>, -C(O)NR<sup>a</sup>R<sup>b</sup>, -OC(O)NR<sup>a</sup>R<sup>b</sup>, -SO<sub>3</sub>H, -NH<sub>2</sub>, -NHR<sup>a</sup>, -N(R<sup>a</sup>R<sup>b</sup>), -COOR<sup>a</sup>, -CHO, -CONH<sub>2</sub>, -CONHR<sup>a</sup>, -CON(R<sup>a</sup>R<sup>b</sup>), -NHCOR<sup>a</sup>, -NRCOR<sup>a</sup>, -NHCONH<sub>2</sub>, -NHCONR<sup>a</sup>H, -NHCON(R<sup>a</sup>R<sup>b</sup>), -NR<sup>c</sup>CONH<sub>2</sub>, -NR<sup>c</sup>CONR<sup>a</sup>H, -NR<sup>c</sup>CON(R<sup>a</sup>R<sup>b</sup>), -C(=NH)-NH<sub>2</sub>, -C(=NH)-NHR<sup>a</sup>, -C(=NH)-N(R<sup>a</sup>R<sup>b</sup>), -C(=NR<sup>c</sup>)-NH<sub>2</sub>, -C(=NR<sup>c</sup>)-NHR<sup>a</sup>, -C(=NR<sup>c</sup>)-N(R<sup>a</sup>R<sup>b</sup>), -NH-C(=NH)-NH<sub>2</sub>, -NH-C(=NH)-NHR<sup>a</sup>, -NH-C(=NR<sup>c</sup>)-N(R<sup>a</sup>R<sup>b</sup>), -NR<sup>d</sup>H-C(=NH)-NH<sub>2</sub>, -NR<sup>d</sup>-C(=NH)-NHR<sup>a</sup>, -NR<sup>d</sup>-C(=NH)-N(R<sup>a</sup>R<sup>b</sup>), -NR<sup>d</sup>-C(=NR<sup>c</sup>)-NH<sub>2</sub>, -NR<sup>d</sup>-C(=NR<sup>c</sup>)-N(R<sup>a</sup>R<sup>b</sup>), -NHNH<sub>2</sub>, -NHNHR<sup>a</sup>, -NHR<sup>a</sup>R<sup>b</sup>, -SO<sub>2</sub>NH<sub>2</sub>, -SO<sub>2</sub>NHR<sub>a</sub>, -SO<sub>2</sub>NR<sup>a</sup>R<sup>b</sup>, -CH=CHR<sup>a</sup>, -CH=CR<sup>a</sup>R<sup>b</sup>, -CR<sup>c</sup>=CR<sup>a</sup>R<sup>b</sup>, CR<sup>c</sup>=CHR<sup>a</sup>, -CR<sup>c</sup>=CR<sup>a</sup>R<sup>b</sup>, -CCR<sup>a</sup>, -SH, -SO<sub>k</sub>R<sup>a</sup> (k is 0, 1 or 2), -S(O)<sub>k</sub>OR<sup>a</sup> (k is 0, 1 or 2) and -NH-C(=NH)-NH<sub>2</sub>. R<sup>a</sup>-R<sup>d</sup> are each independently an aliphatic, substituted aliphatic, benzyl, substituted benzyl, aromatic or substituted aromatic group, preferably an alkyl, benzylic or aryl group. In addition, -NR<sup>a</sup>R<sup>b</sup>, taken together, can also form a substituted or unsubstituted non-aromatic heterocyclic group. A non-aromatic heterocyclic group, benzylic group or aryl group can also have an aliphatic or substituted aliphatic group as a substituent. A substituted aliphatic group can also have a non-aromatic heterocyclic ring, a substituted a non-aromatic heterocyclic ring, benzyl, substituted benzyl, aryl or substituted aryl group as a substituent. A substituted aliphatic, non-aromatic heterocyclic group, substituted aryl, or substituted benzyl group can have more than one substituent.

A hydrogen-bond donating group is a functional group having a partially positively-charged hydrogen atom (e.g., -OH, -NH<sub>2</sub>, -SH) or a group (e.g., an ester) that metabolizes into a group capable of donating a hydrogen bond.

Double bonds indicated in a structure as:  are intended to include both the (E)- and (Z)-configuration. Preferably, double bonds are in the (E)-configuration.

A sugar is an aldehyde or ketone derivative of a straight-chain polyhydroxy alcohol, which contains at least three carbon atoms. A sugar can exist as a linear molecule or, preferably, as a cyclic molecule (e.g., in the pyranose or furanose form). Preferably, a sugar is a monosaccharide such as glucose or glucuronic acid. In embodiments of the invention where, for example, prolonged residence of a compound derivatized with a sugar is desired, the sugar is preferably a non-naturally occurring sugar. For example, one or more hydroxyl groups are substituted with another group, such as a halogen (e.g., chlorine). The stereochemical configuration at one or more carbon atoms can also be altered, as

compared to a naturally occurring sugar. One example of a suitable non-naturally occurring sugar is sucralose.

A fatty acid is a carboxylic acid having a long-chained hydrocarbon moiety. Typically, a fatty acid has an even number of carbon atoms ranging from 12 to 24, often 5 from 14 to 20. Fatty acids can be saturated or unsaturated and substituted or unsubstituted, but are typically unsubstituted. Fatty acids can be naturally or non-naturally occurring. In embodiments of the invention where, for example, prolonged residence time of a compound having a fatty acid moiety is desired, the fatty acid is preferably non-naturally occurring. The acyl group of a fatty acid consists of the hydrocarbon moiety and the carbonyl moiety 10 of the carboxylic acid functionality, but excludes the -OH moiety associated with the carboxylic acid functionality.

Also included in the present invention are salts, particularly pharmaceutically acceptable salts, of the sirtuin-activating compounds described herein. The compounds of the present invention that possess a sufficiently acidic, a sufficiently basic, or both 15 functional groups, can react with any of a number of inorganic bases, and inorganic and organic acids, to form a salt. Acids commonly employed to form acid addition salts are inorganic acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, phosphoric acid, and the like, and organic acids such as p-toluenesulfonic acid, methanesulfonic acid, oxalic acid, p-bromophenyl-sulfonic acid, carbonic acid, succinic 20 acid, citric acid, benzoic acid, acetic acid, and the like. Examples of such salts include the sulfate, pyrosulfate, bisulfate, sulfite, bisulfite, phosphate, monohydrogenphosphate, dihydrogenphosphate, metaphosphate, pyrophosphate, chloride, bromide, iodide, acetate, propionate, decanoate, caprylate, acrylate, formate, isobutyrate, caproate, heptanoate, 25 propiolate, oxalate, malonate, succinate, suberate, sebacate, fumarate, maleate, butyne-1,4-dioate, hexyne-1,6-dioate, benzoate, chlorobenzoate, methylbenzoate, dinitrobenzoate, hydroxybenzoate, methoxybenzoate, phthalate, sulfonate, xylenesulfonate, phenylacetate, phenylpropionate, phenylbutyrate, citrate, lactate, gamma-hydroxybutyrate, glycolate, tartrate, methanesulfonate, propanesulfonate, naphthalene-1-sulfonate, naphthalene-2-sulfonate, mandelate, and the like.

30 Base addition salts include those derived from inorganic bases, such as ammonium or alkali or alkaline earth metal hydroxides, carbonates, bicarbonates, and the like. Such bases useful in preparing the salts of this invention thus include sodium hydroxide, potassium hydroxide, ammonium hydroxide, potassium carbonate, and the like.

In an exemplary embodiment, a sirtuin-activating compound may traverse the cytoplasmic membrane of a cell. For example, a compound may have a cell-permeability of at least about 20%, 50%, 75%, 80%, 90% or 95%.

Sirtuin-activating compounds described herein may also have one or more of the  
5 following characteristics: the compound may be essentially non-toxic to a cell or subject; the sirtuin-activating compound may be an organic molecule or a small molecule of 2000 amu or less, 1000 amu or less; a compound may have a half-life under normal atmospheric conditions of at least about 30 days, 60 days, 120 days, 6 months or 1 year; the compound may have a half-life in solution of at least about 30 days, 60 days, 120 days, 6 months or 1  
10 year; a sirtuin-activating compound may be more stable in solution than resveratrol by at least a factor of about 50%, 2 fold, 5 fold, 10 fold, 30 fold, 50 fold or 100 fold; a sirtuin-activating compound may promote deacetylation of the DNA repair factor Ku70; a sirtuin-activating compound may promote deacetylation of RelA/p65; a compound may increase general turnover rates and enhance the sensitivity of cells to TNF-induced apoptosis.

15 In certain embodiments, a sirtuin-activating compound does not have any substantial ability to inhibit a histone deacetylase (HDACs) class I, a HDAC class II, or HDACs I and II, at concentrations (e.g., *in vivo*) effective for activating the deacetylase activity of the sirtuin. For instance, in preferred embodiments the sirtuin-activating compound is chosen to have an EC<sub>50</sub> for activating sirtuin deacetylase activity that is at least 5 fold less than the EC<sub>50</sub> for inhibition of an HDAC I and/or HDAC II, and even more preferably at least 10 fold, 100 fold or even 1000 fold less. Methods for assaying HDAC I and/or HDAC II activity are well known in the art and kits to perform such assays may be purchased commercially. See e.g., BioVision, Inc. (Mountain View, CA; world wide web at [biovision.com](http://biovision.com)) and Thomas Scientific (Swedesboro, NJ; world wide web at [tomassci.com](http://tomassci.com)).  
20  
25

In certain embodiments, a sirtuin-activating compound does not have any substantial ability to activate SIRT1 orthologs in lower eukaryotes, particularly yeast or human pathogens, at concentrations (e.g., *in vivo*) effective for activating the deacetylase activity of human SIRT1. For instance, in preferred embodiments a sirtuin-activating compound is chosen to have an EC<sub>50</sub> for activating human SIRT1 deacetylase activity that is at least 5 fold less than the EC<sub>50</sub> for activating yeast Sir2 (such as *Candida*, *S. cerevisiae*, etc.), and even more preferably at least 10 fold, 100 fold or even 1000 fold less.  
30

In certain embodiments, a sirtuin-activating compound may have the ability to activate one or more sirtuin protein homologs, such as, for example, one or more of human SIRT1, SIRT2, SIRT3, SIRT4, SIRT5, SIRT6, or SIRT7. In other embodiments, a SIRT1 activator does not have any substantial ability to activate other sirtuin protein homologs, such as, for example, one or more of human SIRT2, SIRT3, SIRT4, SIRT5, SIRT6, or SIRT7, at concentrations (e.g., *in vivo*) effective for activating the deacetylase activity of human SIRT1. For instance, a sirtuin-activating compound may be chosen to have an EC<sub>50</sub> for activating human SIRT1 deacetylase activity that is at least 5 fold less than the EC<sub>50</sub> for activating one or more of human SIRT2, SIRT3, SIRT4, SIRT5, SIRT6, or SIRT7, and even more preferably at least 10 fold, 100 fold or even 1000 fold less.

In certain embodiments, a sirtuin-activating compound may have a binding affinity for a SIRT1 protein of about 10<sup>-9</sup>M, 10<sup>-10</sup>M, 10<sup>-11</sup>M, 10<sup>-12</sup>M or less. A sirtuin-activating compound may reduce the K<sub>m</sub> of a SIRT1 protein for its substrate or NAD<sup>+</sup> by a factor of at least about 2, 3, 4, 5, 10, 20, 30, 50 or 100. A sirtuin-activating compound may increase the V<sub>max</sub> of a SIRT1 protein by a factor of at least about 2, 3, 4, 5, 10, 20, 30, 50 or 100. A sirtuin-activating compound may have an EC<sub>50</sub> for activating the deacetylase activity of a SIRT1 protein of less than about 1 nM, less than about 10 nM, less than about 100 nM, less than about 1  $\mu$ M, less than about 10  $\mu$ M, less than about 100  $\mu$ M, or from about 1-10 nM, from about 10-100 nM, from about 0.1-1  $\mu$ M, from about 1-10  $\mu$ M or from about 10-100  $\mu$ M. A sirtuin-activating compound may activate the deacetylase activity of a SIRT1 protein by a factor of at least about 5, 10, 20, 30, 50, or 100, as measured in a cellular assay or in a cell based assay. A sirtuin-activating compound may cause at least about 10%, 30%, 50%, 80%, 2 fold, 5 fold, 10 fold, 50 fold or 100 fold greater induction of the deacetylase activity of SIRT1 relative to the same concentration of resveratrol. A sirtuin-activating compound may have an EC<sub>50</sub> for activating SIRT5 that is at least about 10 fold, 20 fold, 30 fold, 50 fold greater than that for activating SIRT1.

### 3. Exemplary Uses

In another aspect, the invention provides methods for increasing the level or activity of a sirtuin protein, increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing, etc. As described further below,

the methods comprise administering to a subject in need thereof a pharmaceutically effective amount of a sirtuin-activating compound.

In certain aspects, the sirtuin-activating compounds described herein may be taken alone or in combination with other compounds. In one embodiment, a mixture of two or more sirtuin-activating compounds may be administered to a subject in need thereof. In another embodiment, a sirtuin-activating compound may be administered with one or more of the following compounds: resveratrol, butein, fisetin, piceatannol, or quercetin. In an exemplary embodiment, a sirtuin-activating compound may be administered in combination with nicotinic acid. In yet another embodiment, one or more sirtuin activating compounds may be administered with one or more therapeutic agents for the treatment or prevention of various diseases, including, for example, cancer, diabetes, neurodegenerative diseases, cardiovascular disease, blood clotting, inflammation, flushing, obesity, ageing, stress, etc. In various embodiments, combination therapies comprising a sirtuin-activating compound may refer to (1) pharmaceutical compositions that comprise one or more sirtuin-activating compounds in combination with one or more therapeutic agents; and (2) co-administration of one or more sirtuin-activating compounds with one or more therapeutic agents wherein the sirtuin-activating compound and therapeutic agent have not been formulated in the same compositions. When using separate formulations, the sirtuin-activating compound may be administered at the same, intermittent, staggered, prior to, subsequent to, or combinations thereof, with the administration of another therapeutic agent.

In certain embodiments, methods for reducing, preventing or treating diseases or disorders using a sirtuin-activating compound may also comprise increasing the protein level of a sirtuin, such as SIRT1 in a human cell or a homologue of any of the sirtuins in other organisms. Increasing protein levels can be achieved by introducing into a cell one or more copies of a nucleic acid that encodes a sirtuin. For example, the level of SIRT1 can be increased in a mammalian cell by introducing into the mammalian cell a nucleic acid encoding SIRT1, e.g., having the amino acid sequence set forth in SEQ ID NO: 2. The nucleic acid may be under the control of a promoter that regulates the expression of the SIRT1 nucleic acid. Alternatively, the nucleic acid may be introduced into the cell at a location in the genome that is downstream of a promoter. Methods for increasing the level of a protein using these methods are well known in the art.

A nucleic acid that is introduced into a cell to increase the protein level of a sirtuin may encode a protein that is at least about 80%, 85%, 90%, 95%, 98%, or 99% identical to the sequence of a sirtuin, e.g., SEQ ID NO: 2. For example, the nucleic acid encoding the protein may be at least about 80%, 85%, 90%, 95%, 98%, or 99% identical to SEQ ID NO: 5 1. The nucleic acid may also be a nucleic acid that hybridizes, preferably under stringent hybridization conditions, to a nucleic acid encoding a wild-type sirtuin, e.g., SEQ ID NO: 1. Stringent hybridization conditions may include hybridization and a wash in 0.2 x SSC at 10 65 °C. When using a nucleic acid that encodes a protein that is different from a wild-type sirtuin protein, such as a protein that is a fragment of a wild-type sirtuin, the protein is preferably biologically active, e.g., is capable of deacetylation. It is only necessary to express in a cell a portion of the sirtuin that is biologically active. For example, a protein 15 that differs from wild-type SIRT1 having SEQ ID NO: 2, preferably contains the core structure thereof. The core structure sometimes refers to amino acids 62-293 of SEQ ID NO: 2, which are encoded by nucleotides 237 to 932 of SEQ ID NO: 1, which encompasses the NAD binding as well as the substrate binding domains. The core domain of SIRT1 may 20 also refer to about amino acids 261 to 447 of SEQ ID NO: 2, which are encoded by nucleotides 834 to 1394 of SEQ ID NO: 1; to about amino acids 242 to 493 of SEQ ID NO: 2, which are encoded by nucleotides 777 to 1532 of SEQ ID NO: 1; or to about amino acids 254 to 495 of SEQ ID NO: 2, which are encoded by nucleotides 813 to 1538 of SEQ ID NO: 1. Whether a protein retains a biological function, e.g., deacetylation capabilities, can be determined according to methods known in the art.

Methods for increasing sirtuin protein levels also include methods for stimulating the transcription of genes encoding sirtuins, methods for stabilizing the corresponding mRNAs, methods, and other methods known in the art.

#### 25 *Aging/Stress*

In one embodiment, the invention provides a method extending the lifespan of a cell, extending the proliferative capacity of a cell, slowing ageing of a cell, promoting the survival of a cell, delaying cellular senescence in a cell, mimicking the effects of calorie restriction, increasing the resistance of a cell to stress, or preventing apoptosis of a cell, by 30 contacting the cell with a sirtuin-activating compound of the invention.

The methods described herein may be used to increase the amount of time that cells, particularly primary cells (i.e., cells obtained from an organism, e.g., a human), may be kept alive in a cell culture. Embryonic stem (ES) cells and pluripotent cells, and cells

differentiated therefrom, may also be treated with a sirtuin-activating compound to keep the cells, or progeny thereof, in culture for longer periods of time. Such cells can also be used for transplantation into a subject, e.g., after *ex vivo* modification.

In one embodiment, cells that are intended to be preserved for long periods of time 5 may be treated with a sirtuin-activating compound. The cells may be in suspension (e.g., blood cells, serum, biological growth media, etc.) or in tissues or organs. For example, blood collected from an individual for purposes of transfusion may be treated with a sirtuin-activating compound to preserve the blood cells for longer periods of time. Additionally, blood to be used for forensic purposes may also be preserved using the 10 sirtuin-activating compounds described herein. Other cells that may be treated to extend their lifespan or protect against apoptosis include cells for consumption, e.g., cells from non-human mammals (such as meat) or plant cells (such as vegetables).

Sirtuin-activating compounds may also be applied during developmental and growth phases in mammals, plants, insects or microorganisms, in order to, e.g., alter, 15 retard or accelerate the developmental and/or growth process.

In another embodiment, sirtuin-activating compounds may be used to treat cells useful for transplantation or cell therapy, including, for example, solid tissue grafts, organ transplants, cell suspensions, stem cells, bone marrow cells, etc. The cells or tissue may be an autograft, an allograft, a syngraft or a xenograft. The cells or tissue may be treated 20 with the sirtuin activating compound prior to administration/implantation, concurrently with administration/implantation, and/or post administration/implantation into a subject. The cells or tissue may be treated prior to removal of the cells from the donor individual, *ex vivo* after removal of the cells or tissue from the donor individual, or post implantation into the recipient. For example, the donor or recipient individual may be treated 25 systemically with a sirutin activating compound or may have a subset of cells/tissue treated locally with a sirtuin-activating compound. In certain embodiments, the cells or tissue (or donor/recipient individuals) may additionally be treated with another therapeutic agent useful for prolonging graft survival, such as, for example, an immunosuppressive agent, a cytokine, an angiogenic factor, etc.

30 In yet other embodiments, cells may be treated with a situin-activating compound *in vivo*, e.g., to increase their lifespan or prevent apoptosis. For example, skin can be protected from aging (e.g., developing wrinkles, loss of elasticity, etc.) by treating skin or epithelial cells with a sirtuin-activating compound. In an exemplary embodiment, skin is

contacted with a pharmaceutical or cosmetic composition comprising a sirtuin-activating compound. Exemplary skin afflictions or skin conditions that may be treated in accordance with the methods described herein include disorders or diseases associated with or caused by inflammation, sun damage or natural aging. For example, the 5 compositions find utility in the prevention or treatment of contact dermatitis (including irritant contact dermatitis and allergic contact dermatitis), atopic dermatitis (also known as allergic eczema), actinic keratosis, keratinization disorders (including eczema), epidermolysis bullosa diseases (including penfigus), exfoliative dermatitis, seborrheic dermatitis, erythemas (including erythema multiforme and erythema nodosum), damage 10 caused by the sun or other light sources, discoid lupus erythematosus, dermatomyositis, skin cancer and the effects of natural aging. In another embodiment, sirtuin-activating compounds may be used for the treatment of wounds and/or burns to promote healing, including, for example, first-, second- or third-degree burns and/or a thermal, chemical or electrical burns. The formulations may be administered topically, to the skin or mucosal 15 tissue, as an ointment, lotion, cream, microemulsion, gel, solution or the like, as further described herein, within the context of a dosing regimen effective to bring about the desired result.

Topical formulations comprising one or more sirtuin-activating compounds may also be used as preventive, e.g., chemopreventive, compositions. When used in a 20 chemopreventive method, susceptible skin is treated prior to any visible condition in a particular individual.

Sirtuin-activating compounds may be delivered locally or systemically to a subject. In one embodiment, a sirtuin-activating compound is delivered locally to a tissue or organ 25 of a subject by injection, topical formulation, etc.

In another embodiment, a sirtuin-activating compound may be used for treating or preventing a disease or condition induced or exacerbated by cellular senescence in a subject; methods for decreasing the rate of senescence of a subject, e.g., after onset of senescence; methods for extending the lifespan of a subject; methods for treating or preventing a disease or condition relating to lifespan; methods for treating or preventing a 30 disease or condition relating to the proliferative capacity of cells; and methods for treating or preventing a disease or condition resulting from cell damage or death. In certain embodiments, the method does not act by decreasing the rate of occurrence of diseases

that shorten the lifespan of a subject. In certain embodiments, a method does not act by reducing the lethality caused by a disease, such as cancer.

In yet another embodiment, a sirtuin activating compound may be administered to a subject in order to generally increase the lifespan of its cells and to protect its cells against stress and/or against apoptosis. It is believed that treating a subject with a compound described herein is similar to subjecting the subject to hormesis, i.e., mild stress that is beneficial to organisms and may extend their lifespan.

Sirtuin-activating compounds may be administered to a subject to prevent aging and aging-related consequences or diseases, such as stroke, heart disease, heart failure, arthritis, high blood pressure, and Alzheimer's disease. Other conditions that can be treated include ocular disorders, e.g., associated with the aging of the eye, such as cataracts, glaucoma, and macular degeneration. Sirtuin-activating compounds described herein can also be administered to subjects for treatment of diseases, e.g., chronic diseases, associated with cell death, in order to protect the cells from cell death. Exemplary diseases include those associated with neural cell death or muscular cell death, such as Parkinson's disease, Alzheimer's disease, multiple sclerosis, amniotrophic lateral sclerosis, and muscular dystrophy; AIDS; fulminant hepatitis; diseases linked to degeneration of the brain, such as Creutzfeld-Jakob disease, retinitis pigmentosa and cerebellar degeneration; myelodysplasia such as aplastic anemia; ischemic diseases such as myocardial infarction and stroke; hepatic diseases such as alcoholic hepatitis, hepatitis B and hepatitis C; joint-diseases such as osteoarthritis; atherosclerosis; alopecia; damage to the skin due to UV light; lichen planus; atrophy of the skin; cataract; and graft rejections.

Sirtuin-activating compounds described herein can also be administered to a subject suffering from an acute disease, e.g., damage to an organ or tissue, e.g., a subject suffering from stroke or myocardial infarction or a subject suffering from a spinal cord injury. Sirtuin-activating compounds may also be used to repair an alcoholic's liver.

#### ***Cardiovascular Disease***

In another embodiment, the invention provides a method for treating and/or preventing a cardiovascular disease by administering to a subject in need thereof a sirtuin-activating compound.

Cardiovascular diseases that can be treated or prevented using the sirtuin-activating compounds described herein include cardiomyopathy or myocarditis; such as idiopathic cardiomyopathy, metabolic cardiomyopathy, alcoholic cardiomyopathy, drug-induced

cardiomyopathy, ischemic cardiomyopathy, and hypertensive cardiomyopathy. Also treatable or preventable using methods described herein are atheromatous disorders of the major blood vessels (macrovascular disease) such as the aorta, the coronary arteries, the carotid arteries, the cerebrovascular arteries, the renal arteries, the iliac arteries, the 5 femoral arteries, and the popliteal arteries. Other vascular diseases that can be treated or prevented include those related to the retinal arterioles, the glomerular arterioles, the vasa nervorum, cardiac arterioles, and associated capillary beds of the eye, the kidney, the heart, and the central and peripheral nervous systems. The compounds may also be used for increasing HDL levels in plasma of an individual.

10 Yet other disorders that may be treated with sirtuin activators include restenosis, e.g., following coronary intervention, and disorders relating to an abnormal level of high density and low density cholesterol.

15 In one embodiment, a sirtuin-activating compound may be administered as part of a combination therapeutic with another cardiovascular agent including, for example, an anti-arrhythmic agent, an antihypertensive agent, a calcium channel blocker, a cardioplegic solution, a cardiotonic agent, a fibrinolytic agent, a sclerosing solution, a vasoconstrictor agent, a vasodilator agent, a nitric oxide donor, a potassium channel blocker, a sodium channel blocker, statins, or a natriuretic agent.

20 In one embodiment, a sirtuin-activating compound may be administered as part of a combination therapeutic with an anti-arrhythmia agent. Anti-arrhythmia agents are often organized into four main groups according to their mechanism of action: type I, sodium channel blockade; type II, beta-adrenergic blockade; type III, repolarization prolongation; and type IV, calcium channel blockade. Type I anti-arrhythmic agents include lidocaine, 25 moricizine, mexiletine, tocainide, procainamide, encainide, flecanide, tocainide, phenytoin, propafenone, quinidine, disopyramide, and flecainide. Type II anti-arrhythmic agents include propranolol and esmolol. Type III includes agents that act by prolonging the duration of the action potential, such as amiodarone, artilide, bretylium, clofilium, isobutilide, sotalol, azimilide, dofetilide, dronedarone, ertentilide, ibutilide, tedisamil, and trecetilide. Type IV anti-arrhythmic agents include verapamil, diltiazem, digitalis, 30 adenosine, nickel chloride, and magnesium ions.

In another embodiment, a sirtuin-activating compound may be administered as part of a combination therapeutic with another cardiovascular agent. Examples of cardiovascular agents include vasodilators, for example, hydralazine; angiotensin

converting enzyme inhibitors, for example, captopril; anti-anginal agents, for example, isosorbide nitrate, glyceryl trinitrate and pentaerythritol tetranitrate; anti-arrhythmic agents, for example, quinidine, procainamide and lignocaine; cardiotropics, for example, digoxin and digitoxin; calcium antagonists, for example, verapamil and nifedipine; 5 diuretics, such as thiazides and related compounds, for example, bendrofluazide, chlorothiazide, chlorothalidone, hydrochlorothiazide and other diuretics, for example, furosemide and triamterene, and sedatives, for example, nitrazepam, flurazepam and diazepam.

Other exemplary cardiovascular agents include, for example, a cyclooxygenase inhibitor such as aspirin or indomethacin, a platelet aggregation inhibitor such as clopidogrel, ticlopidine or aspirin, fibrinogen antagonists or a diuretic such as chlorothiazide, hydrochlorothiazide, flumethiazide, hydroflumethiazide, bendroflumethiazide, methylchlorthiazide, trichloromethiazide, polythiazide or benzthiazide as well as ethacrynic acid tricrynahen, chlorthalidone, furosemide, 10 musolimine, bumetanide, triamterene, amiloride and spironolactone and salts of such compounds, angiotensin converting enzyme inhibitors such as captopril, zofenopril, fosinopril, enalapril, ceranopril, cilazopril, delapril, pentopril, quinapril, ramipril, lisinopril, and salts of such compounds, angiotensin II antagonists such as losartan, irbesartan or 15 valsartan, thrombolytic agents such as tissue plasminogen activator (tPA), recombinant tPA, streptokinase, urokinase, prourokinase, and anisoylated plasminogen streptokinase activator complex (APSAC, Eminase, Beecham Laboratories), or animal salivary gland plasminogen activators, calcium channel blocking agents such as verapamil, nifedipine or 20 diltiazem, thromboxane receptor antagonists such as ifetroban, prostacyclin mimetics, or phosphodiesterase inhibitors. Such combination products if formulated as a fixed dose employ the compounds of this invention within the dose range described above and the 25 other pharmaceutically active agent within its approved dose range.

Yet other exemplary cardiovascular agents include, for example, vasodilators, e.g., bencyclane, cinnarizine, citicoline, cyclandelate, cyclonicate, ebumamone, phenoxyethyl, flunarizine, ibudilast, ifenprodil, lomerizine, naphole, nikamate, nosergoline, nimodipine, 30 papaverine, pentifylline, nofedoline, vincamin, vincopetine, vichizyl, pentoxifylline, prostacyclin derivatives (such as prostaglandin E1 and prostaglandin I2), an endothelin receptor blocking drug (such as bosentan), diltiazem, nicorandil, and nitroglycerin. Examples of the cerebral protecting drug include radical scavengers (such as edaravone,

vitamin E, and vitamin C), glutamate antagonists, AMPA antagonists, kainate antagonists, NMDA antagonists, GABA agonists, growth factors, opioid antagonists, phosphatidylcholine precursors, serotonin agonists,  $\text{Na}^+/\text{Ca}^{2+}$  channel inhibitory drugs, and  $\text{K}^+$  channel opening drugs. Examples of the brain metabolic stimulants include amantadine, 5 tiapride, and .gamma.-aminobutyric acid. Examples of the anticoagulant include heparins (such as heparin sodium, heparin potassium, dalteparin sodium, dalteparin calcium, heparin calcium, parnaparin sodium, reviparin sodium, and danaparoid sodium), warfarin, enoxaparin, argatroban, batroxobin, and sodium citrate. Examples of the antiplatelet drug include ticlopidine hydrochloride, dipyridamole, cilostazol, ethyl icosapentate, sarpogrelate 10 hydrochloride, dilazep hydrochloride, trapidil, a nonsteroidal antiinflammatory agent (such as aspirin), beraprost sodium, iloprost, and indobufene. Examples of the thrombolytic drug include urokinase, tissue-type plasminogen activators (such as alteplase, tisokinase, nateplase, pamiteplase, monteplase, and rateplase), and nasaruplase. Examples of the 15 antihypertensive drug include angiotensin converting enzyme inhibitors (such as captopril, alacepril, lisinopril, imidapril, quinapril, temocapril, delapril, benazepril, cilazapril, trandolapril, enalapril, ceronapril, fosinopril, imadapril, mobertpril, perindopril, ramipril, spirapril, and randozapril), angiotensin II antagonists (such as losartan, candesartan, valsartan, eprosartan, and irbesartan), calcium channel blocking drugs (such as aranidipine, efonidipine, nicardipine, bamidipine, benidipine, manidipine, cilnidipine, nisoldipine, 20 nitrendipine, nifedipine, nilvadipine, felodipine, amlodipine, diltiazem, bepridil, clentiazem, phendilin, galopamil, mibefradil, prenylamine, semotiadil, terodiline, verapamil, cilnidipine, elgodipine, isradipine, lacidipine, lercanidipine, nimodipine, cinnarizine, flunarizine, lidoflazine, lomerizine, bencyclane, etafenone, and perhexiline),  $\beta$ -adrenaline receptor blocking drugs (propranolol, pindolol, indenolol, carteolol, bunitrolol, 25 atenolol, acebutolol, metoprolol, timolol, nipradilol, penbutolol, nadolol, tilisolol, carvedilol, bisoprolol, betaxolol, celiprolol, bopindolol, bevantolol, labetalol, alprenolol, amosulalol, arotinolol, befunolol, bucumolol, bufetolol, buferolol, buprandolol, butyldine, butofilolol, carazolol, cetamolol, cloranolol, dilevalol, epanolol, levobunolol, mepindolol, metipranolol, moprolol, nadoxolol, nevibolol, oxprenolol, practol, pronetalol, sotalol, 30 sufinalol, talindolol, tertalol, toliprolol, xybenolol, and esmolol),  $\alpha$ -receptor blocking drugs (such as amosulalol, prazosin, terazosin, doxazosin, bunazosin, urapidil, phentolamine, arotinolol, dapiprazole, fenspiride, indoramin, labetalol, naftopidil, nicergoline, tamsulosin, tolazoline, trimazosin, and yohimbine), sympathetic nerve inhibitors (such as clonidine,

guanfacine, guanabenz, methyldopa, and reserpine), hydralazine, todralazine, budralazine, and cadralazine. Examples of the antianginal drug include nitrate drugs (such as amyl nitrite, nitroglycerin, and isosorbide),  $\beta$ -adrenaline receptor blocking drugs (such as propranolol, pindolol, indenolol, carteolol, bunitrolol, atenolol, acebutolol, metoprolol, 5 timolol, nifradilol, penbutolol, nadolol, tilisolol, carvedilol, bisoprolol, betaxolol, celiprolol, bopindolol, bevantolol, labetalol, alprenolol, amosulalol, arotinolol, befunolol, bucumolol, bufetolol, buferadol, buprandolol, butyliidine, butofilolol, carazolol, cetamolol, cloranolol, dilevalol, epanolol, levobunolol, mepindolol, metipranolol, moprolol, nadoxolol, nevibolol, oxprenolol, practol, pronetalol, sotalol, sufinalol, talindolol, tertalol, 10 toliprolol, andxybenolol), calcium channel blocking drugs (such as aranidipine, efondipine, nicardipine, bamidipine, benidipine, manidipine, cilnidipine, nisoldipine, nitrendipine, nifedipine, nilvadipine, felodipine, amlodipine, diltiazem, bepridil, clentiazem, phendiline, galopamil, mibepradil, prenylamine, semotiadil, terodilane, verapamil, cilnidipine, elgodipine, isradipine, lacidipine, lercanidipine, nimodipine, cinnarizine, flunarizine, 15 lidoflazine, lomerizine, bencyclane, etafenone, and perhexiline) trimetazidine, dipyridamole, etafenone, dilazep, trapidil, nicorandil, enoxaparin, and aspirin. Examples of the diuretic include thiazide diuretics (such as hydrochlorothiazide, methyclothiazide, trichlormethiazide, benzylhydrochlorothiazide, and penflutizide), loop diuretics (such as furosemide, etacrynic acid, bumetanide, piretanide, azosemide, and torasemide), K<sup>+</sup> sparing 20 diuretics (spironolactone, triamterene, and potassium canrenoate), osmotic diuretics (such as isosorbide, D-mannitol, and glycerin), nonthiazide diuretics (such as meticrane, tripamide, chlorthalidone, and mefruside), and acetazolamide. Examples of the cardiotonic include digitalis formulations (such as digitoxin, digoxin, methyldigoxin, deslanoside, vesnarinone, lanatoside C, and proscillaridin), xanthine formulations (such as aminophylline, choline theophylline, dipyrophylline, and proxyphylline), catecholamine formulations (such as dopamine, dobutamine, and docarpamine), PDE III inhibitors (such as amrinone, olprinone, and milrinone), denopamine, ubidecarenone, pimobendan, levosimendan, aminoethylsulfonic acid, vesnarinone, carperitide, and colforsin daropate. Examples of the 25 antiarrhythmic drug include ajmaline, pirmenol, procainamide, cibenzoline, disopyramide, quinidine, aprindine, mexiletine, lidocaine, phenyloin, pilsicainide, propafenone, flecainide, atenolol, acebutolol, sotalol, propranolol, metoprolol, pindolol, amiodarone, nifekalant, diltiazem, bepridil, and verapamil. Examples of the antihyperlipidemic drug include 30 atorvastatin, simvastatin, pravastatin sodium, fluvastatin sodium, clinofibrate, clofibrate,

simfibrate, fenofibrate, bezafibrate, colestimide, and colestyramine. Examples of the immunosuppressant include azathioprine, mizoribine, cyclosporine, tacrolimus, gusperimus, and methotrexate.

***Cell Death/Cancer***

5        Sirtuin-activating compounds may also be administered to subjects who have recently received or are likely to receive a dose of radiation. In one embodiment, the dose of radiation is received as part of a work-related or medical procedure, e.g., working in a nuclear power plant, flying an airplane, an X-ray, CAT scan, or the administration of a radioactive dye for medical imaging; in such an embodiment, the compound is  
10      administered as a prophylactic measure. In another embodiment, the radiation exposure is received unintentionally, e.g., as a result of an industrial accident, terrorist act, or act of war involving radioactive material. In such a case, the compound is preferably administered as soon as possible after the exposure to inhibit apoptosis and the subsequent development of acute radiation syndrome.

15      Based at least on the discovery that certain concentrations of sirtuin-activating compounds prevent deacetylation of p53 in cells and thereby may induce apoptosis in cells, the activating compounds can also be administered to a subject in conditions in which apoptosis of certain cells is desired. For example, cancer may be treated or prevented. Exemplary cancers are those of the brain and kidney; hormone-dependent cancers  
20      including breast, prostate, testicular, and ovarian cancers; lymphomas, and leukemias. In cancers associated with solid tumors, an activating compound may be administered directly into the tumor. Cancer of blood cells, e.g., leukemia, can be treated by administering an activating compound into the blood stream or into the bone marrow. Benign cell growth can also be treated, e.g., warts. Other diseases that can be treated  
25      include autoimmune diseases, e.g., systemic lupus erythematosus, scleroderma, and arthritis, in which autoimmune cells should be removed. Viral infections such as herpes, HIV, adenovirus, and HTLV-1 associated malignant and benign disorders can also be treated by administration of compounds. Alternatively, cells can be obtained from a subject, treated *ex vivo* to remove certain undesirable cells, e.g., cancer cells, and  
30      administered back to the same or a different subject.

Chemotherapeutic agents that may be coadministered with compounds described herein as having anti-cancer activity (e.g., compounds that induce apoptosis, compounds that reduce lifespan or compounds that render cells sensitive to stress) include:

aminoglutethimide, amsacrine, anastrozole, asparaginase, bcg, bicalutamide, bleomycin, buserelin, busulfan, camptothecin, capecitabine, carboplatin, carmustine, chlorambucil, cisplatin, cladribine, clodronate, colchicine, cyclophosphamide, cyproterone, cytarabine, dacarbazine, dactinomycin, daunorubicin, dienestrol, diethylstilbestrol, docetaxel, doxorubicin, epirubicin, estradiol, estramustine, etoposide, exemestane, filgrastim, fludarabine, fludrocortisone, fluorouracil, fluoxymesterone, flutamide, gemcitabine, genistein, goserelin, hydroxyurea, idarubicin, ifosfamide, imatinib, interferon, irinotecan, ironotecan, letrozole, leucovorin, leuprolide, levamisole, lomustine, mechlorethamine, medroxyprogesterone, megestrol, melphalan, mercaptapurine, mesna, methotrexate, mitomycin, mitotane, mitoxantrone, nilutamide, nocodazole, octreotide, oxaliplatin, paclitaxel, pamidronate, pentostatin, plicamycin, porfimer, procarbazine, raltitrexed, rituximab, streptozocin, suramin, tamoxifen, temozolomide, teniposide, testosterone, thioguanine, thiotepa, titanocene dichloride, topotecan, trastuzumab, tretinoin, vinblastine, vincristine, vindesine, and vinorelbine.

These chemotherapeutic agents may be categorized by their mechanism of action into, for example, following groups: anti-metabolites/anti-cancer agents, such as pyrimidine analogs (5-fluorouracil, floxuridine, capecitabine, gemcitabine and cytarabine) and purine analogs, folate antagonists and related inhibitors (mercaptopurine, thioguanine, pentostatin and 2-chlorodeoxyadenosine (cladribine)); antiproliferative/antimitotic agents including natural products such as vinca alkaloids (vinblastine, vincristine, and vinorelbine), microtubule disruptors such as taxane (paclitaxel, docetaxel), vincristin, vinblastin, nocodazole, epothilones and navelbine, epidipodophyllotoxins (teniposide), DNA damaging agents (actinomycin, amsacrine, anthracyclines, bleomycin, busulfan, camptothecin, carboplatin, chlorambucil, cisplatin, cyclophosphamide, cytoxin, dactinomycin, daunorubicin, docetaxel, doxorubicin, epirubicin, hexamethylmelamineoxaliplatin, iphosphamide, melphalan, mechlorethamine, mitomycin, mitoxantrone, nitrosourea, paclitaxel, plicamycin, procarbazine, teniposide, triethylenethiophosphoramide and etoposide (VP16)); antibiotics such as dactinomycin (actinomycin D), daunorubicin, doxorubicin (adriamycin), idarubicin, anthracyclines, mitoxantrone, bleomycins, plicamycin (mithramycin) and mitomycin; enzymes (L-asparaginase which systemically metabolizes L-asparagine and deprives cells which do not have the capacity to synthesize their own asparagine); antiplatelet agents; antiproliferative/antimitotic alkylating agents such as nitrogen mustards (mechlorethamine,

cyclophosphamide and analogs, melphalan, chlorambucil), ethylenimines and methylmelamines (hexamethylmelamine and thiotepa), alkyl sulfonates-busulfan, nitrosoureas (carmustine (BCNU) and analogs, streptozocin), trazenes - dacarbazine (DTIC); antiproliferative/antimitotic antimetabolites such as folic acid analogs (methotrexate); platinum coordination complexes (cisplatin, carboplatin), procarbazine, hydroxyurea, mitotane, aminoglutethimide; hormones, hormone analogs (estrogen, tamoxifen, goserelin, bicalutamide, nilutamide) and aromatase inhibitors (letrozole, anastrozole); anticoagulants (heparin, synthetic heparin salts and other inhibitors of thrombin); fibrinolytic agents (such as tissue plasminogen activator, streptokinase and urokinase), aspirin, COX-2 inhibitors, dipyridamole, ticlopidine, clopidogrel, abciximab; antimigratory agents; antisecretory agents (breveldin); immunosuppressives (cyclosporine, tacrolimus (FK-506), sirolimus (rapamycin), azathioprine, mycophenolate mofetil); anti-angiogenic compounds (TNP-470, genistein) and growth factor inhibitors (vascular endothelial growth factor (VEGF) inhibitors, fibroblast growth factor (FGF) inhibitors, epidermal growth factor (EGF) inhibitors); angiotensin receptor blocker; nitric oxide donors; anti-sense oligonucleotides; antibodies (trastuzumab); cell cycle inhibitors and differentiation inducers (tretinoin); mTOR inhibitors, topoisomerase inhibitors (doxorubicin (adriamycin), amsacrine, camptothecin, daunorubicin, dactinomycin, eniposide, epirubicin, etoposide, idarubicin, irinotecan (CPT-11) and mitoxantrone, topotecan, irinotecan), corticosteroids (cortisone, dexamethasone, hydrocortisone, methylprednisolone, prednisone, and prenisolone); growth factor signal transduction kinase inhibitors; mitochondrial dysfunction inducers and caspase activators; chromatin disruptors.

These chemotherapeutic agents may be used by themselves with a sirtuin-activating compound described herein as inducing cell death or reducing lifespan or increasing sensitivity to stress and/or in combination with other chemotherapeutics agents. Many combinatorial therapies have been developed, including but not limited to those listed in Table 1 shown in Figure 4.

In addition to conventional chemotherapeutics, the sirtuin-activating compounds described herein as capable of inducing cell death or reducing lifespan can also be used with antisense RNA, RNAi or other polynucleotides to inhibit the expression of the cellular components that contribute to unwanted cellular proliferation that are targets of conventional chemotherapy. Such targets are, merely to illustrate, growth factors, growth

factor receptors, cell cycle regulatory proteins, transcription factors, or signal transduction kinases.

Combination therapies comprising sirtuin-activating compounds and a conventional chemotherapeutic agent may be advantageous over combination therapies known in the art because the combination allows the conventional chemotherapeutic agent to exert greater effect at lower dosage. In a preferred embodiment, the effective dose (ED<sub>50</sub>) for a chemotherapeutic agent, or combination of conventional chemotherapeutic agents, when used in combination with a sirtuin-activating compound is at least 2 fold less than the ED<sub>50</sub> for the chemotherapeutic agent alone, and even more preferably at 5 fold, 10 fold or even 25 fold less. Conversely, the therapeutic index (TI) for such chemotherapeutic agent or combination of such chemotherapeutic agent when used in combination with a compound described herein can be at least 2 fold greater than the TI for conventional chemotherapeutic regimen alone, and even more preferably at 5 fold, 10 fold or even 25 fold greater.

### 15 *Neuronal Diseases/Disorders*

In certain aspects, the sirtuin-activating compounds described herein can be used to treat patients suffering from neurodegenerative diseases, and traumatic or mechanical injury to the central nervous system (CNS) or peripheral nervous system (PNS). Neurodegenerative disease typically involves reductions in the mass and volume of the human brain, which may be due to the atrophy and/or death of brain cells, which are far more profound than those in a healthy person that are attributable to aging. Neurodegenerative diseases evolve gradually, after a long period of normal brain function, due to progressive degeneration (e.g., nerve cell dysfunction and death) of specific brain regions. The actual onset of brain degeneration may precede clinical expression by many years. Examples of neurodegenerative diseases include, but are not limited to, Alzheimer's disease (AD), Parkinson's disease (PD), Huntington disease (HD), amyotrophic lateral sclerosis (ALS; Lou Gehrig's disease), diffuse Lewy body disease, chorea-acanthocytosis, primary lateral sclerosis, and Friedreich's ataxia. The compounds of this invention can be used to treat these disorders and others as described below.

30 AD is a chronic, incurable, and unstoppable CNS disorder that occurs gradually, resulting in memory loss, unusual behavior, personality changes, and a decline in thinking abilities. These losses are related to the death of specific types of brain cells and the breakdown of connections between them. AD has been described as childhood

development in reverse. In most people with AD, symptoms appear after the age 60. The earliest symptoms include loss of recent memory, faulty judgment, and changes in personality. Later in the disease, those with AD may forget how to do simple tasks like washing their hands. Eventually people with AD lose all reasoning abilities and become  
5 dependent on other people for their everyday care. Finally, the disease becomes so debilitating that patients are bedridden and typically develop coexisting illnesses.

PD is a chronic, incurable, and unstoppable CNS disorder that occurs gradually and results in uncontrolled body movements, rigidity, tremor, and gait difficulties. These motor system problems are related to the death of brain cells in an area of the brain that produces  
10 dopamine, a chemical that helps control muscle activity. In most people with PD, symptoms appear after age 50. The initial symptoms of PD are a pronounced tremor affecting the extremities, notably in the hands or lips. Subsequent characteristic symptoms of PD are stiffness or slowness of movement, a shuffling walk, stooped posture, and impaired balance. There are wide ranging secondary symptoms such as memory loss,  
15 dementia, depression, emotional changes, swallowing difficulties, abnormal speech, sexual dysfunction, and bladder and bowel problems. These symptoms will begin to interfere with routine activities, such as holding a fork or reading a newspaper. Finally, people with PD become so profoundly disabled that they are bedridden.

ALS (motor neuron disease) is a chronic, incurable, and unstoppable CNS disorder  
20 that attacks the motor neurons, components of the CNS that connect the brain to the skeletal muscles. In ALS, the motor neurons deteriorate and eventually die, and though a person's brain normally remains fully functioning and alert, the command to move never reaches the muscles. Most people who get ALS are between 40 and 70 years old. The first motor neurons that weaken are those leading to the arms or legs. Those with ALS may have  
25 trouble walking, they may drop things, fall, slur their speech, and laugh or cry uncontrollably. Eventually the muscles in the limbs begin to atrophy from disuse. This muscle weakness will become debilitating and a person will need a wheel chair or become unable to function out of bed.

The causes of these neurological diseases have remained largely unknown. They  
30 are conventionally defined as distinct diseases, yet clearly show extraordinary similarities in basic processes and commonly demonstrate overlapping symptoms far greater than would be expected by chance alone. Current disease definitions fail to properly deal with

the issue of overlap and a new classification of the neurodegenerative disorders has been called for.

HD is another neurodegenerative disease resulting from genetically programmed degeneration of neurons in certain areas of the brain. This degeneration causes 5 uncontrolled movements, loss of intellectual faculties, and emotional disturbance. HD is a familial disease, passed from parent to child through a dominant mutation in the wild-type gene. Some early symptoms of HD are mood swings, depression, irritability or trouble driving, learning new things, remembering a fact, or making a decision. As the disease progresses, concentration on intellectual tasks becomes increasingly difficult and the 10 patient may have difficulty feeding himself or herself and swallowing.

Tay-Sachs disease and Sandhoff disease are glycolipid storage diseases caused by the lack of lysosomal  $\beta$ -hexosaminidase (Gravel et al., in The Metabolic Basis of Inherited Disease, eds. Scriver et al., McGraw-Hill, New York, pp. 2839-2879, 1995). In both disorders, GM2 ganglioside and related glycolipid substrates for  $\beta$ -hexosaminidase 15 accumulate in the nervous system and trigger acute neurodegeneration. In the most severe forms, the onset of symptoms begins in early infancy. A precipitous neurodegenerative course then ensues, with affected infants exhibiting motor dysfunction, seizure, visual loss, and deafness. Death usually occurs by 2-5 years of age. Neuronal loss through an apoptotic mechanism has been demonstrated (Huang et al., Hum. Mol. Genet. 6: 1879- 20 1885, 1997).

It is well-known that apoptosis plays a role in AIDS pathogenesis in the immune system. However, HIV-1 also induces neurological disease. Shi et al. (J. Clin. Invest. 98: 1979-1990, 1996) examined apoptosis induced by HIV-1 infection of the CNS in an in vitro model and in brain tissue from AIDS patients, and found that HIV-1 infection of primary 25 brain cultures induced apoptosis in neurons and astrocytes in vitro. Apoptosis of neurons and astrocytes was also detected in brain tissue from 10/11 AIDS patients, including 5/5 patients with HIV-1 dementia and 4/5 nondemented patients.

Neuronal loss is also a salient feature of prion diseases, such as Creutzfeldt-Jakob disease in human, BSE in cattle (mad cow disease), Scrapie Disease in sheep and goats, and 30 feline spongiform encephalopathy (FSE) in cats. The sirtuin activating compounds described herein may be useful for treating or preventing neuronal loss due to these prior diseases.

In another embodiment, a sirtuin activating compound may be used to treat or prevent any disease or disorder involving axonopathy. Distal axonopathy is a type of peripheral neuropathy that results from some metabolic or toxic derangement of peripheral nervous system (PNS) neurons. It is the most common response of nerves to metabolic or toxic disturbances, and as such may be caused by metabolic diseases such as diabetes, renal failure, deficiency syndromes such as malnutrition and alcoholism, or the effects of toxins or drugs. The most common cause of distal axonopathy is diabetes, and the most common distal axonopathy is diabetic neuropathy. The most distal portions of axons are usually the first to degenerate, and axonal atrophy advances slowly towards the nerve's cell body. If the noxious stimulus is removed, regeneration is possible, though prognosis decreases depending on the duration and severity of the stimulus. Those with distal axonopathies usually present with symmetrical stocking-glove sensori-motor disturbances. Deep tendon reflexes and autonomic nervous system (ANS) functions are also lost or diminished in affected areas.

Diabetic neuropathies are neuropathic disorders that are associated with diabetes mellitus. These conditions usually result from diabetic microvascular injury involving small blood vessels that supply nerves (*vasa nervorum*). Relatively common conditions which may be associated with diabetic neuropathy include third nerve palsy; mononeuropathy; mononeuropathy multiplex; diabetic amyotrophy; a painful polyneuropathy; autonomic neuropathy; and thoracoabdominal neuropathy. Clinical manifestations of diabetic neuropathy include, for example, sensorimotor polyneuropathy such as numbness, sensory loss, dysesthesia and nighttime pain; autonomic neuropathy such as delayed gastric emptying or gastroparesis; and cranial neuropathy such as oculomotor (3rd) neuropathies or Mononeuropathies of the thoracic or lumbar spinal nerves.

Peripheral neuropathy is the medical term for damage to nerves of the peripheral nervous system, which may be caused either by diseases of the nerve or from the side-effects of systemic illness. Peripheral neuropathies vary in their presentation and origin, and may affect the nerve or the neuromuscular junction. Major causes of peripheral neuropathy include seizures, nutritional deficiencies, and HIV, though diabetes is the most likely cause. Mechanical pressure from staying in one position for too long, a tumor, intraneuronal hemorrhage, exposing the body to extreme conditions such as radiation, cold temperatures, or toxic substances can also cause peripheral neuropathy.

In an exemplary embodiment, a sirtuin activating compound may be used to treat or prevent multiple sclerosis (MS), including relapsing MS and monosymptomatic MS, and other demyelinating conditions, such as, for example, chronic inflammatory demyelinating polyneuropathy (CIDP), or symptoms associated therewith.

5 MS is a chronic, often disabling disease of the central nervous system. Various and converging lines of evidence point to the possibility that the disease is caused by a disturbance in the immune function, although the cause of this disturbance has not been established. This disturbance permits cells of the immune system to "attack" myelin, the fat containing insulating sheath that surrounds the nerve axons located in the central nervous  
10 system ("CNS"). When myelin is damaged, electrical pulses cannot travel quickly or normally along nerve fiber pathways in the brain and spinal cord. This results in disruption of normal electrical conductivity within the axons, fatigue and disturbances of vision, strength, coordination, balance, sensation, and bladder and bowel function.

As such, MS is now a common and well-known neurological disorder that is  
15 characterized by episodic patches of inflammation and demyelination which can occur anywhere in the CNS. However, almost always without any involvement of the peripheral nerves associated therewith. Demyelination produces a situation analogous to that resulting from cracks or tears in an insulator surrounding an electrical cord. That is, when the insulating sheath is disrupted, the circuit is "short circuited" and the electrical apparatus  
20 associated therewith will function intermittently or not at all. Such loss of myelin surrounding nerve fibers results in short circuits in nerves traversing the brain and the spinal cord that thereby result in symptoms of MS. It is further found that such demyelination occurs in patches, as opposed to along the entire CNS. In addition, such demyelination may be intermittent. Therefore, such occurrences are disseminated in both  
25 time and space.

It is believed that the pathogenesis involves a local disruption of the blood brain barrier which causes a localized immune and inflammatory response, with consequent damage to myelin and hence to neurons.

Clinically, MS exists in both sexes and can occur at any age. However, its most  
30 common presentation is in the relatively young adult, often with a single focal lesion such as a damage of the optic nerve, an area of anesthesia (loss of sensation), or paraesthesia (localize loss of feeling), or muscular weakness. In addition, vertigo, double vision,

localized pain, incontinence, and pain in the arms and legs may occur upon flexation of the neck, as well as a large variety of less common symptoms.

An initial attack of MS is often transient, and it may be weeks, months, or years before a further attack occurs. Some individuals may enjoy a stable, relatively event free condition for a great number of years, while other less fortunate ones may experience a continual downhill course ending in complete paralysis. There is, most commonly, a series of remission and relapses, in which each relapse leaves a patient somewhat worse than before. Relapses may be triggered by stressful events, viral infections or toxins. Therein, elevated body temperature, i.e., a fever, will make the condition worse, or as a reduction of temperature by, for example, a cold bath, may make the condition better.

In yet another embodiment, a sirtuin activating compound may be used to treat trauma to the nerves, including, trauma due to disease, injury (including surgical intervention), or environmental trauma (e.g., neurotoxins, alcoholism, etc.).

The subject sirtuin activators may also be useful to prevent, treat, and alleviate symptoms of various PNS disorders, such as the ones described below. The PNS is composed of the nerves that lead to or branch off from the CNS. The peripheral nerves handle a diverse array of functions in the body, including sensory, motor, and autonomic functions. When an individual has a peripheral neuropathy, nerves of the PNS have been damaged. Nerve damage can arise from a number of causes, such as disease, physical injury, poisoning, or malnutrition. These agents may affect either afferent or efferent nerves. Depending on the cause of damage, the nerve cell axon, its protective myelin sheath, or both may be injured or destroyed.

The term “peripheral neuropathy” encompasses a wide range of disorders in which the nerves outside of the brain and spinal cord—peripheral nerves—have been damaged. Peripheral neuropathy may also be referred to as peripheral neuritis, or if many nerves are involved, the terms polyneuropathy or polyneuritis may be used.

Peripheral neuropathy is a widespread disorder, and there are many underlying causes. Some of these causes are common, such as diabetes, and others are extremely rare, such as acrylamide poisoning and certain inherited disorders. The most common worldwide cause of peripheral neuropathy is leprosy. Leprosy is caused by the bacterium *Mycobacterium leprae*, which attacks the peripheral nerves of affected people.

Leprosy is extremely rare in the United States, where diabetes is the most commonly known cause of peripheral neuropathy. It has been estimated that more than 17

million people in the United States and Europe have diabetes-related polyneuropathy. Many neuropathies are idiopathic; no known cause can be found. The most common of the inherited peripheral neuropathies in the United States is Charcot-Marie-Tooth disease, which affects approximately 125,000 persons.

5 Another of the better known peripheral neuropathies is Guillain-Barré syndrome, which arises from complications associated with viral illnesses, such as cytomegalovirus, Epstein-Barr virus, and human immunodeficiency virus (HIV), or bacterial infection, including *Campylobacter jejuni* and Lyme disease. The worldwide incidence rate is approximately 1.7 cases per 100,000 people annually. Other well-known causes of  
10 peripheral neuropathies include chronic alcoholism, infection of the varicella-zoster virus, botulism, and poliomyelitis. Peripheral neuropathy may develop as a primary symptom, or it may be due to another disease. For example, peripheral neuropathy is only one symptom of diseases such as amyloid neuropathy, certain cancers, or inherited neurologic disorders. Such diseases may affect the PNS and the CNS, as well as other body tissues.

15 Other PNS diseases treatable with the subject sirtuin activators include: Brachial Plexus Neuropathies (diseases of the cervical and first thoracic roots, nerve trunks, cords, and peripheral nerve components of the brachial plexus. Clinical manifestations include regional pain, paresthesia; muscle weakness, and decreased sensation in the upper extremity. These disorders may be associated with trauma, including birth injuries;  
20 thoracic outlet syndrome; neoplasms, neuritis, radiotherapy; and other conditions. See Adams et al., *Principles of Neurology*, 6th ed, pp1351-2); Diabetic Neuropathies (peripheral, autonomic, and cranial nerve disorders that are associated with diabetes mellitus). These conditions usually result from diabetic microvascular injury involving small blood vessels that supply nerves (*vasa nervorum*). Relatively common conditions  
25 which may be associated with diabetic neuropathy include third nerve palsy; mononeuropathy; mononeuropathy multiplex; diabetic amyotrophy; a painful polyneuropathy; autonomic neuropathy; and thoracoabdominal neuropathy (see Adams et al., *Principles of Neurology*, 6th ed, p1325); mononeuropathies (disease or trauma involving a single peripheral nerve in isolation, or out of proportion to evidence of diffuse  
30 peripheral nerve dysfunction). Mononeuropathy multiplex refers to a condition characterized by multiple isolated nerve injuries. Mononeuropathies may result from a wide variety of causes, including ischemia; traumatic injury; compression; connective tissue diseases; cumulative trauma disorders; and other conditions; Neuralgia (intense or

aching pain that occurs along the course or distribution of a peripheral or cranial nerve); Peripheral Nervous System Neoplasms (neoplasms which arise from peripheral nerve tissue). This includes neurofibromas; Schwannomas; granular cell tumors; and malignant peripheral nerve sheath tumors. See DeVita Jr et al., Cancer: Principles and Practice of Oncology, 5th ed, pp1750-1); Nerve Compression Syndromes (mechanical compression of nerves or nerve roots from internal or external causes. These may result in a conduction block to nerve impulses, due to, for example, myelin sheath dysfunction, or axonal loss. The nerve and nerve sheath injuries may be caused by ischemia; inflammation; or a direct mechanical effect; Neuritis (a general term indicating inflammation of a peripheral or cranial nerve). Clinical manifestation may include pain; paresthesias; paresis; or hyperesthesia; Polyneuropathies (diseases of multiple peripheral nerves). The various forms are categorized by the type of nerve affected (e.g., sensory, motor, or autonomic), by the distribution of nerve injury (e.g., distal vs. proximal), by nerve component primarily affected (e.g., demyelinating vs. axonal), by etiology, or by pattern of inheritance.

In one embodiment, a combination drug regimen may include drugs or compounds for the treatment or prevention of neurodegenerative disorders or secondary conditions associated with these conditions. Thus, a combination drug regimen may include one or more sirtuin activators and one or more anti-neurodegeneration agents. For example, one or more sirtuin-activating compounds can be combined with an effective amount of one or more of: L-DOPA; a dopamine agonist; an adenosine A<sub>2A</sub> receptor antagonists; a COMT inhibitor; a MAO inhibitor; an NOS inhibitor; a sodium channel antagonist; a selective N-methyl D-aspartate (NMDA) receptor antagonists; an AMPA/kainate receptor antagonist; a calcium channel antagonist; a GABA-A receptor agonist; an acetyl-choline esterase inhibitor; a matrix metalloprotease inhibitor; an inhibitor of p38 MAP kinase or c-jun-N-terminal kinases; TPA; NDA antagonists; beta-interferons; growth factors; glutamate inhibitors; and/or as part of a cell therapy.

Exemplary N-NOS inhibitors include 4-(6-amino-pyridin-2-yl)-3-methoxyphenol 6-[4-(2-dimethylamino-ethoxy)-2-methoxy-phenyl]-pyridin-2-yl-amine, 6-[4-(2-dimethylamino-ethoxy)-2,3-dimethyl-phenyl]-pyridin-2-yl-amine, 6-[4-(2-pyrrolidinyl-ethoxy)-2,3-dimethyl-p-henyl]-pyridin-2-yl-amine, 6-[4-(4-(n-methyl)piperidinyloxy)-2,3-dimethyl-p-henyl]-pyridin-2-yl-amine, 6-[4-(2-dimethylamino-ethoxy)-3-methoxy-phenyl]-pyridin-2-yl-amine, 6-[4-(2-pyrrolidinyl-ethoxy)-3-methoxy-phenyl]-pyridin-2-yl-amine, 6-{4-[2-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-ethoxy]-3-methoxy-phenyl}-

pyridin-2-yl-amine, 6-{3-methoxy-4-[2-(4-phenethyl-piper-azin-1-yl)-ethoxy]-phenyl}-  
pyridin-2-yl-amine, 6-{3-methoxy-4-[2-(4-methyl-piperazin-1-yl)-ethoxy]-phenyl}-  
pyridin-2-yl-amine, 6-{4-[2-(4-dimethylamin-o-piperidin-1-yl)-ethoxy]-3-methoxy-  
phenyl}-pyridin-2-yl-amine, 6-[4-(2-dimethylamino-ethoxy)-3-ethoxy-phenyl]-pyridin-2-  
5 yl-amine, 6-[4-(2-pyrrolidinyl-ethoxy)-3-ethoxy-phenyl]-pyridin-2-yl-amine, 6-[4-(2-  
dimethylamino-ethoxy)-2-isopropyl-phenyl]-pyridin-2-yl-amine, 4-(6-amino-pyridin-yl)-3-  
cyclopropyl-phenol 6-[2-cyclopropyl-4-(2-dimethylamino-ethoxy)-phenyl]-pyridin-2-yl-  
amine, 6-[2-cyclopropyl-4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-pyridin-2-yl-amine, 3-[3-(6-  
amino-pyridin-2-yl)-4-cycl-0propyl-phenoxy]-pyrrolidine-1-carboxylic acid tert-butyl ester  
10 6-[2-cyclopropyl-4-(1-methyl-pyrrolidin-3-yl-oxy)-phenyl]-pyridin-2-yl-amine, 4-(6-  
amino-pyridin-2-yl)-3-cyclobutyl-phenol 6-[2-cyclobutyl-4-(2-dimethylamino-ethoxy)-  
phenyl]-pyridin-2-yl-amine, 6-[2-cyclobutyl-4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-pyridin-  
2-yl-amine, 6-[2-cyclobutyl-4-(1-methyl-pyrrolidin-3-yl-oxy)-phenyl]-pyridin-2-yl-amine,  
4-(6-amino-pyridin-2-yl)-3-cyclopentyl-phenol 6-[2-cyclopentyl-4-(2-dimethylamino-  
15 ethoxy)-phenyl]-pyridin-2-yl-amine, 6-[2-cyclopentyl-4-(2-pyrrolidin-1-yl-ethoxy)-  
phenyl]-pyridin-2-yl-amine, 3-[4-(6-amino-pyridin-2-yl)-3-methoxy-phenoxy]-pyrrolidine-  
1-carboxylic acid tert butyl ester 6-[4-(1-methyl-pyrrolidin-3-yl-oxy)-2-methoxy-phenyl]-  
pyridin-2-yl-amine, 4-[4-(6-amino-pyridin-2-yl)-3-methoxy-phenoxy]-piperidine-1-  
carboxylic acid tert butyl ester 6-[2-methoxy-4-(1-methyl-piperidin-4-yl-oxy)-phenyl]-  
20 pyridin-2-yl-amine, 6-[4-(allyloxy)-2-methoxy-phenyl]-pyridin-2-yl-amine, 4-(6-amino-  
pyridin-2-yl)-3-methoxy-6-allyl-phenol 12 and 4-(6-amino-pyridin-2-yl)-3-methoxy-2-  
allyl-phenol 13 4-(6-amino-pyridin-2-yl)-3-methoxy-6-propyl-phenol 6-[4-(2-  
dimethylamino-ethoxy)-2-methoxy-5-propyl-phenyl]-pyridin-2-yl-amine, 6-[2-isopropyl-4-  
25 (pyrrolidin-3-yl-oxy)-phenyl]-pyridin-2-yl-amine, 6-[2-isopropyl-4-(piperidin-3-yl-oxy)-  
phenyl]-pyridin-2-yl-amine, 6-[2-isopropyl-4-(1-methyl-azetidin-3-yl-oxy)-phenyl]-  
pyridin-2-yl-amine, 6-[2-isopropyl-4-(1-methyl-piperidin-4-yl-oxy)-phenyl]-pyridin-2-yl-  
amine, 6-[2-isopropyl-4-(1-methyl-pyrrolidin-3-yl-oxy)-phenyl]-pyridin-2-yl-amine, 6-[2-isopropyl-4-  
30 (2-methyl-2-aza-bicyclo[2.2.1]hept-5-yl-oxy)-phenyl]-pyridin-2-yl-amine, 6-[4-(2-  
dimethylamino-ethoxy)-2-methoxy-phenyl]-pyridin-2-yl-amine, 6-{4-[2-(benzyl-methyl-  
amino)-ethoxy]-2-methoxy-phenyl}-pyridin-2-yl-amine, 6-[2-methoxy-4-(2-pyrrolidin-1-  
yl-ethoxy)-phenyl]-pyridin-2-yl-amine, 2-(6-amino-pyridin-2-yl)-5-(2-dimethylamino-  
ethoxy)-phenol 2-[4-(6-amino-pyridin-2-yl)-3-methoxy-phenoxy]-acetamide 6-[4-(2-

amino-ethoxy)-2-methoxy-phenyl]-pyridin-2-yl-amine, 6-{4-[2-(3,4-dihydro-1h-isoquinolin-2-yl)-ethoxy]-2-methoxy-phenyl}-pyridin-2-yl-amine, 2-[4-(6-amino-pyridin-2-yl)-3-methoxy-phenoxy]-ethanol 6-{2-methoxy-4-[2-(2,2,6,6-tetramethyl-piperidin-1-yl)-ethoxy]-phenyl}-pyridin-2-yl-amine, 6-{4-[2-(2,5-dimethyl-pyrrolidin-1-yl)-ethoxy]-2-methoxy-phenyl}-pyridin-2-yl-amine, 6-{4-[2-(2,5-dimethyl-pyrrolidin-1-yl)-ethoxy]-2-methoxy-phenyl}-pyridin-2-yl-amine, 2-[4-(6-amino-pyridin-2-yl)-3-methoxy-phenoxy]-1-(2,2,6,6-tetramethyl-piperidin-1-yl)-ethanone 6-[2-methoxy-4-(1-methyl-pyrrolidin-2-yl-methoxy)-phenyl]-pyridin-2-yl-amine, 6-[4-(2-dimethylamino-ethoxy)-2-propoxy-phenyl]-pyridin-2-yl-amine, 6-{4-[2-(benzyl-methyl-amino)-ethoxy]-2-propoxy-phenyl}-pyridin-2-yl-amine-e 6-[4-(2-ethoxy-ethoxy)-2-methoxy-phenyl]-pyridin-2-yl-amine, 6-[4-(2-dimethylamino-ethoxy)-2-isopropoxy-phenyl]-pyridin-2-yl-amine, 6-[4-(2-ethoxy-ethoxy)-2-isopropoxy-phenyl]-pyridin-2-yl-amine, 6-[2-methoxy-4-(3-methyl-butoxy)-phenyl]-pyridin-2-yl-amine, 6-[4-(2-dimethylamino-ethoxy)-2-ethoxy-phenyl]-pyridin-2-yl-amine, 6-{4-[2-(benzyl-methyl-amino)-ethoxy]-2-ethoxy-phenyl}-pyridin-2-yl-amine, 6-[2-ethoxy-4-(3-methyl-butoxy)-phenyl]-pyridin-2-yl-amine, 1-(6-amino-3-aza-bicyclo[3.1.0]hex-3-yl)-2-[4-(6-amino-pyridin-2-yl)-3-ethoxy-phenoxy]-ethanone 6-[2-ethoxy-4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-pyridin-2-yl-amine, 3-{2-[4-(6-amino-pyridin-2-yl)-3-ethoxy-phenoxy]-ethyl}-3-aza-bicyclo[3.1.0]hex-6-yl-amine, 1-(6-amino-3-aza-bicyclo[3.1.0]hex-3-yl)-2-[4-(6-amino-pyridin-2-yl)-3-methoxy-phenoxy]-ethanone 3-{2-[4-(6-amino-pyridin-2-yl)-3-methoxy-phenoxy]-ethyl}-3-aza-bicyclo[3.1.0]hex-6-yl-amine, 6-[2-isopropoxy-4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-pyridin-2-yl-amine, 6-{4-[2-(benzyl-methyl-amino)-ethoxy]-2-isopropoxy-phenyl}-pyridin-2-yl-amine, 6-[4-(2-dimethylamino-ethoxy)-2-methoxy-5-propyl-phenyl]-pyridin-2-yl-amine, 6-[5-allyl-4-(2-dimethylamino-ethoxy)-2-methoxy-phenyl]-pyridin-2-yl-amine, 6-[5-allyl-2-methoxy-4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-pyridin-2-yl-amine, 6-[3-allyl-4-(2-dimethylamino-ethoxy)-2-methoxy-phenyl]-pyridin-2-yl-amine, 6-[2-methoxy-4-(pyrrolidin-3-yl-oxy)-phenyl]-pyridin-2-yl-amine, 6-[2-methoxy-4-(1-methyl-pyrrolidin-3-yl-oxy)-phenyl]-pyridin-2-yl-amine, 6-[2-ethoxy-4-(pyrrolidin-3-yl-oxy)-phenyl]-pyridin-2-yl-amine, 6-[2-isopropoxy-4-(pyrrolidin-3-yl-oxy)-phenyl]-pyridin-2-yl-amine, 6-[2-methoxy-4-(piperidin-4-yl-oxy)-phenyl]-pyridin-2-yl-amine, 6-[2-methoxy-4-(2,2,6,6-tetramethyl-piperidin-4-yl-oxy)-phenyl]-pyridin-2-yl-amine, 6-[2-isopropoxy-4-(pyrrolidin-3-yl-oxy)-phenyl]-pyridin-2-yl-amine, 3-[4-(6-amino-pyridin-2-yl)-3-methoxy-phenoxy]-azetidine-1-carboxylic acid tert-butyl ester 6-[4-(azetidin-3-yl-oxy)-2-methoxy-phenyl]-pyridin-2-yl-

amine, 6-[2-methoxy-4-(1-methyl-azetidin-3-yl-oxy)-phenyl]-pyridin-2-yl-amine, 6-[2-isopropoxy-4-(pyrrolidin-3-yl-oxy)-phenyl]-pyridin-2-yl-amine, 6-[2-isopropoxy-4-(pyrrolidin-3-yl-oxy)-phenyl]-pyridin-2-yl-amine, 6-[2-methoxy-4-(pyrrolidin-3-yl-oxy)-phenyl]-pyridin-2-yl-amine, 6-[2-methoxy-4-(1-methyl-pyrrolidin-3-yl-oxy)-phenyl]-pyridin-2-yl-amine, 6-[2-methoxy-4-(1-methyl-pyrrolidin-3-yl-oxy)-phenyl]-pyridin-2-yl-amine, 6-[2-methoxy-4-(2-methyl-2-aza-bicyclo[2.2.1]hept-5-yl-oxy)-phenyl]-pyridin-2-yl-amine, 6-[2-methoxy-4-(1-methyl-piperidin-4-yl-oxy)-phenyl]-pyridin-2-yl-amine, 6-[4-(1-ethyl-piperidin-4-yl-oxy)-2-methoxy-phenyl]-pyridin-2-yl-amine, 6-[5-allyl-2-methoxy-4-(1-methyl-pyrrolidin-3-yl-oxy)-phenyl]-pyridin-2-yl-amine, 6-[4-(2-dimethylaminoethoxy)-2,6-dimethyl-phenyl]-pyridin-2-yl-amine, 6-[2,6-dimethyl-4-(3-piperidin-1-yl-propoxy)-phenyl]-pyridin-2-yl-amine, 6-[2,6-dimethyl-4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-pyridin-2-yl-amine, 6-{2,6-dimethyl-4-[3-(4-methyl-piperazin-1-yl)-propoxy]-phenyl}-pyridin-2-yl-amine, 6-[2,6-dimethyl-4-(2-morpholin-4-yl-ethoxy)-phenyl]-pyridin-2-yl-amine, 6-{4-[2-(benzyl-methyl-amino)-ethoxy]-2,6-dimethyl-phenyl}-pyridin-2-yl-amine, 2-[4-(6-amino-pyridin-2-yl)-3,5-dimethyl-phenoxy]-acetam-ide 6-[4-(2-aminoethoxy)-2,6-dimethyl-phenyl]-pyridin-2-yl-amine, 6-[2-isopropyl-4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-pyridin-2-yl-amine, 2-(2,5-dimethyl-pyrrolidin-1-yl)-6-[2-isopropyl-4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-pyridine 6-{4-[2-(3,5-dimethyl-piperidin-1-yl)-ethoxy]-2-isopropyl-phenyl}-pyridin-2-yl-amine, 6-[4-(2-dimethylaminoethoxy)-2-isopropyl-phenyl]-pyridin-2-yl-amine, 6-[2-tert-butyl-4-(2-dimethylaminoethoxy)-phenyl]-pyridin-2-yl-amine, 6-[2-tert-butyl-4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-pyridin-2-yl-amine, 6-[4-(2-pyrrolidinyl-ethoxy)-2,5-dimethyl-phenyl]-pyridin-2-yl-amine, 6-[4-(2-dimethylaminoethoxy)-2,5-dimethyl-phenyl]-pyridin-2-yl-amine, 6-[4-(2-(4-phenethylpiperazin-1-yl)-ethoxy)-2,5-dimethyl-phenyl]-pyridin-2-yl-amine, 6-[2-cyclopropyl-4-(2-dimethylamino-1-methyl-ethoxy)-phenyl]-pyridin-2-yl-amine, 6-[cyclobutyl-4-(2-dimethylamino-1-methyl-ethoxy)-phenyl]-pyridin-2-yl-amine, 6-[4-(allyloxy)-2-cyclobutyl-phenyl]-pyridin-2-ylamine, 2-allyl-4-(6-amino-pyridin-2-yl)-3-cyclobutyl-phenol and 2-allyl-4-(6-amino-pyridin-2-yl)-5-cyclobutyl-phenol 4-(6-amino-pyridin-2-yl)-5-cyclobutyl-2-propyl-phenol 4-(6-amino-pyridin-2-yl)-3-cyclobutyl-2-propyl-phenol 6-[2-cyclobutyl-4-(2-dimethylamino-1-methyl-ethoxy)-5-propyl-phenyl]-pyridin-2-yl-amine, 6-[2-cyclobutyl-4-(2-dimethylamino-1-methyl-ethoxy)-3-propyl-phenyl]-pyridin-2-yl-amine, 6-[2-cyclobutyl-4-(2-dimethylaminoethoxy)-5-propyl-phenyl]-pyridin-2-yl-amine, 6-[2-cyclobutyl-4-(2-dimethylaminoethoxy)-3-propyl-phenyl]-pyridin-2-yl-amine, 6-[2-cyclobutyl-4-(1-

methyl-pyrroli-din-3-yl-oxy)-5-propyl-phenyl]-pyridin-2-yl-amine, 6-[cyclobutyl-4-(1-  
 methy-l-pyrrolidin-3-yl-oxy)-3-propyl-phenyl]-pyridin-2-yl-amine, 2-(4-benzyloxy-5-  
 hydroxy-2-methoxy-phenyl)-6-(2,5-dimethyl-pyrrol-1-yl)-p-yridine 6-[4-(2-  
 dimethylamino-ethoxy)-5-ethoxy-2-methoxy-phenyl]-pyridin-2-yl-amine, 6-[5-ethyl-2-  
 5 methoxy-4-(1-methyl-piperidin-4-yl-oxy)-phenyl]-pyr-idin-2-yl-amine, 6-[5-ethyl-2-  
 methoxy-4-(piperidin-4-yl-oxy)-phenyl]-pyridi-n-2-yl-amine, 6-[2,5-dimethoxy-4-(1-  
 methyl-pyrrolidin-3-yl-oxy)-phenyl]-pyr-idin-2-yl-amine, 6-[4-(2-dimethylamino-ethoxy)-  
 5-ethyl-2-methoxy-phenyl]-py-ridin-2-yl-amine.

Exemplary NMDA receptor antagonist include (+)-(1*S*, 2*S*)-1-(4-hydroxy-phenyl)-  
2-(4-hydroxy-4-phenylpiperidino)-1-propanol, (1*S*, 2*S*)-1-(4-hydroxy-3-methoxyphenyl)-  
2-(4-hydroxy-4-phenylpiperidino)-1-propanol, (3*R*, 4*S*)-3-(4-(4-fluorophenyl)-4-  
hydroxypiperidin-1-yl)-chroman-4,7-diol, (1*R*<sup>\*</sup>, 2*R*<sup>\*</sup>)-1-(4-hydroxy-3-methylphenyl)-2-  
(4-(4-fluoro-phenyl)-4-hydroxypiperidin-1-yl)-propan-1-ol-mesylate or a pharmaceutically  
acceptable acid addition salt thereof.

Exemplary dopamine agonist include ropinirole; L-dopa decarboxylase inhibitorss  
such as carbidopa or benserazide, bromocriptine, dihydroergocryptine, etisulergine, AF-14,  
alaptide, pergolide, piribedil; dopamine D1 receptor agonists such as A-68939, A-77636,  
dihydrexine, and SKF-38393; dopamine D2 receptor agonists such as carbergoline, lisuride,  
N-0434, naxagolide, PD-118440, pramipexole, quinpirole and ropinirole; dopamine/ $\beta$ -  
adrenergic receptor agonists such as DPDMS and dopexamine; dopamine/5-HT uptake  
inhibitor/5-HT-1A agonists such as roxindole; dopamine/opiate receptor agonists such as  
NIH-10494;  $\alpha$ 2-adrenergic antagonist/dopamine agonists such as terguride;  $\alpha$ 2-adrenergic  
antagonist/dopamine D2 agonists such as ergolines and talipexole; dopamine uptake  
inhibitors such as GBR-12909, GBR-13069, GYKI-52895, and NS-2141; monoamine  
oxidase-B inhibitors such as selegiline, N-(2-butyl)-N-methylpropargylamine, N-methyl-N-  
(2-pentyl)propargylamine, AGN-1133, ergot derivatives, lazabemide, LU-53439, MD-  
280040 and mofegiline; and COMT inhibitors such as CGP-28014.

Exemplary acetyl cholinesterase inhibitors include donepezil, 1-(2-methyl-1H-benzimidazol-5-yl)-3-[1-(phenylmethyl)-4-piperidinyl]-1-propanone; 1-(2-phenyl-1H-benzimidazol-5-yl)-3-[1-(phenylmethyl)-4-piperidinyl]-1-pr-ovanone; 1-(1-ethyl-2-methyl-1H-benzimidazol-5-yl)-3-[1-(phenylmethyl)-4-piperidinyl]-1-propanone; 1-(2-methyl-6-benzothiazolyl)-3-[1-(phenylmethyl)-4-piperidinyl]-1-propanone; 1-(2-methyl-6-benzothiazolyl)-3-[1-[(2-methyl-4-thiazolyl)methyl]-4-piperidinyl]-1-propanone; 1-(5-

methyl-benzo[b]thie-n-2-yl)-3-[1-(phenylmethyl)4-piperidinyl]-1-propanone; 1-(6-methylbenzo[b]thien-2-yl)-3-[1-(phenylmethyl)-4-piperidinyl]-1-prop-anone; 1-(3,5-dimethylbenzo[b]thien-2-yl)-3-[1-(phenylmethyl)-4-piperidin-yl]-1-propanone; 1-(benzo[b]thien-2-yl)-3-[1-(phenylmethyl)-4-piperidinyl]-1-propanone; 1-(benzofuran-2-yl)-3-[1-(phenylmethyl)-4-piperidinyl]-1-propanone; 1-(1-phenylsulfonyl-6-methyl-indol-2-yl)-3-[1-(phenylmethyl)-4-piperidinyl]-1-propanone; 1-(6-methyl-indol-2-yl)-3-[1-(phenylmethyl)-4-piperidinyl]-1-propanone; 1-(1-phenylsulfonyl-5-amino-indol-2-yl)-3-[1-(phenylmethyl)-4-piperidinyl]-1-propanone; 1-(5-amino-indol-2-yl)-3-[1-(phenylmethyl)-4-piperidinyl]-1-propanone; and 1-(5-acetylamino-indol-2-yl)-3-[1-(phenylmethyl)-4-piperidinyl]-1-propanone. 1-(6-quinolyl)-3-[1-(phenylmethyl)-4-piperidinyl]-1-propanone; 1-(5-indolyl)-3-[1-(phenylmethyl)-4-piperidinyl]-1-propanone; 1-(5-benzthienyl)-3-[1-(phenylmethyl)-4-piperidinyl]-1-propanone; 1-(6-quinazolyl)-3-[1-(phenylmethyl)-4-piperidinyl]-1-propanone; 1-(6-benzoxazolyl)-3-[1-(phenylmethyl)-4-piperidinyl]-1-propanone; 1-(5-benzofuranyl)-3-[1-(phenylmethyl)-4-piperidinyl]-1-propanone; 1-(5-methyl-benzimidazol-2-yl)-3-[1-(phenylmethyl)-4-piperidinyl]-1-propa-none; 1-(6-methyl-benzimidazol-2-yl)-3-[1-(phenylmethyl)-4-piperidinyl]-1-propanone; 1-(5-chloro-benzo[b]thien-2-yl)-3-[1-(phenylmethyl)-4-piperidin-yl]-1-propanone; 1-(5-azaindol-2-yl)-3-[1-(phenylmethyl)4-piperidinyl]-1-p-ropanone; 1-(6-azabenzo[b]thien-2-yl)-3-[1-(phenylmethyl)-4-piperidinyl]-1-propanone; 1-(1H-2-oxo-pyrrolo[2',3',5,6]benzo[b]thieno-2-yl)-3-[1-(phenylmethyl)-4-piperidinyl]-1-propanone; 1-(6-methyl-benzothiazol-2-yl)-3-[1-(phenylmethyl)-4-piperidinyl]-1-propanone; 1-(6-methoxy-indol-2-yl)-3-[1-(phenylmethyl)-4-piperidinyl]-1-propanone; 1-(6-methoxy-benzo[b]thien-2-yl)-3-[1-(phenylmethyl)-4-piperidinyl]-1-propanone; 1-(6-acetylamino-benzo[b]thien-2-yl)-3-[1-(phenylmethyl)-4-piperidinyl]-1-propanone; 1-(5-acetylamino-benzo[b]thien-2-yl)-3-[1-(phenylmethyl)-4-piperidinyl]-1-propanone; 6-hydroxy-3-[2-[1-(phenylmethyl)-4-piperidin-yl]ethyl]-1,2-benzisoxazole; 5-methyl-3-[2-[1-(phenylmethyl)-4-piperidinyl]-ethyl]-1,2-benzisoxazole; 6-methoxy-3[2-[1(phenylmethyl)-4-piperidinyl]ethyl]-1,2-benzisoxazole; 6-acetamide-3-[2-[1-(phenylmethyl)-4-piperidinyl]-ethyl]-1,2-benzisoxazole; 6-benzisoxazole; 6-amino-3-[2-[1-(phenylmethyl)-4-piperidinyl]ethyl]-1,2-benzisoxazole; 6-(4-morpholinyl)-3-[2-[1-(phenylmethyl)-4-piperidin-yl]ethyl]-1,2-benzisoxazole; 5,7-dihydro-3-[2-[1-(phenylmethyl)-4-piperidi-nyl]ethyl]-6H-pyrrolo[4,5-f]-1,2-benzisoxazol-6-one; 3-[2-[1-(phenylmethyl)-4-piperidinyl]ethyl]-1,2-benzisothiazole; 3-[2-[1-(phenylmethyl)-4-piperidinyl]ethenyl]-1,2-benzisoxazole; 6-phenylamino-3-[2-[1-

(phenylmethyl)-4-piperidinyl]ethyl]-1,2,-benzisoxaz-ole; 6-(2-thiazoly)-3-[2-[1-  
 (phenylmethyl)-4-piperidinyl]ethyl]-1,2-benzis-oxazole; 6-(2-oxazolyl)-3-[2-[1-  
 (phenylmethyl)-4-piperidinyl]ethyl]-1,2-be-nzisoxazole; 6-pyrrolidinyl-3-[2-[1-  
 (phenylmethyl)-4-piperidinyl]ethyl]-1,-2-benzisoxazole; 5,7-dihydro-5,5-dimethyl-3-[2-[1-  
 5 (phenylmethyl)-4-piperid-iny1]ethyl]-6H-pyrrolo[4,5-f]-1,2-benzisoxazole-6-one; 6,8-  
 dihydro-3-[2-[1-(phenylmethyl)-4-piperidinyl]ethyl]-7H-pyrrolo[5,4-g]-1,2-benzisoxazole-  
 7-one; 3-[2-[1-(phenylmethyl)-4-piperidinyl]ethyl]-5,6,-8-trihydro-7H-isoxazolo[4,5-g]-  
 quinolin-7-one; 1-benzyl-4-((5,6-dimethoxy-1-indanon)-2-yl)methylpiperidine, 1-benzyl-4-  
 ((5,6-dimethoxy-1-indanon)-2-ylidenyl)methylpiperidine, 1-benzyl-4-((5-methoxy-1-  
 10 indanon)-2-yl)methylp-iperidine, 1-benzyl-4-((5,6-diethoxy-1-indanon)-2-  
 yl)methylpiperidine, 1-benzyl-4-((5,6-methylenedioxy-1-indanon)-2-yl)methylpiperidine,  
 1-(m-nitrobenzyl)-4-((5,6-dimethoxy-1-indanon)-2-yl)methylpiperidine, 1-  
 cyclohexymethyl-4-((5,6-dimethoxy-1-indanon)-2-yl)methylpiperidine, 1-(m-florobenzyl)-  
 15 4-((5,6-dimethoxy-1-indanon)-2-yl)methylpiperidine, 1-benzyl-4-((5,6-dimethoxy-1-  
 indanon)-2-yl)propylpiperidine, and 1-benzyl-4-((5-isopropoxy-6-methoxy-1-indanon)-2-  
 yl)methylpiperidine.

Exemplary calcium channel antagonists include diltiazem, omega-conotoxin GVIA, methoxyverapamil, amlodipine, felodipine, lacidipine, and mibefradil.

Exemplary GABA-A receptor modulators include clomethiazole; IDDB; gaboxadol  
 20 (4,5,6,7-tetrahydroisoxazolo[5,4-c]pyridin-3-ol); ganaxolone (3.alpha.-hydroxy-3.beta.-  
 methyl-5.alpha.-pregnan-20-one); fengabine (2-[(butylimino)-(2-chlorophenyl)methyl]-4-  
 chlorophenol); 2-(4-methoxyphenyl)-2,5,6,7,8,9-hexahydro-pyrazolo[4,3-c]cinnolin-3-one;  
 7-cyclobutyl-6-(2-methyl-2H-1,2,4-triazol-3-ylmethoxy)-3-phenyl-1,2,4-triazolo[4,3-  
 b]pyridazine; (3-fluoro-4-methylphenyl)-N-({-1-[(2-methylphenyl)methyl]-benzimidazol-  
 25 2-yl} methyl)-N-pentylcarboxamide; and 3-(aminomethyl)-5-methylhexanoic acid.

Exemplary potassium channel openers include diazoxide, flupirtine, pinacidil, levcromakalim, rilmakalim, chromakalim, PCO-400 and SKP-450 (2-[2"(1", 3"-  
 dioxolone)-2-methyl]-4-(2'-oxo-1'-pyrrolidinyl)-6-nitro-2H-1-benzopyra-n).

Exemplary AMPA/kainate receptor antagonists include 6-cyano-7-nitroquinoxalin-  
 30 2,3-di-one (CNQX); 6-nitro-7-sulphamoylbenzo[f]quinoxaline-2,3-dione (NBQX); 6,7-  
 dinitroquinoxaline-2,3-dione (DNQX); 1-(4-aminophenyl)-4-methyl-7,8-m-ethylenedioxy-  
 5H-2,3-benzodiazepine hydrochloride; and 2,3-dihydroxy-6-nitro-7-sulfamoylbenzo-  
 [f]quinoxaline.

Exemplary sodium channel antagonists include ajmaline, procainamide, flecainide and riluzole.

Exemplary matrix-metalloprotease inhibitors include 4-[4-(4-fluorophenoxy)benzenesulfon-ylamino]tetrahydropyran-4-carboxylic acid hydroxyamide; 5-Methyl-5-(4-(4'-fluorophenoxy)-phenoxy)-pyrimidine-2,4,6-trione; 5-n-Butyl-5-(4-(4'-fluorophenoxy)-phenoxy)-pyrimidine-2,4,6-trione and prinomistat.

Exemplary inhibitors of p38 MAP kinase and c-jun-N-terminal kinases include pyridyl imidazoles, such as PD 169316, isomeric PD 169316, SB 203580, SB 202190, SB 220026, and RWJ 67657. Others are described in US Patent 6,288,089, and incorporated by reference herein.

In an exemplary embodiment, a combination therapy for treating or preventing MS comprises a therapeutically effective amount of one or more sirtuin activating compounds and one or more of Avonex® (interferon beta-1a), Tysabri® (natalizumab), or Fumaderm® (BG-12/Oral Fumarate).

In another embodiment, a combination therapy for treating or preventing diabetic neuropathy or conditions associated therewith comprises a therapeutically effective amount of one or more sirtuin activating compounds and one or more of tricyclic antidepressants (TCAs) (including, for example, imipramine, amitriptyline, desipramine and nortriptyline), serotonin reuptake inhibitors (SSRIs) (including, for example, fluoxetine, paroxetine, sertralene, and citalopram) and antiepileptic drugs (AEDs) (including, for example, gabapentin, carbamazepine, and topiramate).

### ***Blood Coagulation Disorders***

In other aspects, the sirtuin-activating compounds described herein can be used to treat or prevent blood coagulation disorders (or hemostatic disorders). As used interchangeably herein, the terms "hemostasis", "blood coagulation," and "blood clotting" refer to the control of bleeding, including the physiological properties of vasoconstriction and coagulation. Blood coagulation assists in maintaining the integrity of mammalian circulation after injury, inflammation, disease, congenital defect, dysfunction or other disruption. After initiation of clotting, blood coagulation proceeds through the sequential activation of certain plasma proenzymes to their enzyme forms (see, for example, Coleman, R. W. et al. (eds.) *Hemostasis and Thrombosis, Second Edition*, (1987)). These plasma glycoproteins, including Factor XII, Factor XI, Factor IX, Factor X, Factor VII, and prothrombin, are zymogens of serine proteases. Most of these blood clotting enzymes are

effective on a physiological scale only when assembled in complexes on membrane surfaces with protein cofactors such as Factor VIII and Factor V. Other blood factors modulate and localize clot formation, or dissolve blood clots. Activated protein C is a specific enzyme that inactivates procoagulant components. Calcium ions are involved in many of the component reactions. Blood coagulation follows either the intrinsic pathway, where all of the protein components are present in blood, or the extrinsic pathway, where the cell-membrane protein tissue factor plays a critical role. Clot formation occurs when fibrinogen is cleaved by thrombin to form fibrin. Blood clots are composed of activated platelets and fibrin.

Further, the formation of blood clots does not only limit bleeding in case of an injury (hemostasis), but may lead to serious organ damage and death in the context of atherosclerotic diseases by occlusion of an important artery or vein. Thrombosis is thus blood clot formation at the wrong time and place. It involves a cascade of complicated and regulated biochemical reactions between circulating blood proteins (coagulation factors), blood cells (in particular platelets), and elements of an injured vessel wall.

Accordingly, the present invention provides anticoagulation and antithrombotic treatments aiming at inhibiting the formation of blood clots in order to prevent or treat blood coagulation disorders, such as myocardial infarction, stroke, loss of a limb by peripheral artery disease or pulmonary embolism.

As used interchangeably herein, “modulating or modulation of hemostasis” and “regulating or regulation of hemostasis” includes the induction (e.g., stimulation or increase) of hemostasis, as well as the inhibition (e.g., reduction or decrease) of hemostasis.

In one aspect of the invention, the invention provides a method for reducing or inhibiting hemostasis in a subject by administering a sirtuin-activating compound. The compositions and methods disclosed herein are useful for the treatment or prevention of thrombotic disorders. As used herein, the term “thrombotic disorder” includes any disorder or condition characterized by excessive or unwanted coagulation or hemostatic activity, or a hypercoagulable state. Thrombotic disorders include diseases or disorders involving platelet adhesion and thrombus formation, and may manifest as an increased propensity to form thromboses, e.g., an increased number of thromboses, thrombosis at an early age, a familial tendency towards thrombosis, and thrombosis at unusual sites. Examples of thrombotic disorders include, but are not limited to, thromboembolism, deep vein thrombosis, pulmonary embolism, stroke, myocardial infarction, miscarriage,

thrombophilia associated with anti-thrombin III deficiency, protein C deficiency, protein S deficiency, resistance to activated protein C, dysfibrinogenemia, fibrinolytic disorders, homocystinuria, pregnancy, inflammatory disorders, myeloproliferative disorders, arteriosclerosis, angina, e.g., unstable angina, disseminated intravascular coagulation,  
5 thrombotic thrombocytopenic purpura, cancer metastasis, sickle cell disease, glomerular nephritis, and drug induced thrombocytopenia (including, for example, heparin induced thrombocytopenia). In addition, the subject sirtuin-activating compounds are administered to prevent thrombotic events or to prevent re-occlusion during or after therapeutic clot lysis or procedures such as angioplasty or surgery.

10 In another embodiment, a combination drug regimen may include drugs or compounds for the treatment or prevention of blood coagulation disorders or secondary conditions associated with these conditions. Thus, a combination drug regimen may include one or more sirtuin-activating compounds and one or more anti-coagulation or anti-thrombosis agents. For example, one or more sirtuin-activating compounds can be  
15 combined with an effective amount of one or more of: aspirin, heparin, and oral Warfarin that inhibits Vit K-dependent factors, low molecular weight heparins that inhibit factors X and II, thrombin inhibitors, inhibitors of platelet GP IIbIIIa receptors, inhibitors of tissue factor (TF), inhibitors of human von Willebrand factor, inhibitors of one or more factors involved in hemostasis (in particular in the coagulation cascade). In addition, sirtuin-  
20 activating compounds can be combined with thrombolytic agents, such as t-PA, streptokinase, retilase, TNK-t-PA, and staphylokinase.

### *Obesity*

In another aspect, sirtuin-activating compounds may be used for treating or preventing weight gain or obesity in a subject. For example, sirtuin-activating compounds  
25 may be used, for example, to treat or prevent hereditary obesity, dietary obesity, hormone related obesity, obesity related to the administration of medication, to reduce the weight of a subject, or to reduce or prevent weight gain in a subject. A subject in need of such a treatment may be a subject who is obese, likely to become obese, overweight, or likely to become overweight. Subjects who are likely to become obese or overweight can be  
30 identified, for example, based on family history, genetics, diet, activity level, medication intake, or various combinations thereof.

In yet other embodiments, sirtuin-activating compounds may be administered to subjects suffering from a variety of other diseases and conditions that may be treated or

prevented by promoting weight loss in the subject. Such diseases include, for example, high blood pressure, hypertension, high blood cholesterol, dyslipidemia, type 2 diabetes, insulin resistance, glucose intolerance, hyperinsulinemia, coronary heart disease, angina pectoris, congestive heart failure, stroke, gallstones, cholecystitis and cholelithiasis, gout, 5 osteoarthritis, obstructive sleep apnea and respiratory problems, some types of cancer (such as endometrial, breast, prostate, and colon), complications of pregnancy, poor female reproductive health (such as menstrual irregularities, infertility, irregular ovulation), bladder control problems (such as stress incontinence); uric acid nephrolithiasis; psychological disorders (such as depression, eating disorders, distorted body image, and 10 low self esteem). Stunkard AJ, Wadden TA. (Editors) *Obesity: theory and therapy*, Second Edition. New York: Raven Press, 1993. Finally, patients with AIDS can develop lipodystrophy or insulin resistance in response to combination therapies for AIDS.

In another embodiment, a sirtuin-activating compound may be used for inhibiting adipogenesis or fat cell differentiation, whether *in vitro* or *in vivo*. In particular, high 15 circulating levels of insulin and/or insulin like growth factor (IGF) 1 will be prevented from recruiting preadipocytes to differentiate into adipocytes. Such methods may be used for treating or preventing obesity.

In other embodiments, a sirtuin-activating compound may be used for reducing appetite and/or increasing satiety, thereby causing weight loss or avoidance of weight gain. 20 A subject in need of such a treatment may be a subject who is overweight, obese or a subject likely to become overweight or obese. The method may comprise administering daily or, every other day, or once a week, a dose, e.g., in the form of a pill, to a subject. The dose may be an "appetite reducing dose."

A method may further comprise monitoring the weight of the subject and/or the 25 level of activation of sirtuins, for example, in adipose tissue.

In an exemplary embodiment, a sirtuin-activating compound may be administered as a combination therapy for treating or preventing weight gain or obesity. For example, one or more sirtuin-activating compounds may be administered in combination with one or more anti-obesity agents. Exemplary anti-obesity agents include, for example, 30 phenylpropanolamine, ephedrine, pseudoephedrine, phentermine, a cholecystokinin-A agonist, a monoamine reuptake inhibitor (such as sibutramine), a sympathomimetic agent, a serotonergic agent (such as dexfenfluramine or fenfluramine), a dopamine agonist (such as bromocriptine), a melanocyte-stimulating hormone receptor agonist or mimetic, a

melanocyte-stimulating hormone analog, a cannabinoid receptor antagonist, a melanin concentrating hormone antagonist, the OB protein (leptin), a leptin analog, a leptin receptor agonist, a galanin antagonist or a GI lipase inhibitor or decreaser (such as orlistat). Other anorectic agents include bombesin agonists, dehydroepiandrosterone or analogs thereof, 5 glucocorticoid receptor agonists and antagonists, orexin receptor antagonists, urocortin binding protein antagonists, agonists of the glucagon-like peptide-1 receptor such as Exendin and ciliary neurotrophic factors such as Axokine.

In another embodiment, a sirtuin-activating compound may be administered to reduce drug-induced weight gain. For example, a sirtuin activating compound may be 10 administered as a combination therapy with medications that may stimulate appetite or cause weight gain, in particular, weight gain due to factors other than water retention. Examples of medications that may cause weight gain, include for example, diabetes treatments, including, for example, sulfonylureas (such as glipizide and glyburide), thiazolidinediones (such as pioglitazone and rosiglitazone), meglitinides, nateglinide, 15 repaglinide, sulphonylurea medicines, and insulin; anti-depressants, including, for example, tricyclic antidepressants (such as amitriptyline and imipramine), irreversible monoamine oxidase inhibitors (MAOIs), selective serotonin reuptake inhibitors (SSRIs), bupropion, paroxetine, and mirtazapine; steroids, such as, for example, prednisone; hormone therapy; lithium carbonate; valproic acid; carbamazepine; chlorpromazine; thiothixene; beta 20 blockers (such as propranolol); alpha blockers (such as clonidine, prazosin and terazosin); and contraceptives including oral contraceptives (birth control pills) or other contraceptives containing estrogen and/or progesterone (Depo-Provera, Norplant, Ortho), testosterone or Megestrol. In another exemplary embodiment, sirtuin-activating compounds may be administered as part of a smoking cessation program to prevent weight gain or reduce 25 weight already gained.

#### ***Metabolic Disorders/Diabetes***

In another aspect, sirtuin-activating compounds may be used for treating or preventing a metabolic disorder, such as insulin-resistance, a pre-diabetic state, type II diabetes, and/or complications thereof. Administration of a sirtuin-activating compound 30 may increase insulin sensitivity and/or decrease insulin levels in a subject. A subject in need of such a treatment may be a subject who has insulin resistance or other precursor symptom of type II diabetes, who has type II diabetes, or who is likely to develop any of these conditions. For example, the subject may be a subject having insulin resistance, e.g.,

having high circulating levels of insulin and/or associated conditions, such as hyperlipidemia, dyslipogenesis, hypercholesterolemia, impaired glucose tolerance, high blood glucose sugar level, other manifestations of syndrome X, hypertension, atherosclerosis and lipodystrophy.

5 In an exemplary embodiment, a sirtuin-activating compound may be administered as a combination therapy for treating or preventing a metabolic disorder. For example, one or more sirtuin-activating compounds may be administered in combination with one or more anti-diabetic agents. Exemplary anti-diabetic agents include, for example, an aldose reductase inhibitor, a glycogen phosphorylase inhibitor, a sorbitol dehydrogenase inhibitor,  
10 a protein tyrosine phosphatase 1B inhibitor, a dipeptidyl protease inhibitor, insulin (including orally bioavailable insulin preparations), an insulin mimetic, metformin, acarbose, a peroxisome proliferator-activated receptor- $\gamma$  (PPAR- $\gamma$ ) ligand such as troglitazone, rosiglitazone, pioglitazone or GW-1929, a sulfonylurea, glipizide, glyburide, or chlorpropamide wherein the amounts of the first and second compounds result in a  
15 therapeutic effect. Other compoundsanti-diabetic agents include a glucosidase inhibitor, a glucagon-like peptide-1 (GLP-1), insulin, a PPAR  $\alpha/\gamma$  dual agonist, a meglitinide and an  $\alpha$ P2 inhibitor. In an exemplary embodiment, an anti-diabetic agent may be a dipeptidyl peptidase IV (DP-IV or DPP-IV) inhibitor, such as, for example LAF237 from Novartis (NVP DPP728; 1-[[[2-[(5-cyanopyridin-2-yl)amino] ethyl]amino]acetyl]-2- cyano-(S)-  
20 pyrrolidine) or MK-04301 from Merck (see e.g., Hughes et al., Biochemistry 38: 11597-603 (1999)).

### ***Inflammatory Diseases***

25 In other aspects, the sirtuin-activating compounds described herein can be used to treat or prevent a disease or disorder associated with inflammation. Sirtuin-activating compounds may be administered prior to the onset of, at, or after the initiation of inflammation. When used prophylactically, the compounds are preferably provided in advance of any inflammatory response or symptom. Administration of the compounds may prevent or attenuate inflammatory responses or symptoms.

Exemplary inflammatory conditions include, for example, multiple sclerosis,  
30 rheumatoid arthritis, psoriatic arthritis, degenerative joint disease, spondyloarthropathies, gouty arthritis, systemic lupus erythematosus, juvenile arthritis, rheumatoid arthritis, osteoarthritis, osteoporosis, diabetes (e.g., insulin dependent diabetes mellitus or juvenile onset diabetes), menstrual cramps, cystic fibrosis, inflammatory bowel disease, irritable

bowel syndrome, Crohn's disease, mucous colitis, ulcerative colitis, gastritis, esophagitis, pancreatitis, peritonitis, Alzheimer's disease, shock, ankylosing spondylitis, gastritis, conjunctivitis, pancreatitis (acute or chronic), multiple organ injury syndrome (e.g., secondary to septicemia or trauma), myocardial infarction, atherosclerosis, stroke, 5 reperfusion injury (e.g., due to cardiopulmonary bypass or kidney dialysis), acute glomerulonephritis, vasculitis, thermal injury (i.e., sunburn), necrotizing enterocolitis, granulocyte transfusion associated syndrome, and/or Sjogren's syndrome. Exemplary inflammatory conditions of the skin include, for example, eczema, atopic dermatitis, contact dermatitis, urticaria, scleroderma, psoriasis, and dermatosis with acute 10 inflammatory components.

In another embodiment, a sirtuin-activating compound may be used to treat or prevent allergies and respiratory conditions, including asthma, bronchitis, pulmonary fibrosis, allergic rhinitis, oxygen toxicity, emphysema, chronic bronchitis, acute respiratory distress syndrome, and any chronic obstructive pulmonary disease (COPD). 15 The compounds may be used to treat chronic hepatitis infection, including hepatitis B and hepatitis C.

Additionally, a sirtuin-activating compound may be used to treat autoimmune diseases and/or inflammation associated with autoimmune diseases such as organ-tissue autoimmune diseases (e.g., Raynaud's syndrome), scleroderma, myasthenia gravis, 20 transplant rejection, endotoxin shock, sepsis, psoriasis, eczema, dermatitis, multiple sclerosis, autoimmune thyroiditis, uveitis, systemic lupus erythematosus, Addison's disease, autoimmune polyglandular disease (also known as autoimmune polyglandular syndrome), and Grave's disease.

In certain embodiments, one or more sirtuin-activating compounds described 25 herein may be taken alone or in combination with other compounds useful for treating or preventing inflammation. Exemplary anti-inflammatory agents include, for example, steroids (e.g., cortisol, cortisone, fludrocortisone, prednisone, 6.alpha.-methylprednisone, triamcinolone, betamethasone or dexamethasone), nonsteroidal antiinflammatory drugs (NSAIDS (e.g., aspirin, acetaminophen, tolmetin, ibuprofen, mefenamic acid, piroxicam, nabumetone, rofecoxib, celecoxib, etodolac or nimesulide). In another embodiment, the 30 other therapeutic agent is an antibiotic (e.g., vancomycin, penicillin, amoxicillin, ampicillin, cefotaxime, ceftriaxone, cefixime, rifampin/metronidazole, doxycycline or streptomycin). In another embodiment, the other therapeutic agent is a PDE4 inhibitor

(e.g., roflumilast or rolipram). In another embodiment, the other therapeutic agent is an antihistamine (e.g., cyclizine, hydroxyzine, promethazine or diphenhydramine). In another embodiment, the other therapeutic agent is an anti-malarial (e.g., artemisinin, artemether, artsunate, chloroquine phosphate, mefloquine hydrochloride, doxycycline hyolate, proguanil hydrochloride, atovaquone or halofantrine). In one embodiment, the other therapeutic agent is drotrecogin alfa.

Further examples of anit-inflammatory agents include, for example, aceclofenac, acemetacin, e-acetamidocaproic acid, acetaminophen, acetaminosalol, acetanilide, acetylsalicylic acid, S-adenosylmethionine, alclofenac, alclometasone, alfentanil, algestone, allylprodine, alminoprofen, aloxiaprin, alphaprodine, aluminum bis(acetylsalicylate), amcinonide, amfenac, aminochlorthenoxazin, 3-amino-4-hydroxybutyric acid, 2-amino-4-picoline, aminopropylon, aminopyrine, amixetrine, ammonium salicylate, ampiroxicam, amtolmetin guacil, anileridine, antipyrine, antrafenine, apazone, beclomethasone, bendazac, benorylate, benoxaprofen, benzpiperylon, benzydamine, benzylmorphine, bermoprofen, betamethasone, betamethasone-17-valerate, bezitramide, .alpha.-bisabolol, bromfenac, p-bromoacetanilide, 5-bromosalicylic acid acetate, bromosaligenin, bucetin, bucloxic acid, bucolome, budesonide, bufexamac, bumadizon, buprenorphine, butacetin, butibufen, butorphanol, carbamazepine, carbiphene, carprofen, carsalam, chlorobutanol, chloroprednisone, chlorthenoxazin, choline salicylate, cinchophen, cinmetacin, ciramadol, clidanac, clobetasol, clocortolone, clometacin, clonitazene, clonixin, clopirac, cloprednol, clove, codeine, codeine methyl bromide, codeine phosphate, codeine sulfate, cortisone, cortivazol, cropropamide, crotethamide, cyclazocene, deflazacort, dehydrotestosterone, desomorphine, desonide, desoximetasone, dexamethasone, dexamethasone-21-isonicotinate, dexoxadrol, dextromoramide, dextropropoxyphene, deoxycorticosterone, dezocine, diamprodime, diamorphone, diclofenac, difenamizole, difenpiramide, diflorasone, diflucortolone, diflunisal, difluprednate, dihydrocodeine, dihydrocodeinone enol acetate, dihydromorphine, dihydroxyaluminum acetylsalicylate, dimenoxadol, dimepheptanol, dimethylthiambutene, dioxaphetyl butyrate, dipipanone, diprocetyl, dipyrone, ditazol, droxicam, emorfazole, enfenamic acid, enoxolone, epirizole, eptazocene, etersalate, ethenzamide, ethoheptazine, ethoxazene, ethylmethylthiambutene, ethylmorphine, etodolac, etofenamate, etonitazene, eugenol, felbinac, fenbufen, fenclozic acid, fendosal, fenoprofen, fentanyl, fentiazac, fepradinol, feprazone, floctafenine,

fluazacort, flucloronide, flufenamic acid, flumethasone, flunisolide, flunixin,  
flunoxaprofen, fluocinolone acetonide, fluocinonide, fluocinolone acetonide, fluocortin  
butyl, fluocortolone, fluoresone, fluorometholone, fluperolone, flupirtine, fluprednidene,  
5 fluprednisolone, fluproquazone, flurandrenolide, flurbiprofen, fluticasone, formocortal,  
fosfosal, gentisic acid, glafenine, glucametacin, glycol salicylate, guaiazulene, halcinonide,  
halobetasol, halometasone, haloprednone, heroin, hydrocodone, hydrocortamate,  
hydrocortisone, hydrocortisone acetate, hydrocortisone succinate, hydrocortisone  
hemisuccinate, hydrocortisone 21-lysinate, hydrocortisone cypionate, hydromorphone,  
hydroxypethidine, ibufenac, ibuprofen, ibuproxam, imidazole salicylate, indomethacin,  
10 indoprofen, isofezolac, isoflupredone, isoflupredone acetate, isoladol, isomethadone,  
isonixin, isoxepac, isoxicam, ketobemidone, ketoprofen, ketorolac, p-lactophenetide,  
lefatamine, levallorphan, levorphanol, levophenacyl-morphan, lofentanil, lonazolac,  
lornoxicam, loxoprofen, lysine acetylsalicylate, mazipredone, meclofenamic acid,  
medrysone, mefenamic acid, meloxicam, meperidine, meprednisone, meptazinol,  
15 mesalamine, metazocine, methadone, methotriimeprazine, methylprednisolone,  
methylprednisolone acetate, methylprednisolone sodium succinate, methylprednisolone  
suleptnate, metiazinic acid, metofoline, metopon, mofebutazone, mofezolac, mometasone,  
morazone, morphine, morphine hydrochloride, morphine sulfate, morpholine salicylate,  
myrophine, nabumetone, nalbuphine, nalorphine, 1-naphthyl salicylate, naproxen,  
narceine, nefopam, nicomorphine, nifenazone, niflumic acid, nimesulide, 5'-nitro-2'-  
20 propoxyacetanilide, norlevorphanol, normethadone, normorphine, norpipanone, olsalazine,  
opium, oxaceprol, oxametacine, oxaprozin, oxycodone, oxymorphone, oxyphenbutazone,  
papaveretum, paramethasone, paranyline, parsalmide, pentazocine, perisoxal, phenacetin,  
phenadoxone, phenazocine, phenazopyridine hydrochloride, phenocoll, phenoperidine,  
25 phenopyrazone, phenomorphan, phenyl acetylsalicylate, phenylbutazone, phenyl  
salicylate, phenyramidol, piketoprofen, piminodine, pipebuzone, piperylone, pirazolac,  
piritramide, piroxicam, pirprofen, pranoprofen, prednicarbate, prednisolone, prednisone,  
prednival, prednylidene, proglumetacin, proheptazine, promedol, propacetamol,  
properidine, propiram, propoxyphene, propyphenazone, proquazone, protizinic acid,  
30 proxazole, ramifenazone, remifentanil, rimazolium metilsulfate, salacetamide, salicin,  
salicylamide, salicylamide o-acetic acid, salicylic acid, salicylsulfuric acid, salsalate,  
salverine, simetride, sufentanil, sulfasalazine, sulindac, superoxide dismutase, suprofen,  
suxibuzone, talniflumate, tenidap, tenoxicam, terofenamate, tetrandrine,

thiazolinobutazone, tiaprofenic acid, tiaramide, tilidine, tinordine, tixocortol, tolfenamic acid, tolmetin, tramadol, triamcinolone, triamcinolone acetonide, tropesin, viminol, xenbucin, ximoprofen, zaltoprofen and zomepirac.

In an exemplary embodiment, a sirtuin-activating compound may be administered with a selective COX-2 inhibitor for treating or preventing inflammation. Exemplary selective COX-2 inhibitors include, for example, deracoxib, parecoxib, celecoxib, valdecoxib, rofecoxib, etoricoxib, lumiracoxib, 2-(3,5-difluorophenyl)-3-- [4-(methylsulfonyl)phenyl]-2-cyclopenten-1-one, (S)-6,8-dichloro-2-(trifluoromethyl)-2H-1-benzopyran-3-carboxylic acid, 2-(3,4-difluorophenyl)-4-(3-- hydroxy-3-methyl-1-butoxy)-5-[4-(methylsulfonyl)phenyl]-3-(2H)-pyridazinone, 4-[5-(4-fluorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide, tert-butyl 1 benzyl-4-[(4-oxopiperidin-1-yl)sulfonyl]piperidine-4-carboxylate, 4-[5-(phenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide, salts and prodrugs thereof.

### ***Flushing***

In another aspect, sirtuin-activating compounds may be used for reducing the incidence or severity of flushing and/or hot flashes which are symptoms of a disorder. For instance, the subject method includes the use of sirtuin-activating compounds, alone or in combination with other agents, for reducing incidence or severity of flushing and/or hot flashes in cancer patients. In other embodiments, the method provides for the use of sirtuin-activating compounds to reduce the incidence or severity of flushing and/or hot flashes in menopausal and post-menopausal woman.

In another aspect, a sirtuin-activating compound may be used as a therapy for reducing the incidence or severity of flushing and/or hot flashes which are side-effects of another drug therapy, e.g., drug-induced flushing. In certain embodiments, a method for treating and/or preventing drug-induced flushing comprises administering to a patient in need thereof a formulation comprising at least one flushing inducing compound and at least one sirtuin activating compound. In other embodiments, a method for treating drug induced flushing comprises separately administering one or more compounds that induce flushing and one or more sirtuin-activating compounds, e.g., wherein the sirtuin-activating compound and flushing inducing agent have not been formulated in the same compositions. When using separate formulations, the sirtuin-activating compound may be administered (1) at the same as administration of the flushing inducing agent, (2) intermittently with the flushing inducing agent, (3) staggered relative to administration of

the flushing inducing agent, (4) prior to administration of the flushing inducing agent, (5) subsequent to administration of the flushing inducing agent, and (6) various combination thereof. Exemplary flushing inducing agents include, for example, niacin, faloxifene, antidepressants, anti-psychotics, chemotherapeutics, calcium channel blockers, and  
5 antibiotics.

In one embodiment, a sirtuin-activating compound may be used to reduce flushing side effects of a vasodilator or an antilipemic agent (including anticholesteremic agents and lipotropic agents). In an exemplary embodiment, a sirtuin activating compound may be used to reduce flushing associated with the administration of niacin.

10 Nicotinic acid, 3-pyridinecarboxylic acid or niacin, is an antilipidemic agent that is marketed under, for example, the trade names Nicolar®, SloNiacin®, Nicobid® and Time Release Niacin®. Nicotinic acid has been used for many years in the treatment of lipidemic disorders such as hyperlipidemia, hypercholesterolemia and atherosclerosis. This compound has long been known to exhibit the beneficial effects of reducing total  
15 cholesterol, low density lipoproteins or "LDL cholesterol," triglycerides and apolipoprotein a (Lp(a)) in the human body, while increasing desirable high density lipoproteins or "HDL cholesterol".

Typical doses range from about 1 gram to about 3 grams daily. Nicotinic acid is normally administered two to four times per day after meals, depending upon the dosage  
20 form selected. Nicotinic acid is currently commercially available in two dosage forms. One dosage form is an immediate or rapid release tablet which should be administered three or four times per day. Immediate release ("IR") nicotinic acid formulations generally release nearly all of their nicotinic acid within about 30 to 60 minutes following ingestion. The other dosage form is a sustained release form which is suitable for administration two to  
25 four times per day. In contrast to IR formulations, sustained release ("SR") nicotinic acid formulations are designed to release significant quantities of drug for absorption into the blood stream over specific timed intervals in order to maintain therapeutic levels of nicotinic acid over an extended period such as 12 or 24 hours after ingestion.

As used herein, the term "nicotinic acid" is meant to encompass nicotinic acid or a  
30 compound other than nicotinic acid itself which the body metabolizes into nicotinic acid, thus producing essentially the same effect as nicotinic acid. Exemplary compounds that produce an effect similar to that of nicotinic acid include, for example, nicotinyl alcohol

tartrate, d-glucitol hexanicotinate, aluminum nicotinate, niceritrol and d,1-alpha-tocopheryl nicotinate. Each such compound will be collectively referred to herein as "nicotinic acid."

In another embodiment, the invention provides a method for treating and/or preventing hyperlipidemia with reduced flushing side effects. The method comprises the steps of administering to a subject in need thereof a therapeutically effective amount of nicotinic acid and a sirtuin-activating compound in an amount sufficient to reduce flushing. In an exemplary embodiment, the nicotinic acid and/or sirtuin-activating compound may be administered nocturnally.

In another representative embodiment, the method involves the use of sirtuin-activating compounds to reduce flushing side effects of raloxifene. Raloxifene acts like estrogen in certain places in the body, but is not a hormone. It helps prevent osteoporosis in women who have reached menopause. Osteoporosis causes bones to gradually grow thin, fragile, and more likely to break. Evista slows down the loss of bone mass that occurs with menopause, lowering the risk of spine fractures due to osteoporosis. A common side effect of raloxifene is hot flashes (sweating and flushing). This can be uncomfortable for women who already have hot flashes due to menopause.

In another representative embodiment, the method involves the use of sirtuin-activating compounds to reduce flushing side effects of antidepressants or anti-psychotic agent. For instance, the sirtuin-activating compound can be used in conjunction (administered separately or together) with a serotonin reuptake inhibitor, a 5HT2 receptor antagonist, an anticonvulsant, a norepinephrine reuptake inhibitor, an  $\alpha$ -adrenoreceptor antagonist, an NK-3 antagonist, an NK-1 receptor antagonist, a PDE4 inhibitor, an Neuropeptide Y5 Receptor Antagonists, a D4 receptor antagonist, a 5HT1A receptor antagonist, a 5HT1D receptor antagonist, a CRF antagonist, a monoamine oxidase inhibitor, or a sedative-hypnotic drug.

In certain embodiments, a sirtuin-activating compound may be used as part of a treatment with a serotonin reuptake inhibitor (SRI) to reduce flushing. In certain preferred embodiments, the SRI is a selective serotonin reuptake inhibitor (SSRI), such as a fluoxetinoid (fluoxetine, norfluoxetine) or a nefazodonoid (nefazodone, hydroxynefazodone, oxonefazodone). Other exemplary SSRI's include duloxetine, venlafaxine, milnacipran, citalopram, fluvoxamine, paroxetine and sertraline. The STAC can also be used as part of a treatment with sedative-hypnotic drug, such as selected from the group consisting of a benzodiazepine (such as alprazolam, chlordiazepoxide,

clonazepam, chlorazepate, clobazam, diazepam, halazepam, lorazepam, oxazepam and prazepam), zolpidem, and barbiturates. In still other embodiments, a sirtuin-activating compound may be used as part of a treatment with a 5-HT1A receptor partial agonist, such as selected from the group consisting of buspirone, flesinoxan, gepirone and ipsapirone.

5 Sirtuin-activating compounds can also be used as part of a treatment with a norepinephrine reuptake inhibitor, such as selected from tertiary amine tricyclics and secondary amine tricyclics. Exemplary tertiary amine tricyclic include amitriptyline, clomipramine, doxepin, imipramine and trimipramine. Exemplary secondary amine tricyclic include amoxapine, desipramine, maprotiline, nortriptyline and protriptyline. In certain embodiments, a sirtuin-  
10 activating compound may be used as part of a treatment with a monoamine oxidase inhibitor, such as selected from the group consisting of isocarboxazid, phenelzine, tranylcypromine, selegiline and moclobemide.

In still another representative embodiment, a sirtuin-activating compound may be used to reduce flushing side effects of chemotherapeutic agents, such as cyclophosphamide,  
15 tamoxifen.

In another embodiment, a sirtuin-activating compound may be used to reduce flushing side effects of calcium channel blockers, such as amlodipine.

In another embodiment, a sirtuin-activating compound may be used to reduce flushing side effects of antibiotics. For example, sirtuin-activating compounds can be used  
20 in combination with levofloxacin. Levofloxacin is used to treat infections of the sinuses, skin, lungs, ears, airways, bones, and joints caused by susceptible bacteria. Levofloxacin also is frequently used to treat urinary infections, including those resistant to other antibiotics, as well as prostatitis. Levofloxacin is effective in treating infectious diarrheas caused by *E. coli*, *campylobacter jejuni*, and *shigella* bacteria. Levofloxacin also can be  
25 used to treat various obstetric infections, including mastitis.

#### ***Other Uses***

Sirtuin-activating compounds may be used for treating or preventing viral infections (such as infections by influenza, herpes or papilloma virus) or as antifungal agents. In certain embodiments, a sirtuin-activating compound may be administered as  
30 part of a combination drug therapy with another therapeutic agent for the treatment of viral diseases, including, for example, acyclovir, ganciclovir and zidovudine. In another embodiment, a sirtuin-activating compound may be administered as part of a combination drug therapy with another anti-fungal agent including, for example, topical anti-fungals

such as ciclopirox, clotrimazole, econazole, miconazole, nystatin, oxiconazole, terconazole, and tolnaftate, or systemic anti-fungal such as fluconazole (Diflucan), itraconazole (Sporanox), ketoconazole (Nizoral), and miconazole (Monistat I.V.).

Subjects that may be treated as described herein include eukaryotes, such as 5 mammals, e.g., humans, ovines, bovines, equines, porcines, canines, felines, non-human primate, mice, and rats. Cells that may be treated include eukaryotic cells, e.g., from a subject described above, or plant cells, yeast cells and prokaryotic cells, e.g., bacterial cells. For example, activating compounds may be administered to farm animals to improve their ability to withstand farming conditions longer.

10 Sirtuin-activating compounds may also be used to increase lifespan, stress resistance, and resistance to apoptosis in plants. In one embodiment, a compound is applied to plants, e.g., on a periodic basis, or to fungi. In another embodiment, plants are genetically modified to produce a compound. In another embodiment, plants and fruits are treated with a compound prior to picking and shipping to increase resistance to damage 15 during shipping. Plant seeds may also be contacted with compounds described herein, e.g., to preserve them.

In other embodiments, sirtuin-activating compounds may be used for modulating 20 lifespan in yeast cells. Situations in which it may be desirable to extend the lifespan of yeast cells include any process in which yeast is used, e.g., the making of beer, yogurt, and bakery items, e.g., bread. Use of yeast having an extended lifespan can result in using less yeast or in having the yeast be active for longer periods of time. Yeast or other mammalian cells used for recombinantly producing proteins may also be treated as described herein.

Compounds may also be used to increase lifespan, stress resistance and resistance 25 to apoptosis in insects. In this embodiment, compounds would be applied to useful insects, e.g., bees and other insects that are involved in pollination of plants. In a specific embodiment, a compound would be applied to bees involved in the production of honey. Generally, the methods described herein may be applied to any organism, e.g., eukaryote, that may have commercial importance. For example, they can be applied to fish 30 (aquaculture) and birds (e.g., chicken and fowl).

Higher doses of compounds may also be used as a pesticide by interfering with the regulation of silenced genes and the regulation of apoptosis during development. In this

embodiment, a compound may be applied to plants using a method known in the art that ensures the compound is bio-available to insect larvae, and not to plants.

At least in view of the link between reproduction and longevity (Longo and Finch, Science, 2002), the compounds can be applied to affect the reproduction of organisms such as insects, animals and microorganisms.

#### 4. Assays

Yet other methods contemplated herein include screening methods for identifying compounds or agents that modulate sirtuins. An agent may be a nucleic acid, such as an aptamer. Assays may be conducted in a cell based or cell free format. For example, an assay may comprise incubating (or contacting) a sirtuin with a test agent under conditions in which a sirtuin can be activated by an agent known to activate the sirtuin, and monitoring or determining the level of activation of the sirtuin in the presence of the test agent relative to the absence of the test agent. The level of activation of a sirtuin can be determined by determining its ability to deacetylate a substrate. Exemplary substrates are acetylated peptides which can be obtained from BIOMOL (Plymouth Meeting, PA). Preferred substrates include peptides of p53, such as those comprising an acetylated K382. A particularly preferred substrate is the Fluor de Lys-SIRT1 (BIOMOL), i.e., the acetylated peptide Arg-His-Lys-Lys. Other substrates are peptides from human histones H3 and H4 or an acetylated amino acid. Substrates may be fluorogenic. The sirtuin may be SIRT1 or Sir2 or a portion thereof. For example, recombinant SIRT1 can be obtained from BIOMOL. The reaction may be conducted for about 30 minutes and stopped, e.g., with nicotinamide. The HDAC fluorescent activity assay/drug discovery kit (AK-500, BIOMOL Research Laboratories) may be used to determine the level of acetylation. Similar assays are described in Bitterman et al. (2002) J. Biol. Chem. 277:45099. The level of activation of the sirtuin in an assay may be compared to the level of activation of the sirtuin in the presence of one or more (separately or simultaneously) compounds described herein, which may serve as positive or negative controls. Sirtuins for use in the assays may be full length sirtuin proteins or portions thereof. Since it has been shown herein that activating compounds appear to interact with the N-terminus of SIRT1, proteins for use in the assays include N-terminal portions of sirtuins, e.g., about amino acids 1-176 or 1-255 of SIRT1; about amino acids 1-174 or 1-252 of Sir2.

In one embodiment, a screening assay comprises (i) contacting a sirtuin with a test agent and an acetylated substrate under conditions appropriate for the sirtuin to deacetylate the substrate in the absence of the test agent ; and (ii) determining the level of acetylation of the substrate, wherein a lower level of acetylation of the substrate in the presence of the test agent relative to the absence of the test agent indicates that the test agent stimulates deacetylation by the sirtuin, whereas a higher level of acetylation of the substrate in the presence of the test agent relative to the absence of the test agent indicates that the test agent inhibits deacetylation by the sirtuin.

Methods for identifying an agent that modulates, e.g., stimulate or inhibit, sirtuins *in vivo* may comprise (i) contacting a cell with a test agent and a substrate that is capable of entering a cell in the presence of an inhibitor of class I and class II HDACs under conditions appropriate for the sirtuin to deacetylate the substrate in the absence of the test agent ; and (ii) determining the level of acetylation of the substrate, wherein a lower level of acetylation of the substrate in the presence of the test agent relative to the absence of the test agent indicates that the test agent stimulates deacetylation by the sirtuin, whereas a higher level of acetylation of the substrate in the presence of the test agent relative to the absence of the test agent indicates that the test agent inhibits deacetylation by the sirtuin. A preferred substrate is an acetylated peptide, which is also preferably fluorogenic, as further described herein. The method may further comprise lysing the cells to determine the level of acetylation of the substrate. Substrates may be added to cells at a concentration ranging from about 1 $\mu$ M to about 10mM, preferably from about 10 $\mu$ M to 1mM, even more preferably from about 100 $\mu$ M to 1mM, such as about 200 $\mu$ M. A preferred substrate is an acetylated lysine, e.g.,  $\epsilon$ -acetyl lysine (Fluor de Lys, FdL) or Fluor de Lys-SIRT1. A preferred inhibitor of class I and class II HDACs is trichostatin A (TSA), which may be used at concentrations ranging from about 0.01 to 100 $\mu$ M, preferably from about 0.1 to 10 $\mu$ M, such as 1 $\mu$ M. Incubation of cells with the test compound and the substrate may be conducted for about 10 minutes to 5 hours, preferably for about 1-3 hours. Since TSA inhibits all class I and class II HDACs, and that certain substrates, e.g., Fluor de Lys, is a poor substrate for SIRT2 and even less a substrate for SIRT3-7, such an assay may be used to identify modulators of SIRT1 *in vivo*.

## 5. Pharmaceutical Compositions

The sirtuin-activating compounds described herein may be formulated in a conventional manner using one or more physiologically acceptable carriers or excipients. For example, sirtuin-activating compounds and their physiologically acceptable salts and solvates may be formulated for administration by, for example, injection, inhalation or insufflation (either through the mouth or the nose) or oral, buccal, parenteral or rectal administration. In one embodiment, a sirtuin-activating compound may be administered locally, at the site where the target cells are present, i.e., in a specific tissue, organ, or fluid (e.g., blood, cerebrospinal fluid, etc.).

Sirtuin-activating compounds can be formulated for a variety of modes of administration, including systemic and topical or localized administration. Techniques and formulations generally may be found in Remington's Pharmaceutical Sciences, Meade Publishing Co., Easton, PA. For systemic administration, injection is preferred, including intramuscular, intravenous, intraperitoneal, and subcutaneous. For injection, the compounds can be formulated in liquid solutions, preferably in physiologically compatible buffers such as Hank's solution or Ringer's solution. In addition, the compounds may be formulated in solid form and redissolved or suspended immediately prior to use. Lyophilized forms are also included.

For oral administration, the pharmaceutical compositions may take the form of, for example, tablets, lozanges, or capsules prepared by conventional means with pharmaceutically acceptable excipients such as binding agents (e.g., pregelatinised maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose); fillers (e.g., lactose, microcrystalline cellulose or calcium hydrogen phosphate); lubricants (e.g., magnesium stearate, talc or silica); disintegrants (e.g., potato starch or sodium starch glycolate); or wetting agents (e.g., sodium lauryl sulphate). The tablets may be coated by methods well known in the art. Liquid preparations for oral administration may take the form of, for example, solutions, syrups or suspensions, or they may be presented as a dry product for constitution with water or other suitable vehicle before use. Such liquid preparations may be prepared by conventional means with pharmaceutically acceptable additives such as suspending agents (e.g., sorbitol syrup, cellulose derivatives or hydrogenated edible fats); emulsifying agents (e.g., lecithin or acacia); non-aqueous vehicles (e.g., ationd oil, oily esters, ethyl alcohol or fractionated vegetable oils); and preservatives (e.g., methyl or propyl-p-hydroxybenzoates or sorbic acid). The preparations may also contain buffer salts, flavoring, coloring and sweetening agents as appropriate. Preparations for oral

administration may be suitably formulated to give controlled release of the active compound.

For administration by inhalation, sirtuin-activating compounds may be conveniently delivered in the form of an aerosol spray presentation from pressurized packs or a nebuliser, with the use of a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In the case of a pressurized aerosol the dosage unit may be determined by providing a valve to deliver a metered amount. Capsules and cartridges of e.g., gelatin, for use in an inhaler or insufflator may be formulated containing a powder mix of the compound and a suitable powder base such as lactose or starch.

Sirtuin-activating compounds may be formulated for parenteral administration by injection, e.g., by bolus injection or continuous infusion. Formulations for injection may be presented in unit dosage form, e.g., in ampoules or in multi-dose containers, with an added preservative. The compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents. Alternatively, the active ingredient may be in powder form for constitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use.

Sirtuin-activating compounds may also be formulated in rectal compositions such as suppositories or retention enemas, e.g., containing conventional suppository bases such as cocoa butter or other glycerides.

In addition to the formulations described previously, sirtuin-activating compounds may also be formulated as a depot preparation. Such long acting formulations may be administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection. Thus, for example, sirtuin-activating compounds may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.

Pharmaceutical compositions (including cosmetic preparations) may comprise from about 0.00001 to 100% such as from 0.001 to 10% or from 0.1% to 5% by weight of one or more sirtuin-activating compounds described herein.

In one embodiment, a sirtuin-activating compound described herein, is incorporated into a topical formulation containing a topical carrier that is generally suited

to topical drug administration and comprising any such material known in the art. The topical carrier may be selected so as to provide the composition in the desired form, e.g., as an ointment, lotion, cream, microemulsion, gel, oil, solution, or the like, and may be comprised of a material of either naturally occurring or synthetic origin. It is preferable 5 that the selected carrier not adversely affect the active agent or other components of the topical formulation. Examples of suitable topical carriers for use herein include water, alcohols and other nontoxic organic solvents, glycerin, mineral oil, silicone, petroleum jelly, lanolin, fatty acids, vegetable oils, parabens, waxes, and the like.

Formulations may be colorless, odorless ointments, lotions, creams, 10 microemulsions and gels.

Sirtuin-activating compounds may be incorporated into ointments, which generally are semisolid preparations which are typically based on petrolatum or other petroleum derivatives. The specific ointment base to be used, as will be appreciated by those skilled in the art, is one that will provide for optimum drug delivery, and, preferably, will provide 15 for other desired characteristics as well, e.g., emolliency or the like. As with other carriers or vehicles, an ointment base should be inert, stable, nonirritating and nonsensitizing. As explained in Remington's (*supra*) ointment bases may be grouped in four classes: oleaginous bases; emulsifiable bases; emulsion bases; and water-soluble bases. Oleaginous ointment bases include, for example, vegetable oils, fats obtained from animals, and 20 semisolid hydrocarbons obtained from petroleum. Emulsifiable ointment bases, also known as absorbent ointment bases, contain little or no water and include, for example, hydroxystearin sulfate, anhydrous lanolin and hydrophilic petrolatum. Emulsion ointment bases are either water-in-oil (W/O) emulsions or oil-in-water (O/W) emulsions, and include, for example, cetyl alcohol, glyceryl monostearate, lanolin and stearic acid. 25 Exemplary water-soluble ointment bases are prepared from polyethylene glycols (PEGs) of varying molecular weight; again, reference may be had to Remington's, *supra*, for further information.

Sirtuin-activating compounds may be incorporated into lotions, which generally are preparations to be applied to the skin surface without friction, and are typically liquid 30 or semiliquid preparations in which solid particles, including the active agent, are present in a water or alcohol base. Lotions are usually suspensions of solids, and may comprise a liquid oily emulsion of the oil-in-water type. Lotions are preferred formulations for treating large body areas, because of the ease of applying a more fluid composition. It is

generally necessary that the insoluble matter in a lotion be finely divided. Lotions will typically contain suspending agents to produce better dispersions as well as compounds useful for localizing and holding the active agent in contact with the skin, e.g., methylcellulose, sodium carboxymethylcellulose, or the like. An exemplary lotion 5 formulation for use in conjunction with the present method contains propylene glycol mixed with a hydrophilic petrolatum such as that which may be obtained under the trademark Aquaphor<sup>TM</sup> from Beiersdorf, Inc. (Norwalk, Conn.).

Sirtuin-activating compounds may be incorporated into creams, which generally are viscous liquid or semisolid emulsions, either oil-in-water or water-in-oil. Cream bases 10 are water-washable, and contain an oil phase, an emulsifier and an aqueous phase. The oil phase is generally comprised of petrolatum and a fatty alcohol such as cetyl or stearyl alcohol; the aqueous phase usually, although not necessarily, exceeds the oil phase in volume, and generally contains a humectant. The emulsifier in a cream formulation, as explained in Remington 's, *supra*, is generally a nonionic, anionic, cationic or amphoteric 15 surfactant.

Sirtuin-activating compounds may be incorporated into microemulsions, which generally are thermodynamically stable, isotropically clear dispersions of two immiscible liquids, such as oil and water, stabilized by an interfacial film of surfactant molecules (Encyclopedia of Pharmaceutical Technology (New York: Marcel Dekker, 1992), volume 20 9). For the preparation of microemulsions, surfactant (emulsifier), co-surfactant (co-emulsifier), an oil phase and a water phase are necessary. Suitable surfactants include any surfactants that are useful in the preparation of emulsions, e.g., emulsifiers that are typically used in the preparation of creams. The co-surfactant (or "co-emulsifier") is generally selected from the group of polyglycerol derivatives, glycerol derivatives and 25 fatty alcohols. Preferred emulsifier/co-emulsifier combinations are generally although not necessarily selected from the group consisting of: glycetyl monostearate and polyoxyethylene stearate; polyethylene glycol and ethylene glycol palmitostearate; and caprylic and capric triglycerides and oleoyl macrogolglycerides. The water phase includes not only water but also, typically, buffers, glucose, propylene glycol, polyethylene glycols, 30 preferably lower molecular weight polyethylene glycols (e.g., PEG 300 and PEG 400), and/or glycerol, and the like, while the oil phase will generally comprise, for example, fatty acid esters, modified vegetable oils, silicone oils, mixtures of mono- di- and triglycerides, mono- and di-esters of PEG (e.g., oleoyl macrogol glycerides), etc.

Sirtuin-activating compounds may be incorporated into gel formulations, which generally are semisolid systems consisting of either suspensions made up of small inorganic particles (two-phase systems) or large organic molecules distributed substantially uniformly throughout a carrier liquid (single phase gels). Single phase gels 5 can be made, for example, by combining the active agent, a carrier liquid and a suitable gelling agent such as tragacanth (at 2 to 5%), sodium alginate (at 2-10%), gelatin (at 2-15%), methylcellulose (at 3-5%), sodium carboxymethylcellulose (at 2-5%), carbomer (at 0.3-5%) or polyvinyl alcohol (at 10-20%) together and mixing until a characteristic semisolid product is produced. Other suitable gelling agents include 10 methylhydroxycellulose, polyoxyethylene-polyoxypropylene, hydroxyethylcellulose and gelatin. Although gels commonly employ aqueous carrier liquid, alcohols and oils can be used as the carrier liquid as well.

Various additives, known to those skilled in the art, may be included in formulations, e.g., topical formulations. Examples of additives include, but are not limited 15 to, solubilizers, skin permeation enhancers, opacifiers, preservatives (e.g., anti-oxidants), gelling agents, buffering agents, surfactants (particularly nonionic and amphoteric surfactants), emulsifiers, emollients, thickening agents, stabilizers, humectants, colorants, fragrance, and the like. Inclusion of solubilizers and/or skin permeation enhancers is particularly preferred, along with emulsifiers, emollients and preservatives. An optimum 20 topical formulation comprises approximately: 2 wt. % to 60 wt. %, preferably 2 wt. % to 50 wt. %, solubilizer and/or skin permeation enhancer; 2 wt. % to 50 wt. %, preferably 2 wt. % to 20 wt. %, emulsifiers; 2 wt. % to 20 wt. % emollient; and 0.01 to 0.2 wt. % preservative, with the active agent and carrier (e.g., water) making of the remainder of the formulation.

25 A skin permeation enhancer serves to facilitate passage of therapeutic levels of active agent to pass through a reasonably sized area of unbroken skin. Suitable enhancers are well known in the art and include, for example: lower alkanols such as methanol ethanol and 2-propanol; alkyl methyl sulfoxides such as dimethylsulfoxide (DMSO), decylmethylsulfoxide ( $C_{10}$  MSO) and tetradecylmethyl sulfboxide; pyrrolidones such as 2-decylmethylsulfoxide (C<sub>10</sub> MSO) and tetradecylmethyl sulfboxide; pyrrolidones such as 2-pyrrolidone, N-methyl-2-pyrrolidone and N-(hydroxyethyl)pyrrolidone; urea; N,N-diethyl-m-toluamide; C<sub>2</sub>-C<sub>6</sub> alkanediols; miscellaneous solvents such as dimethyl 30 formamide (DMF), N,N-dimethylacetamide (DMA) and tetrahydrofurfuryl alcohol; and the 1-substituted azacycloheptan-2-ones, particularly 1-n-dodecylcyclazacycloheptan-2-

one (laurocapram; available under the trademark Azone<sup>RTM</sup> from Whitby Research Incorporated, Richmond, Va.).

Examples of solubilizers include, but are not limited to, the following: hydrophilic ethers such as diethylene glycol monoethyl ether (ethoxydiglycol, available commercially as Transcutol<sup>RTM</sup>) and diethylene glycol monoethyl ether oleate (available commercially as Softcutol<sup>RTM</sup>); polyethylene castor oil derivatives such as polyoxy 35 castor oil, polyoxy 40 hydrogenated castor oil, etc.; polyethylene glycol, particularly lower molecular weight polyethylene glycals such as PEG 300 and PEG 400, and polyethylene glycol derivatives such as PEG-8 caprylic/capric glycerides (available commercially as Labrasol<sup>RTM</sup>); alkyl 5 methyl sulfoxides such as DMSO; pyrrolidones such as 2-pyrrolidone and N-methyl-2-pyrrolidone; and DMA. Many solubilizers can also act as absorption enhancers. A single solubilizer may be incorporated into the formulation, or a mixture of solubilizers may be 10 incorporated therein.

Suitable emulsifiers and co-emulsifiers include, without limitation, those 15 emulsifiers and co-emulsifiers described with respect to microemulsion formulations. Emollients include, for example, propylene glycol, glycerol, isopropyl myristate, polypropylene glycol-2 (PPG-2) myristyl ether propionate, and the like.

Other active agents may also be included in formulations, e.g., other anti-inflammatories, analgesics, antimicrobial agents, antifungal agents, antibiotics, 20 vitamins, antioxidants, and sunblock agents commonly found in sunscreen formulations including, but not limited to, anthranilates, benzophenones (particularly benzophenone-3), camphor derivatives, cinnamates (e.g., octyl methoxycinnamate), dibenzoyl methanes (e.g., butyl methoxydibenzoyl methane), p-aminobenzoic acid (PABA) and derivatives thereof, and salicylates (e.g., octyl salicylate).

25 In certain topical formulations, the active agent is present in an amount in the range of approximately 0.25 wt. % to 75 wt. % of the formulation, preferably in the range of approximately 0.25 wt. % to 30 wt. % of the formulation, more preferably in the range of approximately 0.5 wt. % to 15 wt. % of the formulation, and most preferably in the range of approximately 1.0 wt. % to 10 wt. % of the formulation.

30 Topical skin treatment compositions can be packaged in a suitable container to suit its viscosity and intended use by the consumer. For example, a lotion or cream can be packaged in a bottle or a roll-ball applicator, or a propellant-driven aerosol device or a container fitted with a pump suitable for finger operation. When the composition is a

cream, it can simply be stored in a non-deformable bottle or squeeze container, such as a tube or a lidded jar. The composition may also be included in capsules such as those described in U.S. Pat. No. 5,063,507. Accordingly, also provided are closed containers containing a cosmetically acceptable composition as herein defined.

5 In an alternative embodiment, a pharmaceutical formulation is provided for oral or parenteral administration, in which case the formulation may comprises an activating compound-containing microemulsion as described above, but may contain alternative pharmaceutically acceptable carriers, vehicles, additives, etc. particularly suited to oral or parenteral drug administration. Alternatively, an activating compound-containing 10 microemulsion may be administered orally or parenterally substantially as described above, without modification.

Phospholipids complexes, e.g., resveratrol-phospholipid complexes, and their preparation are described in US2004116386. Methods for stabilizing active components using polyol/polymer microcapsules, and their preparation are described in 15 US20040108608. Processes for dissolving lipophilic compounds in aqueous solution with amphiphilic block copolymers are described in WO 04/035013.

Conditions of the eye can be treated or prevented by, e.g., systemic, topical, intraocular injection of a sirtuin-activating compound, or by insertion of a sustained release device that releases a sirtuin-activating compound.

20 Sirtuin-activating compounds described herein may be stored in oxygen free environment according to methods in the art. For example, resveratrol or analog thereof can be prepared in an airtight capsule for oral administration, such as Capsugel from Pfizer, Inc.

Cells, e.g., treated *ex vivo* with a sirtuin-activating compound, can be administered 25 according to methods for administering a graft to a subject, which may be accompanied, e.g., by administration of an immunosuppressant drug, e.g., cyclosporin A. For general principles in medicinal formulation, the reader is referred to Cell Therapy: Stem Cell Transplantation, Gene Therapy, and Cellular Immunotherapy, by G. Morstyn & W. Sheridan eds, Cambridge University Press, 1996; and Hematopoietic Stem Cell Therapy, 30 E. D. Ball, J. Lister & P. Law, Churchill Livingstone, 2000.

Toxicity and therapeutic efficacy of sirtuin-activating compounds can be determined by standard pharmaceutical procedures in cell cultures or experimental animals. The LD<sub>50</sub> is the dose lethal to 50% of the population). The ED<sub>50</sub> is the dose

therapeutically effective in 50% of the population. The dose ratio between toxic and therapeutic effects (LD<sub>50</sub>/ED<sub>50</sub>) is the therapeutic index. Sirtuin-activating compounds that exhibit large therapeutic indexes are preferred. While sirtuin-activating compounds that exhibit toxic side effects may be used, care should be taken to design a delivery system that targets such compounds to the site of affected tissue in order to minimize potential damage to uninfected cells and, thereby, reduce side effects.

The data obtained from the cell culture assays and animal studies can be used in formulating a range of dosage for use in humans. The dosage of such compounds may lie within a range of circulating concentrations that include the ED<sub>50</sub> with little or no toxicity. 10 The dosage may vary within this range depending upon the dosage form employed and the route of administration utilized. For any compound, the therapeutically effective dose can be estimated initially from cell culture assays. A dose may be formulated in animal models to achieve a circulating plasma concentration range that includes the IC<sub>50</sub> (i.e., the concentration of the test compound that achieves a half-maximal inhibition of symptoms) 15 as determined in cell culture. Such information can be used to more accurately determine useful doses in humans. Levels in plasma may be measured, for example, by high performance liquid chromatography.

## 6. Kits

Also provided herein are kits, e.g., kits for therapeutic purposes or kits for modulating the lifespan of cells or modulating apoptosis. A kit may comprise one or more sirtuin-activating compounds, e.g., in premeasured doses. A kit may optionally comprise devices for contacting cells with the compounds and instructions for use. Devices include syringes, stents and other devices for introducing a sirtuin-activating compound into a subject or applying it to the skin of a subject.

The practice of the present methods will employ, unless otherwise indicated, conventional techniques of cell biology, cell culture, molecular biology, transgenic biology, microbiology, recombinant DNA, and immunology, which are within the skill of the art. Such techniques are explained fully in the literature. See, for example, Molecular 30 Cloning A Laboratory Manual, 2<sup>nd</sup> Ed., ed. by Sambrook, Fritsch and Maniatis (Cold Spring Harbor Laboratory Press: 1989); DNA Cloning, Volumes I and II (D. N. Glover ed., 1985); Oligonucleotide Synthesis (M. J. Gait ed., 1984); Mullis et al. U.S. Patent No: 4,683,195; Nucleic Acid Hybridization (B. D. Hames & S. J. Higgins eds. 1984);

Transcription And Translation (B. D. Hames & S. J. Higgins eds. 1984); Culture Of Animal Cells (R. I. Freshney, Alan R. Liss, Inc., 1987); Immobilized Cells And Enzymes (IRL Press, 1986); B. Perbal, A Practical Guide To Molecular Cloning (1984); the treatise, Methods In Enzymology (Academic Press, Inc., N.Y.); Gene Transfer Vectors For Mammalian Cells (J. H. Miller and M. P. Calos eds., 1987, Cold Spring Harbor Laboratory); Methods In Enzymology, Vols. 154 and 155 (Wu et al. eds.), Immunochemical Methods In Cell And Molecular Biology (Mayer and Walker, eds., Academic Press, London, 1987); Handbook Of Experimental Immunology, Volumes I-IV (D. M. Weir and C. C. Blackwell, eds., 1986); Manipulating the Mouse Embryo, (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1986).

## EQUIVALENTS

The present invention provides among other things sirtuin-activating compounds and methods of use thereof. While specific embodiments of the subject invention have been discussed, the above specification is illustrative and not restrictive. Many variations of the invention will become apparent to those skilled in the art upon review of this specification. The full scope of the invention should be determined by reference to the claims, along with their full scope of equivalents, and the specification, along with such variations.

20

## INCORPORATION BY REFERENCE


All publications and patents mentioned herein, including those items listed below, are hereby incorporated by reference in their entirety as if each individual publication or patent was specifically and individually indicated to be incorporated by reference. In case of conflict, the present application, including any definitions herein, will control.

Also incorporated by reference in their entirety are any polynucleotide and polypeptide sequences which reference an accession number correlating to an entry in a public database, such as those maintained by The Institute for Genomic Research (TIGR) ([www.tigr.org](http://www.tigr.org)) and/or the National Center for Biotechnology Information (NCBI) ([www.ncbi.nlm.nih.gov](http://www.ncbi.nlm.nih.gov)).

Also incorporated by reference are the following: PCT Publications WO 2005/002672; 2005/002555; and 2004/016726.

**What is claimed is:**

1. A compound represented by Structural Formula (Ia):



5

or a salt thereof, wherein:

Ring A' is a 5- to 7-membered ring optionally fused to a second 5- to 7-membered ring, which is optionally substituted with one to three functional groups selected from the group consisting of halogen, -OR, -CN, -CO<sub>2</sub>R, -OCOR, -OCO<sub>2</sub>R, -C(O)NRR', -OC(O)NRR', -C(O)R, -COR, -SR, -S(O)<sub>n</sub>R, -S(O)<sub>n</sub>OR, -S(O)<sub>n</sub>NRR', -NRR', -NRC(O)OR, -NRC(O)R, -NO<sub>2</sub>, -OSO<sub>3</sub>H, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted non-aromatic heterocyclic and substituted or unsubstituted aryl;

10

Ring B' is a 5- to 7-membered ring optionally substituted with one to four functional groups selected from the group consisting of halogen, -OR, -CN, -CO<sub>2</sub>R, -OCOR, -OCO<sub>2</sub>R, -C(O)NRR', -OC(O)NRR', -C(O)R, -COR, -SR, -S(O)<sub>n</sub>R, -S(O)<sub>n</sub>OR, -S(O)<sub>n</sub>NRR', -NRR', -NRC(O)OR, -NRC(O)R, -NO<sub>2</sub>, -OSO<sub>3</sub>H, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted non-aromatic heterocyclic and substituted or unsubstituted aryl;

15

J is O or S;

L is -C=C- or -NH-(CH<sub>2</sub>)<sub>k</sub>-;

R and R' are independently -H, a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkenyl group, a substituted or unsubstituted non-aromatic heterocyclic group or a substituted or unsubstituted aryl group;

20

a is 0 or 1;

k is an integer from 1 to 4; and


n is 1 or 2,

25

provided that Ring A' and Ring B' are not both phenyl and at least one is substituted with at least one hydrogen bond donating group, and provided that the compound is not 4-((E)-2-(pyridin-4-yl)vinyl)phenol.

30

2. The compound of Claim 1, wherein Ring A' and Ring B' are both aromatic.
3. The compound of Claim 2, wherein a is 0.
- 5
4. The compound of Claim 3, wherein L is -CH=CH-.
5. The compound of Claim 2, wherein a is 1.
- 10 6. The compound of Claim 5, wherein J is O.
7. The compound of Claim 6, wherein k is 1.
8. The compound of Claim 2, wherein one of Ring A' and Ring B' is pyridyl.
- 15
9. The compound of Claim 1, wherein the compound increases the level or activity of a SIRT1 protein.
10. The compound of Claim 9, wherein the compound increases the deacetylase activity of the SIRT1 protein.
- 20
11. The compound of Claim 10, wherein the compound does not substantially have one or more of the following activities: inhibition of PI3-kinase, inhibition of aldoreductase, inhibition of tyrosine kinase, transactivation of EGFR tyrosine kinase, coronary dilation, or spasmolytic activity, at concentrations of the compound that are effective for increasing the deacetylation activity of the SIRT1 protein.
- 25
12. A compound represented by Structural Formula (I):



30

or a salt thereof, wherein:


- W is CH or N;  
X is CH or N;  
Y is CH or N;  
Z is S, O or NH;
- 5            W' is CH or N;  
X' is CH or N;  
Y' is CH or N;  
Z' is S, O or NH;
- R and R' are independently –H, a substituted or unsubstituted alkyl group, a  
10          substituted or unsubstituted alkenyl group, a substituted or unsubstituted non-  
aromatic heterocyclic group or a substituted or unsubstituted aryl group;
- n is 1 or 2;
- 15          Ring A is substituted with at least one hydrogen bond donating group and is  
optionally substituted with one to three functional groups selected from the group  
consisting of halogen, -OR, -CN, -CO<sub>2</sub>R, -OCOR, -OCO<sub>2</sub>R, -C(O)NRR',  
-OC(O)NRR', -C(O)R, -COR, -SR, -S(O)<sub>n</sub>R, -S(O)<sub>n</sub>OR, -S(O)<sub>n</sub>NRR', -NRR',  
-NRC(O)OR, -NRC(O)R, -NO<sub>2</sub>, -OSO<sub>3</sub>H, substituted or unsubstituted alkyl,  
substituted or unsubstituted alkenyl, substituted or unsubstituted non-aromatic  
heterocyclic and substituted or unsubstituted aryl; and
- 20          Ring B is optionally substituted with one to four functional groups selected  
from the group consisting of halogen, -OR, -CN, -CO<sub>2</sub>R, -OCOR, -OCO<sub>2</sub>R,  
-C(O)NRR', -OC(O)NRR', -C(O)R, -COR, -SR, -S(O)<sub>n</sub>R, -S(O)<sub>n</sub>OR, -S(O)<sub>n</sub>NRR',  
-NRR', -NRC(O)OR, -NRC(O)R, -NO<sub>2</sub>, -OSO<sub>3</sub>H, substituted or unsubstituted alkyl,  
substituted or unsubstituted alkenyl, substituted or unsubstituted non-aromatic  
heterocyclic and substituted or unsubstituted aryl.
- 25
13. The compound of Claim 12, wherein the compound increases the level or activity of  
a SIRT1 protein.
- 30          14. The compound of Claim 13, wherein the compound increases the deacetylase  
activity of the SIRT1 protein.

15. The compound of Claim 13, wherein the compound does not substantially have one or more of the following activities: inhibition of PI3-kinase, inhibition of aldoreductase, inhibition of tyrosine kinase, transactivation of EGFR tyrosine kinase, coronary dilation, or spasmolytic activity, at concentrations of the compound that are effective for increasing the deacetylation activity of the SIRT1 protein.

5

16. The compound of Claim 12, wherein the compound is represented by Structural Formula (II):

10




or a salt thereof.

17. The compound of Claim 16, wherein X is CH and Z is NH, O or S, or X is N and Z is S; and X' is CH and Z' is NH, O or S, or X is N and Z is S.

15

18. The compound of Claim 17, wherein the compound is represented by Structural Formula (III):



or a salt thereof, wherein:

20


R<sub>1</sub> is -OR, -OCOR, -OSO<sub>3</sub>H, -SH, -NHR or -COOR;

25

R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub>, R<sub>5</sub> and R<sub>6</sub> are independently -H, halogen, -OR, -CN, -CO<sub>2</sub>R, -OCOR, -OCO<sub>2</sub>R, -C(O)NRR', -OC(O)NRR', -C(O)R, -COR, -SR, -S(O)<sub>n</sub>R, -S(O)<sub>n</sub>OR, -S(O)<sub>n</sub>NRR', -NRR', -NRC(O)OR, -NRC(O)R, -NO<sub>2</sub>, -OSO<sub>3</sub>H, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl or substituted or unsubstituted aryl; and

R<sub>7</sub> and R<sub>8</sub> are independently -H, a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkenyl group or a substituted or unsubstituted aryl group.

- 5 19. The compound of Claim 18, wherein the compound is represented by Structural Formula (IV):



wherein:

10 R<sub>10</sub>, R<sub>11</sub> and R<sub>12</sub> are independently -H, halogen, -OR, -CN, -CO<sub>2</sub>R, -OCO<sub>2</sub>R, -C(O)NRR', -OC(O)NRR', -C(O)R, -COR, -SR, -S(O)<sub>n</sub>R, -S(O)<sub>n</sub>OR, -S(O)<sub>n</sub>NRR', -NRR', -NRC(O)OR, -NRC(O)R, -NO<sub>2</sub>, -OSO<sub>3</sub>H, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl or substituted or unsubstituted aryl, provided that at least one of R<sub>10</sub>, R<sub>11</sub> and R<sub>12</sub> is -OH, -OCOR, -OSO<sub>3</sub>H, -NHR, -SH or -COOR;

15 R<sub>13</sub>, R<sub>14</sub> and R<sub>15</sub> are independently -H, halogen, -OR, -CN, -CO<sub>2</sub>R, -OCO<sub>2</sub>R, -C(O)NRR', -OC(O)NRR', -C(O)R, -COR, -SR, -S(O)<sub>n</sub>R, -S(O)<sub>n</sub>OR, -S(O)<sub>n</sub>NRR', -NRR', -NRC(O)OR, -NRC(O)R, -NO<sub>2</sub>, -OSO<sub>3</sub>H, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl or substituted or unsubstituted aryl.


- 20 20. The compound of Claim 19, wherein at least one of R<sub>10</sub>, R<sub>11</sub> and R<sub>12</sub> is -OR, -OCOR, or -OSO<sub>3</sub>H.
21. The compound of Claim 20, wherein two of R<sub>10</sub>, R<sub>11</sub> and R<sub>12</sub> are -OR, -OCOR, or -OSO<sub>3</sub>H.
- 25 22. The compound of Claim 21, wherein at least one of R<sub>13</sub>, R<sub>14</sub> and R<sub>15</sub> is -OR, -OCOR, -OSO<sub>3</sub>H, -NHR, -SH or -COOR.

23. The compound of Claim 22, wherein at least one of R<sub>13</sub>, R<sub>14</sub> and R<sub>15</sub> is -OR, -OCOR, or -OSO<sub>3</sub>H.
- 5 24. The compound of Claim 19, wherein at least one of R<sub>10</sub>, R<sub>11</sub> and R<sub>12</sub> is a dihalomethyl group.
25. The compound of Claim 24, wherein the dihalomethyl group is a difluoromethyl group.
- 10 26. A pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and a compound represented by Structural Formula (I):
- (I),
- or a pharmaceutically acceptable salt thereof, wherein:
- 15           W is CH or N;  
         X is CH or N;  
         Y is CH or N;  
         Z is S, O or NH;  
         W' is CH or N;
- 20           X' is CH or N;  
         Y' is CH or N;  
         Z' is S, O or NH;
- 25           R and R' are independently -H, a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkenyl group, substituted or unsubstituted non-aromatic heterocyclic or a substituted or unsubstituted aryl group;
- n is 1 or 2;
- Ring A is substituted with at least one hydrogen bond donating group and is optionally substituted with one to three functional groups selected from the group consisting of halogen, -OR, -CN, -CO<sub>2</sub>R, -OCOR, -OCO<sub>2</sub>R, -C(O)NRR', -OC(O)NRR', -C(O)R, -COR, -SR, -S(O)<sub>n</sub>R, -S(O)<sub>n</sub>OR, -S(O)<sub>n</sub>NRR', -NRR', -NRC(O)OR, -NRC(O)R, -NO<sub>2</sub>, -OSO<sub>3</sub>H, substituted or unsubstituted alkyl,
- 30

substituted or unsubstituted alkenyl, substituted or unsubstituted non-aromatic heterocyclic and substituted or unsubstituted aryl; and

Ring B is optionally substituted with one to four functional groups selected from the group consisting of halogen, -OR, -CN, -CO<sub>2</sub>R, -OCOR, -OCO<sub>2</sub>R, -C(O)NRR', -OC(O)NRR', -C(O)R, -COR, -SR, -S(O)<sub>n</sub>R, -S(O)<sub>n</sub>OR, -S(O)<sub>n</sub>NRR', -NRR', -NRC(O)OR, -NRC(O)R, -NO<sub>2</sub>, -OSO<sub>3</sub>H, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted non-aromatic heterocyclic and substituted or unsubstituted aryl.

10 27. A compound represented by Structural Formula (V):



or a salt thereof, wherein:

A is O, NH or S;

15 R<sub>20</sub>, R<sub>21</sub>, R<sub>22</sub>, R<sub>23</sub> and R<sub>24</sub> are independently -H, halogen, -OR, -CN, -CO<sub>2</sub>R, -OCOR, -OCO<sub>2</sub>R, -C(O)NRR', -OC(O)NRR', -C(O)R, -COR, -SR, -S(O)<sub>n</sub>R, -S(O)<sub>n</sub>OR, -S(O)<sub>n</sub>NRR', -NRR', -NRC(O)OR, -NRC(O)R, -NO<sub>2</sub>, -OSO<sub>3</sub>H, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted non-aromatic heterocyclic or substituted or unsubstituted aryl;


20 R and R' are independently -H, a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkenyl group, a substituted or unsubstituted non-aromatic heterocyclic group or a substituted or unsubstituted aryl group;

n is 1 or 2; and


25 Ring C is optionally substituted with one to four functional groups selected from the group consisting of halogen, -OR, -CN, -CO<sub>2</sub>R, -OCOR, -OCO<sub>2</sub>R, -C(O)NRR', -OC(O)NRR', -C(O)R, -COR, -SR, -S(O)<sub>n</sub>R, -S(O)<sub>n</sub>OR, -S(O)<sub>n</sub>NRR', -NRR', -NRC(O)OR, -NRC(O)R, -NO<sub>2</sub>, -OSO<sub>3</sub>H, substituted or unsubstituted alkyl,

substituted or unsubstituted alkenyl, substituted or unsubstituted non-aromatic heterocyclic and substituted or unsubstituted aryl.


28. The compound of Claim 27, wherein the compound increases the level or activity of  
5 a SIRT1 protein.
29. The compound of Claim 28, wherein the compound increases the deacetylase activity of the SIRT1 protein.
- 10 30. The compound of Claim 28, wherein the compound does not substantially have one or more of the following activities: inhibition of PI3-kinase, inhibition of aldoreductase, inhibition of tyrosine kinase, transactivation of EGFR tyrosine kinase, coronary dilation, or spasmolytic activity, at concentrations of the compound that are effective for increasing the deacetylation activity of the SIRT1  
15 protein.
31. The compound of Claim 27, wherein the compound is represented by Structural Formula (VI):



- 20 32. The compound of Claim 31, wherein the compound is represented by Structural Formula (VII):



- 33. The compound of Claim 32, wherein Ring C is unsubstituted.
- 5    34. The compound of Claim 33, wherein A is O.
- 35. The compound of Claim 34, wherein one or two of R<sub>20</sub>, R<sub>21</sub>, R<sub>22</sub>, R<sub>23</sub> and R<sub>24</sub> are -OR, -OCOR, -OSO<sub>3</sub>H, -NHR, -SH or -COOR and the remainder of R<sub>20</sub>, R<sub>21</sub>, R<sub>22</sub>, R<sub>23</sub> and R<sub>24</sub> are -H.
- 10    36. The compound of Claim 35, wherein one or two of R<sub>20</sub>, R<sub>21</sub>, R<sub>22</sub>, R<sub>23</sub> and R<sub>24</sub> are -OR, -OCOR, or -OSO<sub>3</sub>H.
- 15    37. The compound of Claim 36, wherein one or two of R<sub>21</sub>, R<sub>22</sub> and R<sub>23</sub> are -OR, -OCOR, or -OSO<sub>3</sub>H.
- 38. The compound of Claim 35, wherein one or two of R<sub>20</sub>, R<sub>21</sub>, R<sub>22</sub>, R<sub>23</sub> and R<sub>24</sub> are a dihalomethyl group.
- 20    39. The compound of Claim 38, wherein the dihaloalkyl group is a difluoromethyl group.
- 40. A pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and a compound represented by Structural Formula (V):



or a pharmaceutically acceptable salt thereof, wherein:

A is O, NH or S;


5           R<sub>20</sub>, R<sub>21</sub>, R<sub>22</sub>, R<sub>23</sub> and R<sub>24</sub> are independently –H, halogen, -OR, -CN, -CO<sub>2</sub>R, -OCOR, -OCO<sub>2</sub>R, -C(O)NRR', -OC(O)NRR', -C(O)R, -COR, -SR, -S(O)<sub>n</sub>R, -S(O)<sub>n</sub>OR, -S(O)<sub>n</sub>NRR', -NRR', -NRC(O)OR, -NRC(O)R, -NO<sub>2</sub>, -OSO<sub>3</sub>H, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted non-aromatic heterocyclic or substituted or unsubstituted aryl;

10          R and R' are independently –H, a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkenyl group, a substituted or unsubstituted non-aromatic heterocyclic group or a substituted or unsubstituted aryl group;

n is 1 or 2; and

15          Ring C is optionally substituted with one to four functional groups selected from the group consisting of halogen, -OR, -CN, -CO<sub>2</sub>R, -OCOR, -OCO<sub>2</sub>R, -C(O)NRR', -OC(O)NRR', -C(O)R, -COR, -SR, -S(O)<sub>n</sub>R, -S(O)<sub>n</sub>OR, -S(O)<sub>n</sub>NRR', -NRR', -NRC(O)OR, -NRC(O)R, -NO<sub>2</sub>, -OSO<sub>3</sub>H, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted non-aromatic heterocyclic and substituted or unsubstituted aryl.

20    41. A compound represented by Structural Formula (VIII):



or a salt thereof, wherein:

A is O, NH or S;

X'' is CH or N;

Z" is NH, O or S;

R and R' are independently -H, a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkenyl group, a substituted or unsubstituted non-aromatic heterocyclic group or a substituted or unsubstituted aryl group;


5 n is 1 or 2;

Ring D is optionally substituted with one to four functional groups selected from the group consisting of halogen, -OR, -CN, -CO<sub>2</sub>R, -OCOR, -OCO<sub>2</sub>R, -C(O)NRR', -OC(O)NRR', -C(O)R, -COR, -SR, -S(O)<sub>n</sub>R, -S(O)<sub>n</sub>OR, -S(O)<sub>n</sub>NRR', -NRR', -NRC(O)OR, -NRC(O)R, -NO<sub>2</sub>, -OSO<sub>3</sub>H, substituted or unsubstituted alkyl, 10 substituted or unsubstituted alkenyl, substituted or unsubstituted non-aromatic heterocyclic and substituted or unsubstituted aryl; and

15 Ring E is optionally substituted with one to three functional groups selected from the group consisting of halogen, -OR, -CN, -CO<sub>2</sub>R, -OCO<sub>2</sub>R, -OCOR, -C(O)NRR', -OC(O)NRR', -C(O)R, -COR, -SR, -S(O)<sub>n</sub>R, -S(O)<sub>n</sub>OR, -S(O)<sub>n</sub>NRR', -NRR', -NRC(O)OR, -NRC(O)R, -NO<sub>2</sub>, -OSO<sub>3</sub>H, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted non-aromatic heterocyclic and substituted or unsubstituted aryl.


42. The compound of Claim 41, wherein the compound increases the level or activity of  
20 a SIRT1 protein.
43. The compound of Claim 42, wherein the compound increases the deacetylase activity of the SIRT1 protein.
- 25 44. The compound of Claim 42, wherein the compound does not substantially have one or more of the following activities: inhibition of PI3-kinase, inhibition of aldoreductase, inhibition of tyrosine kinase, transactivation of EGFR tyrosine kinase, coronary dilation, or spasmolytic activity, at concentrations of the compound that are effective for increasing the deacetylation activity of the SIRT1 protein.  
30
45. The compound of Claim 41, wherein A is O.

46. The compound of Claim 45, wherein X" is CH.
47. The compound of Claim 46, wherein the compound is represented by Structural Formula (IX):




5

48. The compound of Claim 47, wherein the compound is represented by Structural Formula (X):



10

49. The compound of Claim 48, wherein the compound is represented by Structural Formula (XI):



15

50. The compound of Claim 49, wherein Z" is NH.

20


51. The compound of Claim 50, wherein Ring D is unsubstituted.
52. The compound of Claim 51, wherein Ring E is substituted with one or two -OR, -OSO<sub>3</sub>H, -OCOR, -NHR, -SH or -COOR groups.

53. The compound of Claim 52, wherein Ring E is substituted with one or two -OR, -OCOR, or -OSO<sub>3</sub>H groups.

54. The compound of Claim 52, wherein Ring E is substituted with one or two dihalomethyl groups.

55. The compound of Claim 54, wherein the dihalomethyl group is a difluoromethyl group.

10 56. A pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and a compound represented by Structural Formula (VIII):



or a pharmaceutically acceptable salt thereof, wherein:

A is O, NH or S;

15 X'' is CH or N;

Z'' is NH, O or S;

R and R' are independently -H, a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkenyl group, a substituted or unsubstituted non-aromatic heterocyclic group or a substituted or unsubstituted aryl group;

20 n is 1 or 2;


Ring D is optionally substituted with one to four functional groups selected from the group consisting of halogen, -OR, -CN, -CO<sub>2</sub>R, -OCOR, -OCO<sub>2</sub>R, -C(O)NRR', -OC(O)NRR', -C(O)R, -COR, -SR, -S(O)<sub>n</sub>R, -S(O)<sub>n</sub>OR, -S(O)<sub>n</sub>NRR', -NRR', -NRC(O)OR, -NRC(O)R, -NO<sub>2</sub>, -OSO<sub>3</sub>H, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted non-aromatic heterocyclic and substituted or unsubstituted aryl; and

25 Ring E is optionally substituted with one to three functional groups selected from the group consisting of halogen, -OR, -CN, -CO<sub>2</sub>R, -OCOR, -OCO<sub>2</sub>R, -C(O)NRR', -OC(O)NRR', -C(O)R, -COR, -SR, -S(O)<sub>n</sub>R, -S(O)<sub>n</sub>OR, -S(O)<sub>n</sub>NRR', -NRR', -NRC(O)OR, -NRC(O)R, -NO<sub>2</sub>, -OSO<sub>3</sub>H, substituted or unsubstituted alkyl,

30

substituted or unsubstituted alkenyl, substituted or unsubstituted non-aromatic heterocyclic and substituted or unsubstituted aryl.

57. A compound represented by Structural Formula (XII):



5


or a salt thereof, wherein:

Ring A is substituted with at least one dihalomethyl group and at least one group capable of donating hydrogen bonds; and


Ring B is optionally substituted.

10

58. The compound of Claim 57, wherein Ring B is substituted with a group capable of donating hydrogen bonds.
- 15 59. The compound of Claim 58, wherein the group capable of donating hydrogen bonds on Rings A and B is -OR, -OCOR or -OSO<sub>3</sub>H.
60. The compound of Claim 59, wherein the dihalomethyl group is difluoromethyl.
- 20 61. The compound of Claim 60, wherein the compound is represented by Structural Formula (XIII):




62. A pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and a compound represented by Structural Formula (XII):



or a pharmaceutically acceptable salt thereof, wherein:

5 Ring A is substituted with at least one dihalomethyl group and at least one group capable of donating hydrogen bonds; and  
Ring B is optionally substituted.

63. A compound represented by Structural Formula (XIV):



10 or a salt thereof, wherein:

$R_{30}$  is  $-OR_z$ ,  $-OCH_3$ ,  $-Cl$ ,  $-OC_6H_5$  or  $-CH_3$ ;


$R_{31}$  is  $-H$ ,  $-OR_z$ ,  $-OCH_3$ ,  $-F$  or  $-CH_3$ ;

$R_{32}$  is  $-OR_z$ ,  $-OCHF_2$ ,  $-OCHCl_2$ ,  $-OCHBr_2$  or  $-OCH_3$ ; and


15  $R_z$  is  $-SO_3H$ , an acyl group or a sugar,

provided that  $R_{32}$  is  $-OCHF_2$ ,  $-OCHCl_2$ ,  $-OCHBr_2$  or  $-OCH_3$  when  $R_{30}$  and  $R_{31}$  are both  $-OH$ .

64. A compound represented by one of the following structural formulae:



5 65. A pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and a compound represented by Structural Formula (XIV):



or a salt thereof, wherein:

R<sub>30</sub> is -OR<sub>z</sub>, -OCH<sub>3</sub>, -Cl, -OC<sub>6</sub>H<sub>5</sub> or -CH<sub>3</sub>;


10 R<sub>31</sub> is -H, -OR<sub>z</sub>, -OCH<sub>3</sub>, -F or -CH<sub>3</sub>;

R<sub>32</sub> is -OR<sub>z</sub>, -OCHF<sub>2</sub>, -OCHCl<sub>2</sub>, -OCHBr<sub>2</sub> or -OCH<sub>3</sub>; and

R<sub>z</sub> is -SO<sub>3</sub>H, an acyl group or a sugar,

provided that R<sub>32</sub> is -OCHF<sub>2</sub>, -OCHCl<sub>2</sub>, -OCHBr<sub>2</sub> or -OCH<sub>3</sub> when R<sub>30</sub> and R<sub>31</sub> are both -OH.

66. A compound represented by Structural Formula (XV):



or a salt thereof, where:

5            j is 1 or 2;

              m is 0 or 1;


              Q is CH or N; and

              Rz' is -H, -SO3H, acyl or a sugar,

provided that the compound is not 4-((E)-2-(pyridin-4-yl)vinyl)phenol.

10


67. A compound represented by Structural Formula (XVI):




or a salt thereof, wherein Q is CH or N, provided that Q is N when the nitrogen atom is para to the double bond.

15

68. The compound of Claim 67, wherein the compound is represented by one of the following structural formulae:



69. A compound represented by Structural Formula (XVII):




(XVII),

or a salt thereof, wherein Q is CH or N.


5

70. The compound of Claim 69, wherein the compound is represented by one of the following structural formulae:



10

71. A compound represented by Structural Formula (XVIII):





or a salt thereof, wherein:

Ring F is substituted with at least one hydrogen bond donating group and the compound is optionally substituted with one or more groups selected from the group consisting of halogen, -OR, -CN, -CO<sub>2</sub>R, -OCOR, -OCO<sub>2</sub>R, -C(O)NRR', -OC(O)NRR', -C(O)R, -COR, -SR, -S(O)<sub>n</sub>R, -S(O)<sub>n</sub>OR, -S(O)<sub>n</sub>NRR', -NRR', -NRC(O)OR, -NRC(O)R, -NO<sub>2</sub>, -OSO<sub>3</sub>H, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted non-aromatic heterocyclic and substituted or unsubstituted aryl;


R and R' are independently -H, a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkenyl group, a substituted or unsubstituted non-aromatic heterocyclic group or a substituted or unsubstituted aryl group; and n is 1 or 2.

- 15 72. The compound of Claim 71, wherein Ring F is substituted with -OR, -OSO<sub>3</sub>H, -OCOR, -SH, -NHR or -COOR.
73. The compound of Claim 72, wherein Ring F is substituted with -OR, -OCOR, or -OSO<sub>3</sub>H.
- 20 74. The compound of Claim 73, wherein the compound is represented by one of the following structural formulae:





75. A pharmaceutical composition comprising a pharmaceutical carrier or diluent and a compound represented by Structural Formula (XVIII):



5

(XVIII),

or a salt thereof, wherein:

Ring F is substituted with at least one hydrogen bond donating group and the compound is optionally substituted with one or more groups selected from the group consisting of halogen, -OR, -CN, -CO<sub>2</sub>R, -OCOR, -OCO<sub>2</sub>R, -C(O)NRR', -OC(O)NRR', -C(O)R, -COR, -SR, -S(O)<sub>n</sub>R, -S(O)<sub>n</sub>OR, -S(O)<sub>n</sub>NRR', -NRR', -NRC(O)OR, -NRC(O)R, -NO<sub>2</sub>, -OSO<sub>3</sub>H, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted non-aromatic heterocyclic and substituted or unsubstituted aryl;

10


15

R and R' are independently -H, a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkenyl group, a substituted or unsubstituted non-aromatic heterocyclic group or a substituted or unsubstituted aryl group; and

n is 1 or 2.

20

76. A pharmaceutical composition comprising a pharmaceutical carrier or diluent and a compound represented by Structural Formula (I):



or a salt thereof, wherein:

Ring A' is a 5- to 7-membered ring is optionally substituted with one to three functional groups selected from the group consisting of halogen, -OR, -CN, -CO<sub>2</sub>R, -OCOR, -OCO<sub>2</sub>R, -C(O)NRR', -OC(O)NRR', -C(O)R, -COR, -SR, -S(O)<sub>n</sub>R, -S(O)<sub>n</sub>OR, -S(O)<sub>n</sub>NRR', -NRR', -NRC(O)OR, -NRC(O)R, -NO<sub>2</sub>, -OSO<sub>3</sub>H, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted non-aromatic heterocyclic and substituted or unsubstituted aryl;

Ring B' is a 5- to 7-membered ring optionally substituted with one to four functional groups selected from the group consisting of halogen, -OR, -CN, -CO<sub>2</sub>R, -OCOR, -OCO<sub>2</sub>R, -C(O)NRR', -OC(O)NRR', -C(O)R, -COR, -SR, -S(O)<sub>n</sub>R, -S(O)<sub>n</sub>OR, -S(O)<sub>n</sub>NRR', -NRR', -NRC(O)OR, -NRC(O)R, -NO<sub>2</sub>, -OSO<sub>3</sub>H, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted non-aromatic heterocyclic and substituted or unsubstituted aryl;

J is O or S;

L is -C=C- or -NH-(CH<sub>2</sub>)<sub>k</sub>-;

R and R' are independently -H, a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkenyl group, a substituted or unsubstituted non-aromatic heterocyclic group or a substituted or unsubstituted aryl group;

a is 0 or 1;

k is an integer from 1 to 4; and

n is 1 or 2,

provided that Ring A' and Ring B' are not both phenyl and at least one is

substituted with at least one hydrogen bond donating group, and provided that the compound is not 4-((E)-2-(pyridin-4-yl)vinyl)phenol.

77. A method for promoting survival of a eukaryotic cell comprising contacting the cell with at least one compound of Formulas (I)-(XVIII), or a pharmaceutically acceptable salt or prodrug thereof.
- 5 78. The method of claim 77, wherein said compound increases at least one of the level or activity of a SIRT1 protein in the cell.
79. The method of claim 77, wherein the compound increases the lifespan of the cell.
- 10 80. The method of claim 77, wherein the compound increases the cell's ability to resist stress.
81. The method of claim 80, wherein the stress is one or more of the following: heatshock, osmotic stress, DNA damage, inadequate salt level, inadequate nitrogen 15 level, or inadequate nutrient level.
82. The method of claim 77, wherein the compound mimics the effect of nutrient restriction on the cell.
- 20 83. The method of claim 77, wherein the compound increases deacetylase activity of the SIRT1 protein.
84. The method of claim 77, wherein the SIRT1 protein is a mammalian protein.
- 25 85. The method of claim 77, wherein the SIRT1 protein is human SIRT1.
86. The method of claim 77, wherein the eukaryotic cell is a mammalian cell.
87. The method of claim 77, wherein the compound does not substantially have one or 30 more of the following activities: inhibition of PI3-kinase, inhibition of aldoreductase, inhibition of tyrosine kinase, transactivation of EGFR tyrosine kinase, coronary dilation, or spasmolytic activity, at concentrations of the

compound that are effective for increasing the deacetylation activity of the SIRT1 protein.

88. A method for treating or preventing a disease or disorder associated with cell death or aging in a subject, comprising administering to a subject in need thereof a therapeutically effective amount of at least one compound of Formulas (I)-(XVIII), or a pharmaceutically acceptable salt or prodrug thereof.  
5
89. The method of claim 87, wherein the aging-related disease is stroke, a cardiovascular disease, arthritis, high blood pressure, or Alzheimer's disease.  
10
90. A method for treating or preventing insulin resistance, a metabolic syndrome, diabetes, or complications thereof, or for increasing insulin sensitivity in a subject, comprising administering to a subject in need thereof a therapeutically effective amount of at least one compound of Formulas (I)-(XVIII), or a pharmaceutically acceptable salt or prodrug thereof.  
15
91. A method for reducing the weight of a subject, or preventing weight gain in a subject, comprising administering to a subject in need thereof a therapeutically effective amount of at least one compound of Formulas (I)-(XVIII), or a pharmaceutically acceptable salt or prodrug thereof.  
20
92. A method for preventing the differentiation of a pre-adipocyte, comprising contacting the pre-adipocyte with at least one compound of Formulas (I)-(XVIII), or a pharmaceutically acceptable salt or prodrug thereof.  
25
93. A method for prolonging the lifespan of a subject comprising administering to a subject a therapeutically effective amount of at least one compound of Formulas (I)-(XVIII), or a pharmaceutically acceptable salt or prodrug thereof.  
30
94. A method for treating or preventing a neurodegenerative disorder in a subject, comprising administering to a subject in need thereof a therapeutically effective

amount of at least one compound of Formulas (I)-(XVIII), or a pharmaceutically acceptable salt or prodrug thereof.

95. The method of claim 93, wherein the neurodegenerative disorder is selected from the group consisting of Alzheimer's disease (AD), Parkinson's disease (PD), Huntington disease (HD), amyotrophic lateral sclerosis (ALS; Lou Gehrig's disease), diffuse Lewy body disease, chorea-acanthocytosis, primary lateral sclerosis, Multiple Sclerosis (MS) and Friedreich's ataxia.
- 10 96. A method for treating or preventing a blood coagulation disorder in a subject, comprising administering to a subject in need thereof a therapeutically effective amount of at least one compound of Formulas (I)-(XVIII), or a pharmaceutically acceptable salt or prodrug thereof.
- 15 97. The method of claim 95, wherein the blood coagulation disorder is selected from the group consisting of thromboembolism, deep vein thrombosis, pulmonary embolism, stroke, myocardial infarction, miscarriage, thrombophilia associated with anti-thrombin III deficiency, protein C deficiency, protein S deficiency, resistance to activated protein C, dysfibrinogenemia, fibrinolytic disorders, homocystinuria, pregnancy, inflammatory disorders, myeloproliferative disorders, arteriosclerosis, angina, disseminated intravascular coagulation, thrombotic thrombocytopenic purpura, cancer metastasis, sickle cell disease, glomerular nephritis, drug induced thrombocytopenia, and re-occlusion during or after therapeutic clot lysis or procedures such as angioplasty or surgery.

25

1 gtcgagcggg agcagaggag gcgagggagg agggccagag aggcaagtgg aagatggcgg  
 61 acgaggcggc cctgcgcctt cagccggcg gctccccctc ggccgggggg gccgacaggg  
 121 aggccgcgtc gtcccccgcc ggggagccgc tccgcaagag gccgcggaga gatggtccc  
 181 gcctcgagcg gagcccgggc gagcccggtg gggccggccc agagcgtgag gtgccggcgg  
 241 cggccagggg ctgccccggt gcggccggcgg cggcgctgtg gcgggaggcg gaggcagagg  
 301 cggcggcggc aggccggggag caagaggccc aggcaactgc ggccggctggg gaaggagaca  
 361 atggggccggg cctgcagggc ccatctcggg agccaccgct ggccgacaac ttgtacgacg  
 421 aagacgacga cgacgagggc gaggaggagg aagaggccgc ggccggcggcg attgggtacc  
 481 gagataacct tctgttcggt gatgaaatta tcactaatgg tttcattcc tgtgaaagtg  
 541 atgaggagga tagagccta catgcaagct ctagtgactg gactccaagg ccacggatag  
 601 gtccatatac tttgttcag caacatctta tgattggcac agatcctcga acaattctta  
 661 aagatttatt gccggaaaca atacctccac ctgagttgga tgatatgaca ctgtggcaga  
 721 ttgttattaa tattccttca gaaccaccaa aaaggaaaaa aagaaaagat attaatacaa  
 781 ttgaagatgc tgtgaaatta ctgcaagagt gcaaaaaaat tatagttcta actggagctg  
 841 gggtgttgt ttcatgtgga atacctgact tcaggtcaag ggatggtatt tatgctcgcc  
 901 ttgctgtaga cttcccagat cttccagatc ctcaagcgat gttgatatt gaatatttca  
 961 gaaaagatcc aagaccattc ttcaagtttcaaaggaaat atatcctgga caattccagc  
 1021 catctctctg tcacaaattc atagccttgc cagataagga agggaaaacta cttcgcaact  
 1081 atacccagaa catagacacg ctggAACAGG ttgcggaaat ccaaaggata attcagtgtc  
 1141 atggttcctt tgcaacagca tcttgcctga tttgtaaata caaagttgac tgtgaagctg  
 1201 tacgaggaga tatttttaat caggtgttc ctcgatgtcc taggtgccc gctgatgaac  
 1261 cgcttgctat catgaaacca gagattgtgt ttttttgtga aaatttacca gaacagttc  
 1321 atagagccat gaagtatgac aaagatgaag ttgacccctt cattgttatt gggcttccc  
 1381 tcaaagtaag accagtagca ctaattccaa gttccataacc ccatgaagtg cctcagatat  
 1441 taattaatag agaacctttg cctcatctgc attttgatgt agagcttctt ggagactgtg  
 1501 atgtcataat taatgaattt gtcataggt taggttgtga atatgccaat cttgctgta  
 1561 accctgtaaa gctttcagaa attactgaaa aacccctccacg aacacaaaaaa gaattggctt  
 1621 atttgtcaga gttgccaccc acaccccttc atgtttcaga agactcaagt tcaccagaaa  
 1681 gaacttcacc accagattt tcagtgttgc tcacactttt agaccaagca gctaagagta  
 1741 atgatgattt agatgtgtct gaatcaaaag gtttatggaa agaaaaacca caggaagtac  
 1801 aaacttctag gaatgttcaa agtattgctg aacagatggaa aaatccggat ttgaagaatg  
 1861 ttggttctag tactggggag aaaaatgaaa gaacttcagt ggcttggaaaca gtgagaaaat  
 1921 gctggctaa tagagtggca aaggagcaga ttagtaggcg gcttgcgtt aatcagtatc  
 1981 tgttttgcc accaaatcgt tacatttcc atggcgctga ggtatattca gactctgaag  
 2041 atgacgtctt atcctcttagt tcttggca gtaacagtga tagtggaca tgccagagtc  
 2101 caagtttaga agaaccatg gaggatgaaa gtgaaattga agaattctac aatggcttag  
 2161 aagatgagcc tgatgttcca gagagagctg gaggagctgg atttggact gatggagatg  
 2221 atcaagaggc attaatgaa gctatatctg taaaacagga agtaacagac atgaactatc  
 2281 catcaaacaa atcatagtg aataattgtg caggtacagg aattgttcca ccagcattag  
 2341 gaacttttagc atgtcaaaat gaatgttac ttgtgaactc gatagagcaa gaaaaccaga  
 2401 aaggtgtaat atttataaggt tggtaaaata gattttttt catggataat tttaacttc  
 2461 attatttctg tactgtaca aactcaacac taactttttt tttttaaaa aaaaaaaaggt  
 2521 actaagtatc ttcaatcagc tgggtgtcaa gactaactt cttttaagg ttcatttgc  
 2581 tgataaaattc atatgtgtat atataatttt tttttttt tcttagtgagt ttcaacatcc  
 2641 ttaaagtttt caaaaagcca tcggaatgtt aaattaatgt aaagggacag ctaatctaga  
 2701 ccaaagaatg gtatttcac ttttctttgt aacattgaat ggttgaagt actcaaaatc  
 2761 tggtacgcta aacttttgat tctttaacac aattttttt aaacactggc attttccaaa  
 2821 actgtggcag ctaactttt aaaatctcaa atgacatgca gtgtgagtag aaggaagtca  
 2881 acaatatgtg gggagagcac tcgggtgtct ttactttaa aagtaatact tggtgctaag

FIGURE 1

2941 aatttcagga ttattgtatt tacgttcaaa tgaagatggc ttttgtactt cctgtggaca  
3001 ttagtagtaatg tctatattgg ctcataaaaac taacctgaaa aacaaataaa tgctttggaa  
3061 atgtttcagt tgcttttagaa acattagtgc ctgcctggat ccccttagtt ttgaaatatt  
3121 tgccattgtt gttaaataac ctatcactgt ggttagagctt gcattgatct tttccacaag  
3181 tattaaactg ccaaaatgtg aatatgc当地 gcctttctga atctataata atggtaacttc  
3241 tactggggag agtgtaatat tttggactgc tggtttccat taatgaggag agcaacaggc  
3301 ccctgattat acagttccaa agtaataaga tgtaattgt aattcagcca gaaagtacat  
3361 gtctcccatt gggaggattt ggtgttaaat accaaactgc tagccctagt attatggaga  
3421 tgaacatgat gatgttaactt gtaatagcag aatagttaat gaatgaaact agttcttata  
3481 atttatctt atttaaaagc tttagcctgcc ttaaaaactag agatcaactt tctcagctgc  
3541 aaaagcttct agtcttcaa gaagtcata cttaatgaaa ttgcacagta agcatttatt  
3601 tttcagacca tttttgaaca tcactcctaa attaataaaag tattcctctg ttgcttttagt  
3661 atttattaca ataaaaaaggg tttgaaatat agctgttctt tatgcataaa acacccagct  
3721 aggaccatta ctgccagaga aaaaaatcgat attgaatggc cattcccta cttataagat  
3781 gtctcaatct gaatttattt ggctacacta aagaatgcag tatatttagt ttccatttg  
3841 catgatgtt gtgtgctata gatgatattt taaattgaaa agttgtttt aaatttattt  
3901 tacagtgaag actgtttca gctctttta tattgtacat agtctttat gtaatttact  
3961 ggcatatgtt ttgttagactg ttaaatgact ggatatcttc cttcaactt taaaatcacaa  
4021 aaccagtgtt ttttacttgc acactgtttt aaagtctatt aaaattgtca tttgactttt  
4081 ttctgttaaa aaaaaaaaaa aaaaaaaaaa

**FIGURE 1 Con't**

1 cgaaagcgcg tctgcggccg caatgtctgc tgagagttgt agttctgtgc cctatcacgg  
61 ccactcccat ttctggtgcc gtcacgggac agagcagtgc gtgacaggac agagcagtgc  
121 gtgacgggac acagtggttg gtgacgggac agagcggtcg gtgacagcct caagggcttc  
181 agcaccgcgc ccatggcaga gccagaccga ctcagattca gactctgagg gaggagccgc  
241 tggtgtgagaa gcagacatgg acttcctgcg gaaccttattc tcccagacgc tcagcctggg  
301 cagccagaag gagcgtctgc tggacgagct gaccttggaa ggggtggccc ggtacatgca  
361 gagcgaacgc tgtcgagag tcatactgttt ggtggagct ggaatctcca catccgcagg  
421 catccccgac tttcgctctc catccaccgg cctctatgac aacctagaga agtaccatct  
481 tccctaccca gaggccatct ttgagatcag ctatttcaag aaacatccgg aacccttctt  
541 cgccctcgcc aaggaactct atcctggca gttcaagcca accatctgtc actacttcat  
601 ggcgcctgctg aaggacaagg ggctactcct ggcgtgtac acgcagaaca tagataccct  
661 ggagcgaata gccgggctgg aacaggagga cttgggtggag ggcacggca cttctacac  
721 atcacactgc gtcagcgcca gctgccggca cgaatacccg ctaagctgga taaaagagaa  
781 gatcttctct gaggtgacgc ccaagtgtga agactgtcag agcctggta agcctgatata  
841 cgtctttttt ggtgagagcc tcccagcgcg tttcttctcc tgtatgcagt cagacttcct  
901 gaagggtggac ctccctctgg tcatgggtac ctccctgcag gtgcagccct ttgcctccct  
961 catcagcaag gcacccctct ccacccctcg cctgctcatc aacaaggaga aagctggcca  
1021 gtcggaccct ttcctggga tgattatggg cctcgagga ggcattggact ttgactccaa  
1081 gaaggcctac agggacgtgg cctggctggg tgaatgcac cagggctgcc tggcccttgc  
1141 tgagctcctt ggatggaaga aggagctgga ggaccttgc cggaggagc acgccagcat  
1201 agatgcccag tcggggcg gggtccccaa ccccagcact tcagcttccc ccaagaagtc  
1261 cccgccaccc gccaaggacg aggccaggac aacagagagg gaaaaacccc agtgcacagct  
1321 gcatctccca ggcgggatgc cgagctcctc agggacagct gagccccaac cgggcctggc  
1381 cccctcttaa ccagcagttc ttgtctgggg agctcagaac atccccaa ctcttacagc  
1441 tccctccccca aaactgggtt cccagcaacc ctggccccc accccagcaa atctctaaca  
1501 cctccttagag gccaaggctt aaacaggcat ctctaccagc cccactgtct ctaaccactc  
1561 ctgggctaag gagtaacctc cctcatctt aactgcccccc acggggccag ggctacccca  
1621 gaacttttaa ctcttccagg acagggagct tcggggcccc actctgtctc ctgccccccgg  
1681 gggcctgtgg ctaagtaaac catactaac ctacccagt gtgggtgtgg gcctctgaat  
1741 ataacccaca cccagcgtag gggagatctg agccgggagg gctcccgagt ctctgccttc  
1801 agctcccaaa gtgggtgggtg ggcccccttc acgtgggacc cacttccat gctggatggg  
1861 cagaagacat tgcttattgg agacaaatta aaaacaaaaaa caactaacaa aaaaaaaaaaa  
1921 aaaaaaaaaa a

**FIGURE 2**

SIR2.1	-----	
SIRT1	-----MADEAALALQPQGGPSAAGADREAASSPAGEPLRKPRRDGPGLERSPGEPGG	53
SIRT2	-----	
SIR2	MNILLMQRIVSFILVVSQGRYFHVGELTMTMLKRPQEESDNNATKKLKTRLTYPCLGK	60
SIR2.1	-----MSRDSGNDSEVAVTHGEVQEITEE---NPEIGSMHITQE	36
SIRT1	AAPEREVPAARGCPGAAAAALWREAEEAAAAGGEQEAQATAAAGEGDNGPGLQGPSRE	113
SIRT2	-----MAEPDPS	7
SIR2	DKVTGKFIFPAITKDDVMNARLFLKDNDLKTFLLEYFLPVEVNSIYIYFMIKLLGFDVKDK	120
SIR2.1	TDISDAPETNTDSSRQRTTESTSVSSESWN-----NDEMMSN-----	74
SIRT1	PPLADNLYDEDDDDEGEEEEEAAAAIGYRDNLFGDEIITNGFHSCESDEEDRASHASS	173
SIRT2	HPLETQAGKVQEAQDSDSSEGGAAG-----	33
SIR2	ELFMALNSNITSNKERSSAELSSIHAKAED-----	151
: . . . .		
SIR2.1	-----LRRAQRLLDDGATPLQIIQQIFPDFNASRIATMSENAHFAILSDLERA	123
SIRT1	SDWTPRPRIGPYTFVQQHLMIGTDPRТИLKDLLPETIPP---PELDDMTLWQIVINILSEP	231
SIRT2	-----GEADMDFLRNLFSQTLSLG	52
SIR2	-----DELTDPLEKKHAVKLKDLQKAINKVL	178
: . .		
SIR2.1	PVRQKLTNYNSLADAVELFKT--KKHILVLTGAGVSVSCGIPDFRS-KDGIYARLRSEFP	180
SIRT1	PKRKKRKDINTIEDAVKLLQE--CKKIVLVTGAGVSVSCGIPDFRS-RDGIYARLAVIDFP	288
SIRT2	SQKERLLDELTLEGVARYMQSERCRRVICLVGAGISTSAGIPDFRSPSTGLYDNLEKYH-	111
SIR2	STRRLRLPNFNTIDHTATLRN--AKKILVLTGAGVSTSLGIPDFRS-SEGFYSKIRHLG-	234
. : : : : : : : : : : *.*.*:*. * * * * * * * : * . :		
SIR2.1	DLPDPPTAMFDIRYFRENPAFPYNFAREIFPGQFVPSVSHRFIKELETSGRLLRNYTONID	240
SIRT1	DLPDPQAMFDIEYFRKDPRPFFKFAKEIYPGQFQPSLCHKFIALSDKEGKLLRNYTONID	348
SIRT2	-LPYPEAIFEISYFKKHPEPFFALAKELYPGQFKPTICHYFMRLLKDKGLLLRCYTQNI	170
SIR2	-LEDpqdVFNLDIFLQDPSVFYNIAHMVLPPENMYSPLHSFIKMLQDKGKLLRNYTONID	293
* * :*: : * :.* :*: : * : : * * : . . * *** * **** *		
SIR2.1	TLEHQQTGIKR--VVECHGSFSKCTCT--RCGQKYDGNEIREEVLAMRVAHCKRCEG----	292
SIRT1	TLEQVAGIQR--IIQCHGSFATASCL--ICKYKVDCEAVRGDIFNQVVPRCPRCPAD---	401
SIRT2	TLERIAGLEQEDLVEAHGTFYTSCHVSASCRHEYPLSWMKEKIFSEVTPKCEDCQS----	226
SIR2	NLESYAGIDPDKLVQCHGSFATASCV--TCHWQIPGEKIFENIRNLELPLCPYCYQKRKQ	351
.** :*: . : : .** :* .. * * : . : . : . * *		
SIR2.1	-----VIKPNIIVFFGEDLGREFHQHVTEDKHKVDLIVVI	326
SIRT1	-----EPLAIMKPEIVFFGENLPEQFHAKYDKDEV DLLIVI	439
SIRT2	-----LVKPDIVFFGESLPARFFFSCMQSDFLKVDLLVM	260
SIR2	YFPMNSGNNTVQTNINFNSPILKSYGVLPDMTFFGEALPSRFHKTIRKDILECDLLICI	411
: : * : . * * * * . *. : * : * : * : :		
SIR2.1	GSSLKVRPVALIPHCVDKNPQILINRESLPHYNADIELLGNCDDIIRDICFSLGGSFTE	386
SIRT1	GSSLKVRPVALIPSSIPHEVPQILINREPLPHLFHDVELLGDCDVIINELCHRLGGEYAK	499
SIRT2	GTSLQVQPFASLISKAPLSTPRLLINKE--KAGQSDPFLG---MIMGLGGMDFDSKK	313
SIR2	GTSLKVAPVSEIVNMVPShVPQILINRDMVTHAEFDLNLLG-----FCDDVAS	459
* : * : * * . : . * : * : * : * : * : :		

FIGURE 3

SIR2.1	LITSYDSIMEQQGK-TKSQKPSQNKRQLISQEDFLNICMKEKRNDDSSDEPTLKKPRMSV	445
SIRT1	LCCNPVKLSEITEKPPRTQKELAYLSELPPPTPLHVSEDSSSPERTSPPDSSVIVTLLDQA	559
SIRT2	AYRDVAWLGECDQGCLALAELLGWKKELEDLVRREHASIDAQSGAGVPNPSTSASPKKSP	373
SIR2	LVAKKCHWDIPHKKWQDLKKIDYNCTEIDKGTYKIKKQPRKKQQ-----	503
	.	:
SIR2.1	ADDSDMDSEKNNFQEIQKHKS E D D D T R N S D D I L K K I K H P R L L S I T E M L H D N -----	496
SIRT1	AKSNDDLDVSES K G C M E E K P Q E V Q T S R N V E S I A E Q M E N P D L K N V G S S T G E K N E R T S V A G T	619
SIRT2	PPAKDEARTTE-----REKPQ-----	389
SIR2	-----	
SIR2.1	-----KCVAISAHQTVFPGAECSDLETKLVR--DVHHETHCESSCGSSCSSNADSEA	548
SIRT1	VRKCWPNRVAKEQISRRLDGQNQYLFLPPNRYIFHGAEVYSDSEDDVLSSSSCGNSDSGT	679
SIRT2	-----	
SIR2	-----	
SIR2.1	N-----QLSRAQS L D D F V L S D E D R K N T I H L D L Q R A D S C D G D F Q Y E L S E T I D P E T F S H L	601
SIRT1	CQSPSLEEPMEDESEIEEFYNGLEDEPDVPERAGGAGFGTDGDDQEAINEAISVKQEVTD	739
SIRT2	-----	
SIR2	-----	
SIR2.1	CEEMRI-- 607	
SIRT1	MNYPSNKS 747	
SIRT2	-----	
SIR2	-----	

**FIGURE 3 Con't**

Name	Therapeutic agents
ABV	Doxorubicin, Bleomycin, Vinblastine
ABVD	Doxorubicin, Bleomycin, Vinblastine, Dacarbazine
AC (Breast)	Doxorubicin, Cyclophosphamide
AC (Sarcoma)	Doxorubicin, Cisplatin
AC (Neuroblastoma)	Cyclophosphamide, Doxorubicin
ACE	Cyclophosphamide, Doxorubicin, Etoposide
ACe	Cyclophosphamide, Doxorubicin
AD	Doxorubicin, Dacarbazine
AP	Doxorubicin, Cisplatin
ARAC-DNR	Cytarabine, Daunorubicin
B-CAVe	Bleomycin, Lomustine, Doxorubicin, Vinblastine
BCVPP	Carmustine, Cyclophosphamide, Vinblastine, Procarbazine, Prednisone
BEACOPP	Bleomycin, Etoposide, Doxorubicin, Cyclophosphamide, Vincristine, Procarbazine, Prednisone, Filgrastim
BEP	Bleomycin, Etoposide, Cisplatin
BIP	Bleomycin, Cisplatin, Ifosfamide, Mesna
BOMP	Bleomycin, Vincristine, Cisplatin, Mitomycin
CA	Cytarabine, Asparaginase
CABO	Cisplatin, Methotrexate, Bleomycin, Vincristine
CAF	Cyclophosphamide, Doxorubicin, Fluorouracil
CAL-G	Cyclophosphamide, Daunorubicin, Vincristine, Prednisone, Asparaginase
CAMP	Cyclophosphamide, Doxorubicin, Methotrexate, Procarbazine
CAP	Cyclophosphamide, Doxorubicin, Cisplatin
CaT	Carboplatin, Paclitaxel
CAV	Cyclophosphamide, Doxorubicin, Vincristine
CAVE ADD	CAV and Etoposide
CA-VP16	Cyclophosphamide, Doxorubicin, Etoposide
CC	Cyclophosphamide, Carboplatin
CDDP/VP-16	Cisplatin, Etoposide
CEF	Cyclophosphamide, Epirubicin, Fluorouracil
CEPP(B)	Cyclophosphamide, Etoposide, Prednisone, with or without/ Bleomycin
CEV	Cyclophosphamide, Etoposide, Vincristine
CF	Cisplatin, Fluorouracil or Carboplatin Fluorouracil
CHAP	Cyclophosphamide or Cyclophosphamide, Altretamine, Doxorubicin, Cisplatin
ChIVPP	Chlorambucil, Vinblastine, Procarbazine, Prednisone
CHOP	Cyclophosphamide, Doxorubicin, Vincristine, Prednisone

**FIGURE 4**

Name	Therapeutic agents
CHOP-BLEO	Add Bleomycin to CHOP
CISCA	Cyclophosphamide, Doxorubicin, Cisplatin
CLD-BOMP	Bleomycin, Cisplatin, Vincristine, Mitomycin
CMF	Methotrexate, Fluorouracil, Cyclophosphamide
CMFP	Cyclophosphamide, Methotrexate, Fluorouracil, Prednisone
CMFVP	Cyclophosphamide, Methotrexate, Fluorouracil, Vincristine, Prednisone
CMV	Cisplatin, Methotrexate, Vinblastine
CNF	Cyclophosphamide, Mitoxantrone, Fluorouracil
CNOP	Cyclophosphamide, Mitoxantrone, Vincristine, Prednisone
COB	Cisplatin, Vincristine, Bleomycin
CODE	Cisplatin, Vincristine, Doxorubicin, Etoposide
COMLA	Cyclophosphamide, Vincristine, Methotrexate, Leucovorin, Cytarabine
COMP	Cyclophosphamide, Vincristine, Methotrexate, Prednisone
Cooper Regimen	Cyclophosphamide, Methotrexate, Fluorouracil, Vincristine, Prednisone
COP	Cyclophosphamide, Vincristine, Prednisone
COPE	Cyclophosphamide, Vincristine, Cisplatin, Etoposide
COPP	Cyclophosphamide, Vincristine, Procarbazine, Prednisone
CP(Chronic lymphocytic leukemia)	Chlorambucil, Prednisone
CP (Ovarian Cancer)	Cyclophosphamide, Cisplatin
CT	Cisplatin, Paclitaxel
CVD	Cisplatin, Vinblastine, Dacarbazine
CVI	Carboplatin, Etoposide, Ifosfamide, Mesna
CVP	Cyclophosphamide, Vincristine, Prednisome
CVPP	Lomustine, Procarbazine, Prednisone
CYVADIC	Cyclophosphamide, Vincristine, Doxorubicin, Dacarbazine
DA	Daunorubicin, Cytarabine
DAT	Daunorubicin, Cytarabine, Thioguanine
DAV	Daunorubicin, Cytarabine, Etoposide
DCT	Daunorubicin, Cytarabine, Thioguanine
DHAP	Cisplatin, Cytarabine, Dexamethasone
DI	Doxorubicin, Ifosfamide
DTIC/Tamoxifen	Dacarbazine, Tamoxifen
DVP	Daunorubicin, Vincristine, Prednisone
EAP	Etoposide, Doxorubicin, Cisplatin
EC	Etoposide, Carboplatin
EFP	Etoposide, Fluorouracil, Cisplatin
ELF	Etoposide, Leucovorin, Fluorouracil
EMA 86	Mitoxantrone, Etoposide, Cytarabine

**FIGURE 4 Con't**

Name	Therapeutic agents
EP	Etoposide, Cisplatin
EVA	Etoposide, Vinblastine
FAC	Fluorouracil, Doxorubicin, Cyclophosphamide
FAM	Fluorouracil, Doxorubicin, Mitomycin
FAMTX	Methotrexate, Leucovorin, Doxorubicin
FAP	Fluorouracil, Doxorubicin, Cisplatin
F-CL	Fluorouracil, Leucovorin
FEC	Fluorouracil, Cyclophosphamide, Epirubicin
FED	Fluorouracil, Etoposide, Cisplatin
FL	Flutamide, Leuprolide
FZ	Flutamide, Goserelin acetate implant
HDMTX	Methotrexate, Leucovorin
Hexa-CAF	Altretamine, Cyclophosphamide, Methotrexate, Fluorouracil
ICE-T	Ifosfamide, Carboplatin, Etoposide, Paclitaxel, Mesna
IDMTX/6-MP	Methotrexate, Mercaptopurine, Leucovorin
IE	Ifosfamide, Etoposide, Mesna
IfoVP	Ifosfamide, Etoposide, Mesna
IPA	Ifosfamide, Cisplatin, Doxorubicin
M-2	Vincristine, Carmustine, Cyclophosphamide, Prednisone, Melphalan
MAC-III	Methotrexate, Leucovorin, Dactinomycin, Cyclophosphamide
MACC	Methotrexate, Doxorubicin, Cyclophosphamide, Lomustine
MACOP-B	Methotrexate, Leucovorin, Doxorubicin, Cyclophosphamide, Vincristine, Bleomycin, Prednisone
MAID	Mesna, Doxorubicin, Ifosfamide, Dacarbazine
m-BACOD	Bleomycin, Doxorubicin, Cyclophosphamide, Vincristine, Dexamethasone, Methotrexate, Leucovorin
MBC	Methotrexate, Bleomycin, Cisplatin
MC	Mitoxantrone, Cytarabine
MF	Methotrexate, Fluorouracil, Leucovorin
MICE	Ifosfamide, Carboplatin, Etoposide, Mesna
MINE	Mesna, Ifosfamide, Mitoxantrone, Etoposide
mini-BEAM	Carmustine, Etoposide, Cytarabine, Melphalan
MOBP	Bleomycin, Vincristine, Cisplatin, Mitomycin
MOP	Mechlorethamine, Vincristine, Procarbazine
MOPP	Mechlorethamine, Vincristine, Procarbazine, Prednisone
MOPP/ABV	Mechlorethamine, Vincristine, Procarbazine, Prednisone, Doxorubicin, Bleomycin, Vinblastine
MP (multiple myeloma)	Melphalan, Prednisone
MP (prostate cancer)	Mitoxantrone, Prednisone
MTX/6-MO	Methotrexate, Mercaptopurine

FIGURE 4 Con't

Name	Therapeutic agents
MTX/6-MP/VP	Methotrexate, Mercaptopurine, Vincristine, Prednisone
MTX-CDDPAdr	Methotrexate, Leucovorin, Cisplatin, Doxorubicin
MV (breast cancer)	Mitomycin, Vinblastine
MV (acute myelocytic leukemia)	Mitoxantrone, Etoposide
M-VAC Methotrexate	Vinblastine, Doxorubicin, Cisplatin
MVP Mitomycin	Vinblastine, Cisplatin
MVPP	Mechlorethamine, Vinblastine, Procarbazine, Prednisone
NFL	Mitoxantrone, Fluorouracil, Leucovorin
NOVP	Mitoxantrone, Vinblastine, Vincristine
OPA	Vincristine, Prednisone, Doxorubicin
OPPA	Add Procarbazine to OPA.
PAC	Cisplatin, Doxorubicin
PAC-I	Cisplatin, Doxorubicin, Cyclophosphamide
PA-CI	Cisplatin, Doxorubicin
PC	Paclitaxel, Carboplatin or Paclitaxel, Cisplatin
PCV	Lomustine, Procarbazine, Vincristine
PE	Paclitaxel, Estramustine
PFL	Cisplatin, Fluorouracil, Leucovorin
POC	Prednisone, Vincristine, Lomustine
ProMACE	Prednisone, Methotrexate, Leucovorin, Doxorubicin, Cyclophosphamide, Etoposide
ProMACE/cytaBOM	Prednisone, Doxorubicin, Cyclophosphamide, Etoposide, Cytarabine, Bleomycin, Vincristine, Methotrexate, Leucovorin, Cotrimoxazole
PRoMACE/MOPP	Prednisone, Doxorubicin, Cyclophosphamide, Etoposide, Mechlorethamine, Vincristine, Procarbazine, Methotrexate, Leucovorin
Pt/VM	Cisplatin, Teniposide
PVA	Prednisone, Vincristine, Asparaginase
PVB	Cisplatin, Vinblastine, Bleomycin
PVDA	Prednisone, Vincristine, Daunorubicin, Asparaginase
SMF	Streptozocin, Mitomycin, Fluorouracil
TAD	Mechlorethamine, Doxorubicin, Vinblastine, Vincristine, Bleomycin, Etoposide, Prednisone
TCF	Paclitaxel, Cisplatin, Fluorouracil
TIP	Paclitaxel, Ifosfamide, Mesna, Cisplatin
TTT	Methotrexate, Cytarabine, Hydrocortisone
Topo/CTX	Cyclophosphamide, Topotecan, Mesna
VAB-6	Cyclophosphamide, Dactinomycin, Vinblastine, Cisplatin, Bleomycin
VAC	Vincristine, Dactinomycin, Cyclophosphamide

**FIGURE 4 Con't**

Name	Therapeutic agents
VACAdr	Vincristine, Cyclophosphamide, Doxorubicin, Dactinomycin, Vincristine
VAD	Vincristine, Doxorubicin, Dexamethasone
VATH	Vinblastine, Doxorubicin, Thiotepa, Flouxymesterone
VBAP	Vincristine, Carmustine, Doxorubicin, Prednisone
VBCMP	Vincristine, Carmustine, Melphalan, Cyclophosphamide, Prednisone
VC	Vinorelbine, Cisplatin
VCAP	Vincristine, Cyclophosphamide, Doxorubicin, Prednisone
VD	Vinorelbine, Doxorubicin
VelP	Vinblastine, Cisplatin, Ifosfamide, Mesna
VIP	Etoposide, Cisplatin, Ifosfamide, Mesna
VM	Mitomycin, Vinblastine
VMCP	Vincristine, Melphalan, Cyclophosphamide, Prednisone
VP	Etoposide, Cisplatin
V-TAD	Etoposide, Thioguanine, Daunorubicin, Cytarabine
5 + 2	Cytarabine, Daunorubicin, Mitoxantrone
7 + 3	Cytarabine with/, Daunorubicin or Idarubicin or Mitoxantrone
"8 in 1"	Methylprednisolone, Vincristine, Lomustine, Procarbazine, Hydroxyurea, Cisplatin, Cytarabine, Dacarbazine

**FIGURE 4 Con't**

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



PCT

(43) International Publication Date  
27 July 2006 (27.07.2006)

(10) International Publication Number  
WO 2006/078941 A3

(51) International Patent Classification:  
*C07D 403/04* (2006.01)      *A61P 3/10* (2006.01)  
*A61K 31/4025* (2006.01)

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(21) International Application Number:  
PCT/US2006/002092

(22) International Filing Date: 20 January 2006 (20.01.2006)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/645,916                    20 January 2005 (20.01.2005) US

(71) Applicant (for all designated States except US): SIRTRIS PHARMACEUTICALS, INC. [US/US]; 790 Memorial Drive, Suite 104, Cambridge, Massachusetts 02139 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): MILBURN, Michael [US/US]; 508 Hollowridge Court, Cary, North Carolina 27519-9725 (US). ECKSTEIN, Jens, W. [DE/US]; 18 Riga Road, Dover, Massachusetts 02030 (US).

(74) Agents: VINCENT, Matthew, P. et al.; Fish & Neave IP Group, Ropes & Gray LLP, One International Place, Boston, Massachusetts 02110-2624 (US).

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(88) Date of publication of the international search report:

22 February 2007

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 2006/078941 A3

(54) Title: NOVEL SIRTUIN ACTIVATING COMPOUNDS AND METHODS OF USE THEREOF

(57) Abstract: Provided herein are novel sirtuin-activating compounds and methods of use thereof. The sirtuin-activating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing. Also provided are compositions comprising a sirtuin-activating compound in combination with another therapeutic agent.

# INTERNATIONAL SEARCH REPORT

International application No

PCT/US2006/002092

**A. CLASSIFICATION OF SUBJECT MATTER**  
 INV. C07D403/04 A61K31/4025 A61P3/10

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data, BEILSTEIN Data, WPI Data, PAJ

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>HOWITZ K T ET AL: "SMALL MOLECULE ACTIVATORS OF SIRTUINS EXTEND SACCHAROMYCES CEREVISIAE LIFESPAN"          NATURE, NATURE PUBLISHING GROUP, LONDON,          GB,          vol. 425, 11 September 2003 (2003-09-11),          pages 191-196, XP001188967          ISSN: 0028-0836          table 1</p> <p>-----</p> <p>-/-</p>	1-97

Further documents are listed in the continuation of Box C.

See patent family annex.

\* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

6 July 2006

Date of mailing of the international search report

22.12.2006

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2  
 NL - 2280 HV Rijswijk  
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
 Fax: (+31-70) 340-3016

Authorized officer

Seelmann, Ingo

## INTERNATIONAL SEARCH REPORT

International application No

PCT/US2006/002092

## C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	PATENT ABSTRACTS OF JAPAN vol. 2000, no. 26, 1 July 2002 (2002-07-01) -& JP 2001 261649 A (SANKYO CO LTD), 26 September 2001 (2001-09-26) abstract; claim 1; tables 1,2,6 -----	1
X	WO 2004/022665 A (NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE; KAMADA, KENJI; IWAS) 18 March 2004 (2004-03-18) claim 1; compound 1 -----	1
X	US 2002/177637 A1 (EPSTEIN ARTHUR J ET AL) 28 November 2002 (2002-11-28) claim 23 -----	1
X	WO 02/057219 A (WELICHEM BIOTECH INC; CHEN, GENHUI; LIU, WEI; LI, JIANXIONG; WEBSTER,) 25 July 2002 (2002-07-25) claim 1 -----	1
X	US 6 355 443 B1 (BOBROW MARK NORMAN ET AL) 12 March 2002 (2002-03-12) claim 1 -----	1
X	EP 0 754 682 A (NIPPON SHINYAKU COMPANY, LIMITED; HIDAKA, HIROYOSHI; D. WESTERN THERAP) 22 January 1997 (1997-01-22) claim 1 -----	1
X	EP 0 334 119 A (BOEHRINGER INGELHEIM PHARMACEUTICALS INC) 27 September 1989 (1989-09-27) claim 1 -----	1
X	US 5 399 575 A (FRIEBE ET AL) 21 March 1995 (1995-03-21) claim 1 -----	1
X	GB 1 356 221 A (PFIZER INC) 12 June 1974 (1974-06-12) claim 1 -----	1
X	PL 172 112 B1 (UNIWERSYTET IM. ADAMA MICKIEWICZA) 29 August 1997 (1997-08-29) figure 2 -----	1,68
X	EP 0 499 415 A (IMPERIAL CHEMICAL INDUSTRIES PLC) 19 August 1992 (1992-08-19) claim 1 -----	1

## INTERNATIONAL SEARCH REPORT

International application No

PCT/US2006/002092

## C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	PORCU M ET AL: "The emerging therapeutic potential of sirtuin-interacting drugs: from cell death to lifespan extension" TRENDS IN PHARMACOLOGICAL SCIENCES, ELSEVIER, HAYWARTH, GB, vol. 26, no. 2, February 2005 (2005-02), pages 94-103, XP004727629 ISSN: 0165-6147 figure 4b	1-97
X	QUIDEAU S: "PLANT POLYPHENOLIC SMALL MOLECULES CAN INDUCE A CALORIE RESTRICTION-MIMETIC LIFE-SPAN EXTENSION BY ACTIVATING SIRTUINS: WILL POLYPHENOLS SOMEDAY BE USED AS CHEMOTHERAPEUTIC DRUGS IN WESTERN MEDICINE?" CHEMBIOCHEM - A EUROPEAN JOURNAL OF CHEMICAL BIOLOGY, WILEY VCH, WEINHEIM, DE, vol. 5, no. 4, 2 April 2004 (2004-04-02), pages 427-430, XP009057585 ISSN: 1439-4227 compounds 4-6	1-97
X	LAZER E S ET AL: "ANTIINFLAMMATORY 2,6-DI-TERT-BUTYL-4-(2-ARYLETHENYL)PHENOLS" JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 32, no. 1, 1989, pages 100-104, XP000973857 ISSN: 0022-2623 compounds 7,11,12,7S	1,68
X	HAROUTOUNIAN S A ET AL: "4'-Hydroxystyryldiazines: Synthesis and Fluorescence Properties" TETRAHEDRON, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 51, no. 6, February 1995 (1995-02), pages 1585-1598, XP004104849 ISSN: 0040-4020 compounds 3A-H,3E	1,68
X	PAPA D; ET AL: "X-Ray Diagnostics. VI." JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, AMERICAN CHEMICAL SOCIETY, WASHINGTON, DC, US, vol. 73, 1951, pages 253-255, XP002388920 compound 5	1,68
		-----
		-----
		-----
		-----

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US2006/002092

### Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1.  Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
  
2.  Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
  
3.  Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

### Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1.  As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
  
2.  As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
  
3.  As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
  
4.  No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

see annex

#### Remark on Protest

- The additional search fees were accompanied by the applicant's protest.
- No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 1-11(part),12-56,66-70,76-97(part)

subject-matter relating to compounds in which at least A or B is a heterocyclic ring and both of A and B are monocyclic

---

2. claims: 57-62, 63-65(part),77-97(part)

subject-matter relating to compounds in which none of A and B is a heterocyclic ring and both of A and B are monocyclic (A and B are Phenyl), one of which is substituted by at least one halogen containing group

---

3. claims: 57-62, 63-65(part),77-97(part)

subject-matter relating to compounds in which none of A and B is a heterocyclic ring and both of A and B are monocyclic (A and B are Phenyl) and none of the rings are not substituted by a halogen containing group

---

4. claims: 1-11(part),71-75,76-97(part)

subject-matter relating to compounds in which A is a bicyclic ring system

---

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/US2006/002092

Patent document cited in search report		Publication date		Patent family member(s)		Publication date
JP 2001261649	A	26-09-2001		NONE		
-----						
WO 2004022665	A	18-03-2004	AU	2003261883 A1		29-03-2004
-----						
US 2002177637	A1	28-11-2002	AU	2002252292 A1		24-09-2002
			CA	2441745 A1		19-09-2002
			CN	1516713 A		28-07-2004
			EP	1434813 A2		07-07-2004
			JP	2005503449 T		03-02-2005
			TW	237042 B		01-08-2005
			WO	02072654 A2		19-09-2002
			US	2005027097 A1		03-02-2005
-----						
WO 02057219	A	25-07-2002	CA	2433417 A1		25-07-2002
			CN	1455766 A		12-11-2003
			EP	1368306 A1		10-12-2003
			JP	2004529085 T		24-09-2004
-----						
US 6355443	B1	12-03-2002	CA	2368190 A1		21-09-2000
			EP	1161555 A1		12-12-2001
			JP	2003524768 T		19-08-2003
			WO	0055358 A1		21-09-2000
-----						
EP 0754682	A	22-01-1997	AT	207057 T		15-11-2001
			CA	2187214 A1		19-10-1995
			CN	1145066 A		12-03-1997
			DE	69523298 D1		22-11-2001
			DE	69523298 T2		27-06-2002
			DK	754682 T3		04-02-2002
			ES	2165911 T3		01-04-2002
			WO	9527699 A1		19-10-1995
			JP	3080405 B2		28-08-2000
			PT	754682 T		28-03-2002
			RU	2138482 C1		27-09-1999
			US	5972976 A		26-10-1999
-----						
EP 0334119	A	27-09-1989	AU	628324 B2		17-09-1992
			AU	3151489 A		21-09-1989
			DD	283602 A5		17-10-1990
			DE	68907095 D1		22-07-1993
			DE	68907095 T2		05-01-1994
			DK	134489 A		22-09-1989
			ES	2056983 T3		16-10-1994
			FI	891295 A		22-09-1989
			HU	50093 A2		28-12-1989
			JP	2004729 A		09-01-1990
			NO	891114 A		22-09-1989
			NZ	228410 A		26-08-1993
			PH	26928 A		03-12-1992
			PT	90066 A		10-11-1989
			ZA	8902086 A		28-11-1990
-----						
US 5399575	A	21-03-1995	AT	148115 T		15-02-1997
			AU	8957491 A		25-06-1992
			CA	2099603 A1		02-06-1992
			DE	4038335 A1		04-06-1992
			WO	9209598 A1		11-06-1992
			EP	0559695 A1		15-09-1993

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/US2006/002092

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
US 5399575	A	ES JP	2097822 T3 6503076 T	16-04-1997 07-04-1994
GB 1356221	A	12-06-1974	CA DE FR IT JP JP	983925 A1 2237732 A1 2150739 A1 1043892 B 57052330 B 57026617 A
PL 172112	B1	29-08-1997	PL	300028 A1
EP 0499415	A	19-08-1992	AU CA CS FI HU IE JP MX NO US ZW	1040992 A 2060107 A1 9200361 A3 920564 A 60488 A2 920175 A1 5092956 A 9200559 A1 920377 A 5236937 A 1492 A1